Here - cloudfront.net

11.10.2015 - Birgit König. Allianz Private Krankenversicherungs-AG |. CEO | Germany. Axel R. Pries. Charité – Universitätsmedizin Berlin |. Dean | Germany. STATEMENTS OF. YOUNG LEADERS IN HEALTH ...... Philharmonic conducted by Sir Simon Rattle, also make for high-class musical enjoyment. BERLIN:.
8MB Größe 17 Downloads 1048 Ansichten
Science · Innovation · Policies

World Health Summit BERLIN, GERMANY OCTOBER 11–13, 2015 Federal Foreign Office  |  BERLIN

SUMMIT VENUE

Europa-Foyer

rücke

fernb Jung

p Europasaal tu s ar St tche i P r a ke di ea ter Me ffice Sp en C O p tu ar n St tatio en es Pr Willy-Brandt-Saal

n

Adenauer-Saal

Stresemann-Saal

Weltsaal

M8 Lounge

Presidential Lounge

Rathenau-Saal

Interview Area

raße

serst rwas Unte

VENUE: Federal Foreign Office Werderscher Markt 1 10117 Berlin ENTRANCE: Unterwasserstraße 10

tio tra gis Re

Bag Counter

WORLD HEALTH SUMMIT BERLIN, GERMANY OCTOBER 11–13, 2015

4

PROGRAM OVERVIEW

PROGRAM OVERVIEW

SUNDAY | OCTOBER 11, 2015 PLENARY HALL WELTSAAL 10:30•– 12:00

MONDAY | OCTOBER 12, 2015 ROOM 1 WILLY-BRANDT

ROOM 2 ADENAUER

ROOM 3 STRESEMANN

ROOM 4 RATHENAU

WS 01

WS 02 | Page 38

WS 03 | Page 40

WS 04 | Page 42

WHS Council Meeting (internal session)

Developing Young Leaders in Health European Students’ Conference (ESC) German Medical Students’ Association (bvmd) Global Health Next Generation Network (GHNGN) Alliance: Monash University Universities Allied for Essential Medicines (UAEM) Young Leaders for Health (YLH) e.V.

Sustainable Research Capacity Strengthening World Health Organization (WHO) Alliance: World Federation of Academic Institutions for Global Health (WFAIGH)

Humanitarian Health Assistance versus Health System Support Harvard Medical School LinkGlobalHealth.org Initiative

15:00•–16:30

17:00•–21:00

09:00•–•1 0:30

11:00•–•12:30

ROOM 1 WILLY-BRANDT

ROOM 2 ADENAUER

ROOM 3 STRESEMANN

ROOM 4 RATHENAU

SYM 01 | Page 64

WS 13 | Page 66

WS 14 | Page 68

WS 15 | Page 70

WS 16 | Page 72

Antimicrobial Resistance Alliance: National University of Singapore (NUS) Robert Koch Institute (RKI)

Cultures and Health Alliance: Charit鍖Universitätsmedizin Berlin Stiftung Preussischer Kulturbesitz (SPK )

Newborn Mortality Alliance: Monash University

Young Physician Leaders Alliance: InterAcademy Medical Panel (IAMP)

Sexual Violence Alliance: Charit鍖Universitätsmedizin Berlin Pennsylvania State University

KEY 02 | Page 74 The Post-2015 Development Agenda Alliance United Nations (UN) World Health Organization Regional Office for Europe Lunchbreak & Startup Presentations & New Voices in Global Health (NVGH) Poster Presentations

14:00•–•15:30

Lunchbreak & New Voices in Global Health (NVGH) Poster Presentations 13:00•– 14:30

PLENARY HALL WELTSAAL

WS 05 | Page 44

WS 06 | Page 46

WS 07 | Page 48

WS 08 | Page 50

Quality Improvement & Patient Safety Geneva Health Forum Alliance: National University of Singapore (NUS) | University of Geneva (UGE) VAMED AG

Migration and Refugee Health Bielefeld University Pulitzer Center on Crisis Reporting

Big Data AbbVie Deutschland GmbH & Co.KG Elsevier GmbH Alliance: Johns Hopkins Bloomberg School of Public Health

Civil Society Participation in Health Policy Processes Brot für die Welt– Evangelischer Ent wicklungsdienst Oxfam Deutschland e.V.

WS 09 | Page 52

WS 10 | Page 54

WS 11 | Page 56

WS 12 | Page 58

Social Entrepreneurs and Traditional Social Organizations Boehringer Ingelheim GmbH & Co.KG Karl Kübel Stiftung für Kind und Familie

Medical Education Alliance: Monash University | National University of Singapore (NUS) | National University Health System (NUHS)

WHS Science & Industry Circle Fraunhofer-Institut für Bildgestützte Medizin MEVIS German Healthcare Partnership (GHP)

Global Health: Research and Development Drugs for Neglected Diseases initiative (DNDi) Global Health Innovative Technology Fund (GHIT)

16:00•–•1 8:00

SYM 02 | Page 76

WS 17 | Page 78

WS 18 | Page 80

WS 19 | Page 82

WS 20 | Page 84

Value-Based Healthcare The Boston Consulting Group (BCG) Berlin Institute of Health (BIH)

Universal Health Coverage German Federal Ministry for Economic Cooperation and Development (BMZ ) German Healthcare Partnership (GHP) Rabin Martin The Graduate Institute Geneva

Equity and Health Literacy Hertie School of Governance World Health Organization (WHO)

Stem Cell Research•– Paving the path to application Innovative Medicines Initiative (IMI) German Stem Cell Network (GSCN) EBiSC StemBancc Berlin Institute of Health (BIH)

A European Efficacy•/•Effectiveness Assessment European Federation of Pharmaceutical Industries and Association (EFPIA) Sanofi

KEY 03 | Page 86 Digital Health European Commission Helmholtz Association of German Research Centres e.V.

19:00•–•23:00

WHS Night | Page 88 Allianz Forum, Pariser Platz 6, 10117 Berlin Allianz Deutschland AG Alliance

KEY 01 | Page 60 Opening Ceremony & Reception German Federal Foreign Office (AA) | German Federal Ministry of Health (BMG) | Alliance | World Health Organization (WHO)

Keynotes

Panel Discussions

Workshops

5

6

PROGRAM OVERVIEW

TABLE OF CONTENTS

TUESDAY | OCTOBER 13, 2015

09:00•–•10:30

11:00•–•12:30

PLENARY HALL WELTSAAL

ROOM 1 WILLY-BRANDT

ROOM 2 ADENAUER

ROOM 3 STRESEMANN

ROOM 4 RATHENAU

SYM 03 | Page 92

WS 21 | Page 94

WS 22 | Page 96

WS 23 | Page 98

WS 24 | Page 100

Ebola: Assessment, Treatment and Prevention Institut Pasteur Alliance The Graduate Institute of International and Development Studies

Antimicrobial Resistance Koch-MetschnikowForum e.V. Alliance: Monash University

Access to Essential Medicines and Health Commodities in Africa German Healthcare Partnership (GHP) UNAIDS

Vision Research Fukushima Medical University Alliance: Charit鍖Universitätsmedizin Berlin

Trade, Diplomacy and Global Health German Federal Foreign Office (AA) Alliance: World Federation of Academic Institutions for Global Health (WFAIGH)

KEY 04 | Page 102 Global Health Policy in the G7/G20 Alliance The Rockefeller Foundation The Global Fund Lunchbreak & New Voices in Global Health (NVGH) Poster Presentations

14:00•–•15:30

16:00 –•17:00

SYM 04 | Page 104

WS 25 | Page 106

WS 26 | Page 108

WS 27 | Page 110

WS 28 | Page 112

NCDs: A Call for Common Action and Sustainable Change Sanofi

Climate Change and Health Leopoldina– German National Academy of Science Alliance: London School of Hygiene & Tropical Medicine

Education and Training of Clinical and Translational Scientists German Centers for Health Research (DZG) Berlin Institute of Health (BIH)

Stress and the City: Flight, Migration and Mental Health Fliedner Klinik Berlin Alliance: Charit鍖Universitätsmedizin Berlin

One World•–• One Health Alliance: InterAcademy Medical Panel (IAMP) Robert Koch Institute (RKI) World Wide Fund for Nature (WWF Germany)

KEY 05 | Page 114 Climate Change and Health Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety (BMUB) Leopoldina–German National Academy of Sciences e.V. Alliance

17:00 –•18:00

KEY 06 | Page 116 Global Health Security & Closing Ceremony Alliance | Munich Security Conference Foundation gGmbH (MSC)

TABLE OF CONTENTS Program Overview¤4 Welcome Messages¤8 WHS Participants & Key Facts¤16 WHS Track Information¤17 WHS Vision, Mission, Goals¤18 WHS Presidents¤20 WHS Scientific Committee & Ambassadors¤21 WHS Council¤22 M8 Alliance¤24 WHS Startup Track¤30 New Voices in Global Health¤32 WHS Night¤34 WHS Community & Social Media¤35 Summit Program, Sunday, October 11, 2015¤37 Summit Program, Monday, October 12, 2015¤63 Summit Program, Tuesday, October 13, 2015¤91 Summit Venue¤120 Accommodation¤122 City of Berlin¤124 Federal Foreign Office¤126 General Information¤130 Media Information¤134 Contacts¤135 Keynote Speakers and Chairs¤136 Speaker Index with Pictures¤144 Speaker List¤157 Supporting Institutions¤159 Summit Partners¤161

7

WELCOME MESSAGES 8

WELCOME MESSAGE ANGELA MERKEL

Germany holds the G7 Presidency in 2015. Health matters are a key item on our agenda. We are primarily focusing on infectious diseases, which are one of the most common causes of death worldwide. The Ebola epidemic in West Africa was a painful reminder of what a devastating impact the uncontrolled outbreaks of such diseases can have. Angela Merkel

Close international cooperation is vital in order to be better prepared for such epidemics in the future or, in the best case scenario, to be able to prevent them in the first place. Whether it is a matter of being able to provide rapid emergency aid at any time or of promoting research in the fight against antimicrobial resistance and neglected tropical diseases, we can only overcome such global challenges if we work together across national and cultural borders and across the scope of professional and political competence.

WELCOME MESSAGE ANGELA MERKEL

The World Health Summit is an excellent venue for expert discussion on the health topics that move us worldwide. We can expect it to deliver valuable input, also as regards the G7 objectives and the post 2015 agenda for sustainable development. As patron of the World Health Summit, I would like to welcome all the participants to Berlin. The conference will open doors for you to new insights, contacts and collaboration. This personal benefit can pay dividends to many people. The hopes of countless numbers of people are resting on this. I am extremely grateful for your great dedication in so many fields.

Angela Merkel Chancellor of the Federal Republic of Germany

2015 nimmt Deutschland die G7-Präsidentschaft wahr. Auf unserer Agenda haben auch Gesundheitsfragen einen zentralen Platz. Unser Augenmerk gilt vor allem Infektionskrankheiten. Sie gehören weltweit zu den häufigsten Todesursachen. Welche verheerenden Folgen unkontrollierte Ausbrüche solcher Krankheiten haben können, hat uns die EbolaEpidemie in Westafrika schmerzlich vor Augen geführt. Um für die Zukunft besser auf solche Epidemien vorbereitet zu sein oder sie bestenfalls sogar verhindern zu können, kommt es vor allem auf einen engen internationalen Schulterschluss an. Ob es nun darum geht, jederzeit rasche Nothilfe gewährleisten zu können oder etwa im Kampf gegen antimikrobielle Resistenzen und vernachlässigte Tropenkrankheiten entsprechende Forschungen voranzutreiben – nur wenn wir über Grenzen von Ländern und Kulturen, über fachliche und politische Zuständigkeiten hinweg zusammenarbeiten, können wir solche globalen Herausforderungen meistern.

Der World Health Summit ist eine hervorragende Plattform für den fachkundigen Austausch über Gesundheitsthemen, die uns weltweit bewegen. So lässt er auch mit Blick auf die Zielsetzungen der G7 oder auf die Post-2015-Agenda für nachhaltige Entwicklung wertvolle Impulse erwarten. Als Schirmherrin des World Health Summit heiße ich alle Teilnehmerinnen und Teil nehmer in Berlin herzlich willkommen. Ihnen öffnet die Tagung Türen zu manch neuen Erkenntnissen, Begegnungen und Kooperationen. Dieser persönliche Gewinn kann sich für viele bezahlt machen. Damit verbinden sich Hoffnungen unzähliger Menschen. Lassen Sie mich Ihnen daher für Ihr vielfältiges Engagement aufrichtig danken. Angela Merkel Bundeskanzlerin der Bundesrepublik Deutschland

9

10

WELCOME MESSAGE FRANÇOIS HOLLANDE

The world climate conference (COP21) will be held in Paris this December. Health and climate are both inextricably linked and interdependent. This was the theme of the World Health Summit 2014, whose participants stressed the importance of international solidarity.

François Hollande

We have witnessed this solidarity in recent months, when the Ebola virus once against struck West Africa. To be effective, this solidarity must be based on exchanges and shared knowledge and experiences. Therefore, by maintaining education as one of the six main themes of the 2015 World Health Summit, there is no doubt that its organizers wanted to highlight the importance of the training period for future health actors to raise their awareness of the main issues for the future: education, prevention, detection. Your involvement and your declarations at this World Health Summit will play an important role in informing the international community. Thank you very much.

François Hollande President of the French Republic

WELCOME MESSAGE JEAN-CLAUDE JUNCKER

La conférence mondiale sur le climat se tiendra à Paris au mois de décembre prochain. Santé et Climat, ces termes sont liés l’un à l’autre, tant l’une dépend de l’autre. Ce fut le thème du sommet mondial de la santé 2014 dont les participants avaient mis l’accent sur l’importance de la solidarité internationale. Cette solidarité, nous l’avons observée ces derniers mois lorsque le virus Ebola s’est à nouveau abattu sur l’Afrique de l’Ouest. Pour être efficace, cette solidarité doit s’appuyer sur l’échange et le partage des connaissances et des expériences. Aussi, en retenant l’éducation parmi les 6 principaux termes du sommet mondial 2015, ses organisateurs ont sans aucun doute voulu souligner l’importance que revêt la période de formation des futurs acteurs de la Santé pour les sensibiliser aux grands enjeux de demain: éducation, prévention, détection. Par votre participation et vos interventions au sommet mondial de la santé, vous avez tous un rôle important: éclairer la communauté internationale. Je vous en remercie chaleureusement. François Hollande Président de la République

As President of the European Commission, I am convinced that, by working together in a focused way on certain health-related issues, we can ensure longer, richer lives for the citizens of Europe and the world. I aim to focus on the issues that matter and make a difference; and to concentrate on those areas where European action can really add value to people’s lives. Although national health policy remains a national competence, there remains a lot we can do together. There are many pressing trends in healthcare. First, we all see the epidemics that can devastate developing countries. Fresh outbreaks like Ebola grab the headlines, while others such as HIV and malaria continue their grim toll. Our common humanity compels us to respond: and I am glad the EU is mobilising in this fight, with political, diplomatic, humanitarian and financial tools – not to mention some promising new research into Ebola treatments. Second, we have a population that is getting older. In Europe today, we see 65 as the age for retirement; but, not so far into the future, one in three adults could be over that age. That poses a challenge for our healthcare systems: set up to focus on acute conditions; but which now must deal increasingly with chronic, degenerative illness. This will call for a systemic change, blurring the boundaries between health and social care, and between home and hospital; and also calls for investment to fight such chronic conditions. And third, there is a growing resistance to antibiotics – a resistance which already today causes 25,000 deaths a year. This is a major public health challenge – calling for a coordinated, committed response.

Yet, alongside these trends, we have many opportunities to improve efficiency, accessibility and resilience of healthcare. From electronic prescriptions to telemonitoring, digital technology can offer Europeans better qual ity care. I would like to see a Europe that is able to exploit those new opportunities: innovative, investing, and digital.

Jean-Claude Juncker

The EU can help Member States address the challenge of increased calls on health services, and more complex technology. Under my Presidency, the European Commission will support the EU’s capacity to deal with crisis situations in food safety or pandemics; especially Ebola. We will develop EU policies on medicines and pharmaceutical products – while taking fully into account that medicines are not goods like any other. We will develop expertise on how health systems perform, feeding into our broader economic policy coordination. And we will ensure that the healthcare sector – like so many others – is able to capture the benefits of a borderless digital single market. In these areas and more, we can work more effectively when we work together. I wish you all the best doing so at the World Health Summit.

Jean-Claude Juncker President of the European Commission

11

12

WELCOME MESSAGE WHS PRESIDENTS

Shunichi Fukuhara

Detlev Ganten

2015 will surely be remembered for magnificent accomplishments in science and medicine. But there have also been unprecedented developments in an area that affects all our lives intimately and directly: global health. Here it is often the catastrophes that linger in public memory: the aftermath of the Ebola epidemic, and reports placing the number of refugees and displaced people at an all-time high. We fight against microbes that have evolved resistance to drugs, permitting them to reclaim entire regions and spread to new ones. We witness the rising toll of climate change, which now affects the health of billions of people. As organizers of the World Health Summit, we hear all these calls to action. The M8 Alliance of Academic Health Centers, Universities, and National Academies is now six years old. In 2009 we gathered at the first World Health Summit, which has become a unique forum for promoting global health through networking and dialogue among medical practitioners, academia, govern-

WELCOME MESSAGE WHS PRESIDENTS

ment, and the private sector. Over the past six years the M8 Alliance has developed a respected and authoritative voice in decision-making on global health issues. Moreover, among the world’s leading academic health centers we have built new bonds of friendship, trust, and collaboration. On that solid foundation, 2015 has been a unique and pivotal year. This year’s WHS Regional Meeting was held six months ago in Japan. From that meeting the M8 Alliance issued a statement in which we strongly emphasized the need for resilient health systems. What does that mean? Some of the attendees were able to see what it means, firsthand. Fukushima Medical University co-sponsored the meeting and kindly invited us to visit. There we saw how the people of Fukushima were still responding to the triple disaster of 2011. We saw how global health issues were manifest at the local level, and how they were being dealt with locally. We saw a population that is aging very rapidly. We saw how even

an economically advanced country can be deeply challenged by an unforeseen crisis. And we saw how the enthusiasm of the next generation of healthcare leaders obliges us to give them the best guidance and opportunities that we can. Coming out of this year’s Regional Meeting, the M8 Alliance’s statement focuses us on resilience and on action. Action, that is, to overcome the challenges of rapid aging, responding to and preparing for crises, and fostering new leaders. While each M8 Alliance member will confront these challenges to resilience in its own way, we will learn from each other, and we will share our experiences with the world. After six years of building a strong base, 2015 may be remembered as the year when we mobilized our base into action. The M8 Alliance will now encourage and support specific actions by its members as they build resilient health systems locally and as they set examples from which the global healthcare community can benefit.

The world is right to expect much from the M8 Alliance. Entering our new actionoriented phase, let us continue working together as we fulfill our founding mission to improve global health. This year’s World Health Summit program reflects that spirit. Thank you all for your support, and welcome to the World Health Summit 2015!

Shunichi Fukuhara

Detlev Ganten

WHS President

WHS President

13

14

WELCOME MESSAGE CHARITÉ, BIH, MDC

Karl Max Einhäupl

Axel Radlach Pries

WELCOME MESSAGE CHARITÉ, BIH, MDC

The first World Health Summit (WHS) was held in 2009 on the occasion of the 300th anniversary of the Charité. The Summit aimed to provide a unique and contemporary platform to address the many pressing challenges facing global health. Bringing together high-ranking representatives from diverse healthrelated sectors worldwide, the Summit was met with widespread enthusiasm, reflecting the need for an open and democratic forum of this kind. The World Health Summit has since been held in Berlin on an annual basis each October and is regarded as the preeminent strategic forum for global health, uniting the fields of academia, politics, the private sector, and civil society.

much has been achieved in the last years and awareness of the importance of this forum and its topics has steadily grown, great challenges remain. Scientific re search has continued to produce new insights into health and has helped forge the development of new medications and treatments, yet global suffering prevails. Indeed, challenges relating to global health are steadily increasing and cannot be resolved by any country or any single healthcare sector alone. As a result, the need for a strong World Health Summit that unites leaders and experts from all healthcare related fields whilst simultaneously facilitating mutual development of sustained and relevant solutions for foreseeable problems is greater than ever.

Upon invitation from the M8 Alliance of Academic Health Centers, Universities and National Academies and under the high patronage of Angela Merkel (Chancellor of the Federal Republic of Germany), François Hollande (President of the French Republic) and Jean-Claude Juncker (President of the European Commission), the World Health Summit enjoys solid political support and serves as a key strategic platform in times of global conflicts, natural disasters and demographic changes. However, whilst

On the international front, WHS Regional Meetings in Singapore (2013), São Paulo (2014) and Kyoto (2015) have become forceful initiatives for solutions to regional problems within the global healthcare context. In Berlin, this call has been addressed by the successful establishment of the Berlin Institute of Health (BIH). The BIH is funded by the Federal Ministry of Education and Research and the Berlin Senate. The BIH represents an impressive and highly significant new institutional collaboration in which the Charit鍖

Universitätsmedizin Berlin, an outstanding university hospital, and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), one of the leading European institutions for biomedical research, join forces. Bringing together the complementary strengths of the MDC and Charité under one roof is what makes the BIH truly unique. In April 2015, the BIH has been transformed into a corporation under public law by the Berlin House of Representatives. The degree of high level political support that the BIH receives reflects the start of a paradigm shift in translational medicine and an even stronger political involvement in global challenges. The 2015 World Health Summit is once again hosted by the Ministry of Foreign Affairs and will focus on topics such as Antimicrobial Resistance; Health in the Post-2015 Development Agenda; Climate Change and Health; Digital Health; Medical Education; and Refugee Health. Each of these topics exercises an immediate and pervasive influence on our daily lives. We welcome the fact that the World Health Summit treats these topics with according attention.

On behalf of Charit鍖Universitätsmedizin Berlin, Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Berlin Institute of Health, it is therefore with great pleasure that we welcome you to this year’s World Health Summit. Our continued and combined efforts to translate research findings from bench to bedside and bedside to bench remain of paramount importance if we wish to sustainably improve the health and lives of people all over the world. The World Health Summit plays an essential role in strengthening this translation and we are confident that the 2015 meeting will stimulate the development of creative solutions and thus facilitate lasting and meaningful progress.

Erwin Böttinger

Thomas Sommer

Karl Max Einhäupl

Erwin Böttinger

Chairman of the Executive Board Charit鍖Universitätsmedizin Berlin

Chief Executive Officer (from November 2015) Berlin Institute of Health (BIH)

Axel Radlach Pries

Thomas Sommer

Dean Charit鍖Universitätsmedizin Berlin

Scientific Director (interim) Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)

15

16

WHS PARTICIPANTS & KEY FACTS

WHS TRACK INFORMATION

PARTICIPANTS AND KEY FACTS Participants Profile The World Health Summit brings together about 1,500 decision makers and representatives of all health-related fields from more than 80 countries to address the most pressing issues that medicine and healthcare systems will face over the next decade and beyond. Who will attend the WHS 2015? • Top-level researchers and members of the scientific community • High-profile political decision-makers • Executives and representatives from the healthcare system • Leaders of the health-related industry and technology sector • Representatives of civil society and foundations • Students and young professionals from all health-related fields

KEY FACTS DATE: October 11•–•13, 2015 VENUE: German Federal Foreign Office Werderscher Markt 1, 10117 Berlin Entrance: Unterwasserstraße 10

Academia

Private Sector

WORLD HEALTH SUMMIT

Policy Makers

Civil Society

Education and Leadership Especially in times of limited resources we need well-trained leaders to build high-performing and sustainable health systems. They will be change agents who will better serve the needs identified by their communities. Thereby they will be contributing to the improvement of health outcomes and health equity. In addition we need to develop interdisciplinary strategies for a more effective health communication system. How can we clearly articulate and support the synergies between health and other sectors? How can we develop shared solutions to drive people-centered, inclusive development? Research and Innovation Cross-sector collaborations between global health and foreign policy programs and new capacity building initiatives are vital to improve the current coordination and to stimulate the financing of health research. This is also crucial to strengthen the links between evidence and policy. To improve the health status of its people and to contribute to its social and economic development a systems approach at the country level is needed. Strengthening a country’s research capacity is mandatory in order to provide a supportive environment for sustainable growth.

Evidence to Policy The links between health, poverty alleviation and development, as well as the role of health in the formulation and implementation of foreign policy have been recognized in the UN Resolution on Global Health and Foreign Policy. Global Health affects all the core functions of foreign policy: achieving security, creating economic wealth, supporting development in low income countries and protecting human dignity. Global Health for Development The outcome document of the Rio+20 United Nations Conference on Sustainable Development gives health a central place as a precondition for, and an outcome and an indicator of all three dimensions of sustainable development: economic growth, social improvement and environmental protection. Health must be a part of the post2015 development agenda. This agenda presents an opportunity to rethink what makes development inclusive, innovative and relevant for everyone. The importance of Universal Health Coverage in enhancing health, social cohesion and sustainable human and economic development is emphasized. It is therefore an essential component of sustainable development and poverty reduction.

17

18

WHS VISION, MISSION, GOALS

KOLUMNENTITEL

The World Health Summit (WHS) is the annual conference of the M8 Alliance of Academic Health Centers, Universities and National Academies. Through the Interacademy Medical Panel (IAMP), it is organized in collaboration with national academies of science in more than 67 countries. VISION

GOALS

The vision behind the World Health Summit is to improve health all over the planet, catalyzing that process through collaboration and open dialogue, and steering tomorrow’s agenda to improve research, education, healthcare, and policy outcomes.

• To bring together all stakeholders at the level of equals • To establish a unique and sustainable high-level forum and network • To help define the future of medicine, research and healthcare • To find answers to major health challenges – both today and tomorrow • To make global recommendations and set health agendas worldwide

MISSION The WHS mission is to bring together researchers, physicians, key government officials, and representatives from industry – as well as from NGOs and healthcare systems all over the world – to address the most pressing issues facing every facet of healthcare and medicine in the upcoming decade and beyond.

19

20

WHS PRESIDENTS

WHS SCIENTIFIC COMMITTEE & AMBASSADORS

PRESIDENTS

FORMER PRESIDENTS

WHS SCIENTIFIC COMMITTEE

WHS AMBASSADORS

The WHS Scientific Committee consists of the M8 Alliance Executive Committee and these members of the WHS Council: SHUNICHI FUKUHARA Dean School of Public Health, Kyoto University, Japan

2014 JOSÉ OTÁVIO AULER JR. Dean University of São Paulo Medical School, Brazil

2013 JOHN EU LI WONG CEO National University Health System, Singapore

DETLEV GANTEN Chairman of the Board Charité Foundation, Germany

2012 MICHAEL J. KLAG Dean Johns Hopkins Bloomberg School of Public Health, USA

2011 STEVE WESSELINGH Dean Monash University, Melbourne, Australia

2010 STEVEN K. SMITH Pro Rector (Health) Imperial College London, United Kingdom

2009 AXEL KAHN Dean Sorbonne Paris Cité, France

RIFAT ATUN Director, Global Health Systems Cluster Harvard T. H. Chan School of Public Health

DAVID DE KRETSER Professor (Reproductive Endocrinology) Monash University

MANFRED DIETEL Director, Institute of Pathology Charit鍖Universitätsmedizin Berlin

REINHARD SCHÄFERS (former) Ambassador Federal Republic of Germany

BÄRBEL-MARIA KURTH Director Robert Koch Institute (RKI)

EDUARDO PISANI Executive Director International Federation of Pharmaceutical Manufacturers & Associations

ERICH R. REINHARDT Chairman Medical Valley EMN e.V.

RAINER SAUERBORN Director Institute of Public Health, Heidelberg University

CHARLES YANKAH Chairman Afrika Kulturinstitut e.V., Berlin

HEINZ RIEDERER Managing Director iNG innovation. Nachhaltigkeit. Gesundheit

GÜNTER STOCK President ALLEA (All European Academies)

TIMO ULRICHS Head Tuberculosis-Division, Koch-MetschnikowForum e.V.

21

22

WHS COUNCIL

WHS COUNCIL

COUNCIL ALA ALWAN Regional Director, Eastern Mediterranean World Health Organization

GUDRUN DOLL-TEPPER Vice President Education German Olympic Sports Confederation

JÖRG HACKER President German Academy of Sciences Leopoldina

RIFAT ATUN Director, Global Health Systems Cluster Harvard T. H. Chan School of Public Health

GEORG DUDA•* Director, Julius Wolff Institut Charit鍖Universitätsmedizin Berlin

SIR ANDREW HAINES Professor (Public Health) London School of Hygiene & Tropical Medicine

GERD BINNIG Director Definiens AG ZULFIQAR BHUTTA Chair, Global Child Health University of Toronto JAMES CHAU Anchorman, CCTV News UNAIDS Goodwill Ambassador PIERRE CORVOL Professor (Experimental Medicine) Collège de France THOMAS CUENI Manager Interpharma, Switzerland MANFRED DIETEL•* Director, Comprehensive Cancer Center Charit鍖Universitätsmedizin Berlin

KLAUS DUGI Corporate Sen.Vice President Medicine Boehringer Ingelheim

ZSUZSANNA JAKAB Regional Director, Europe World Health Organization

THOMAS ESCHENHAGEN Director German Centers for Health Research (DZG)

STEFAN KAUFMANN Director Max Planck Institute for Infection Biology

ARMIN FIDLER Adviser Health Policy and Strategy The World Bank

ILONA KICKBUSCH Director, Global Health Program Graduate Institute Geneva

DAVID DE KRETSER Professor (Reproductive Endocrinology) Monash University TIMOTHY G. EVANS Director, Health Nutrition & Population The World Bank TEDROS GHEBREYESUS Minister of Foreign Affairs Federal Democratic Republic of Ethiopia

BÄRBEL-MARIA KURTH•* Director Robert Koch Institute (RKI) PHILIPPE MEYER Emeritus Professor French Academy of Sciences JOEL MENARD Professor, Faculty of Medicine Paris Descartes JÜRGEN MLYNEK Former President Helmholtz Association of German Research Centres

TIKKI PANG Visiting Professor for Public Policy National University of Singapore ANDREAS PENK Regional President, Europe Pfizer EDUARDO PISANI Executive Director International Federation of Pharmaceutical Manufacturers & Associations WOLFGANG PLISCHKE Former Member of the Board of Management Bayer AG MARTINA POETSCHKE-LANGER Director, Cancer Prevention German Cancer Research Center OLIVIER RAYNAUD Independent Advisor ERICH R. REINHARDT Chairman Medical Valley EMN e.V. HEINZ RIEDERER Managing Director iNG innovation. Nachhaltigkeit. Gesundheit ERNST TH. RIETSCHEL•* Chairman Berlin Institute of Health (BIH)

MATTHIAS SCHELLER•* CEO Albertinen-Diakoniewerk HANS JOACHIM SCHELLNHUBER Director Potsdam Institute for Climate Change Research THOMAS SOMMER•* Scientific Director (interim) Max-Delbrück-Centrum für Molekulare Medizin (MDC) GÜNTER STOCK President ALLEA (All European Academies) TIMO ULRICHS Head, Tuberculosis Division Koch-Metschnikow-Forum e.V. SUSANNE WEBER-MOSDORF Former Assistant Director General World Health Organization (WHO) SONJA WEINREICH Senior Health Advisor Bread for the World VERA ZYLKA-MENHORN Senior Medical Editor Deutsches Ärzteblatt * = Berlin Chapter

23

24

M8 ALLIANCE

M8 ALLIANCE: MEMBER INSTITUTIONS

MISSION

GOALS

The M8 Alliance’s vision is to harness academic excellence to improve global health.

The M8 Alliance is improving global health through pursuit of five strategic goals:

The M8 Alliance of Academic Health Centres, Universities and National Academies is a collaboration between academic institutions committed to improving global health. Working together with political and economic decisionmakers, its primary goal is to develop sciencebased solutions to health challenges all over the world.

• Developing a worldwide network of academic health science centers, and bringing together universities and healthcare providers;

This international network is the outstanding academic foundation upon which the World Health Summit – the pre-eminent annual forum for healthcare dialogue – is built. It functions as a permanent platform for framing the future considerations of global medical developments and health challenges in an equitable fashion. The M8 Alliance promotes both “bench-to-bedside” translation of research and the transformation of current medical care approaches to treating the ill. It is seeking to accomplish this through the creation of a healthcare system focused on the effective prevention of diseases, as well as the adaptation of health-related solutions to rapidly changing living conditions through research in priority areas like shifting demographics, urbanization and climate.

• Facilitating dialogue through the World Health Summit across a global network of stakeholders who are engaged with academic health science centers. These stakeholders include (among others) individuals and institutions active in government, industry and commerce, intergovernmental agencies, healthcare providers, academies of medicine and science, professional associations and the media; • Setting an agenda for global health improvement by addressing issues of interest to academic health science centers, and conveying findings and recommendations based on scientific evidence through the generation of key statements; • Positioning the M8 Alliance as an authoritative, credible and respected influence when it comes to decision-making in global health; and • Creating a knowledge base amongst M8 Alliance members, which directly involves the promotion of mutual learning, research collaboration, the enrichment of educational capabilities and enhanced clinical outcomes.

25

26

M8 ALLIANCE: LEADERSHIP

M8 ALLIANCE: LEADERSHIP

M8 ALLIANCE EXECUTIVE COMMITTEE

SHUNICHI FUKUHARA Acting International President Dean School of Public Health, Kyoto University Academic Publications

M8 ALLIANCE HEADS OF DELEGATION

JOHN EU LI WONG Past International President CEO National University Health System, Singapore

JOSÉ OTÁVIO AULER JR. Past International President Dean University of São Paulo Faculty of Medicine

Development and Membership

Medical Education

DETLEV GANTEN Founding President Chairman of the Board Charité Foundation, Germany

Australia

France

Singapore

USA

CHRISTINA MITCHELL Dean, Monash University, Melbourne

FRÉDÉRIC DARDEL President, Paris Descartes (Paris 5), Sorbonne Paris Cité

JOHN EU LI WONG CEO, National University Health System, Singapore

MICHAEL J. KLAG Dean, Johns Hopkins Bloomberg School of Public Health, Baltimore

BEN CANNY Deputy Dean, Monash University, Melbourne

GÉRARD FRIEDLANDER Dean, Faculty of Medicine, University of Paris Descartes

Switzerland

Brazil JOSÉ OTÁVIO AULER JR. Dean, University of São Paulo Faculty of Medicine EDUARDO KRIEGER President, Brazilian Academy of Sciences

AXEL RADLACH PRIES Dean of Host Institution Charit鍖Universitätsmedizin Berlin

MICHAEL J. KLAG Dean Johns Hopkins Bloomberg School of Public Health

BEN CANNY Associate Dean Monash University Faculty of Medicine

Strategic Co-operation and Stakeholder Liaison

Governance and Fundraising

ANTOINE FLAHAULT Incoming International President Director Institute of Global Health University of Geneva Joint Projects

JEAN-YVES MÉRINDOL Président, Sorbonne Paris Cité

Germany KARL MAX EINHÄUPL CEO, Charit鍖 Universitätsmedizin Berlin

Canada

AXEL RADLACH PRIES Dean, Charit鍖 Universitätsmedizin Berlin

HÉLÈNE BOISJOLY Dean, University of Montreal

Japan

TARIK MÖRÖY President, Clinical Research Institute Montreal (IRCM)

SHUNICHI FUKUHARA Dean, School of Public Health, Kyoto University

China

Russian Federation

XUETAO CAO President, Chinese Academy of Medical Sciences & Peking Union Medical College

IVAN DEDOV President, Russian Academy of Medical Sciences

International HENRI BOUNAMEAUX Dean, Faculty of Medicine, University of Geneva ANTOINE FLAHAULT Professor for Public Health, University of Geneva and Descartes, Université Sorbonne Paris Cité

Uganda NELSON K. SEWANKAMBO Principal, Makerere University

United Kingdom

DEPEI LIU Chinese Academy of Engineering

EVGENY SIDORENKO Vice-President, Russian Academy of Medical Sciences

PETER PIOT Director, London School of Hygiene & Tropical Medicine ELIO RIBOLI Director, School of Public Health, Imperial College London

LAI-MENG LOOI Co-Chair, InterAcademy Medical Panel (IAMP) STEVEN A. WARTMAN President & CEO, Association of Academic Health Centers (AAHC), USA

27

WElCOME TO THE

World health summit Berlin 2015

30

WHS STARTUP TRACK

WHS STARTUP TRACK

WHS STARTUP TRACK 2015

THE 10 FINALISTS

Innovation is the driving force behind every great improvement to human wellbeing. The World Health Summit 2015 gives a voice to startup companies taking responsibility for the improvement of global health.

The “WHS Startup Track” highlights and displays outstanding ideas and innovative business concepts that have the potential to change the way people are diagnosed, cured and informed.

Selection Startups from all over the world applied with a short digital pitch deck. The selection process took into account the originality of the concept, the financial viability of the business, evidence of fundraising or partnership ventures, and most importantly, the potential impact on global public health. Due to the 2015 celebration of 50 Years of German-Israeli Diplomatic Relations, additional credit was given to organizations with a connection to Germany and/or Israel.

Jury • Friedrich von Bohlen und Halbach (dievini Hopp BioTech holding GmbH & Co.KG) • Shari Langemak (Medscape Germany) • Jürgen Zöllner (Charité Foundation) • Hemdat Sagi (Israeli Embassy in Germany) • Mirco Dragowski /Alexander Kölpin (Bundesverband Deutsche Startups e.V.) • Kai Uwe Bindseil (Berlin Partner für Wirtschaft und Technologie) • Min-Sung Sean Kim (XLHealth) • Ana Dujic (German Federal Foreign Office)

More than 70 applications from 17 countries were assessed by the jury to select the 30 shortlisted organizations, which were subsequently invited to the World Health Summit 2015. Of these, 10 finalists will pitch their ideas in front of the audience and jury on Monday, October 12. The Winner of the WHS Startup Track 2015 will be honored at the WHS Night (see page 34 for details).

1965 - 2015 ‫ שנה‬50 ‫ליחסי הדיפלומטיי‬ ‫גרמניה‬-‫ישראל‬ 50 Jahre Diplomatische Beziehungen Deutschland-Israel

Vision Technologies UK Focus: Eye Care Technology www.givevision.net

Rewalk Robotics Israel Focus: Leg Substitution www.rewalk.com

HeartGenetics, Genetics & Biotechnology SA Portugal Focus: Genetic Testing www.heartgenetics.com

Sonormed GmbH Germany Focus: Tinnitus Treatment www.tinnitracks.com

Mediteo Germany Focus: Medication Manager www.mediteo.de

Tissue Analytics, Inc. United States of America Focus: Wound Analysis www.tissue-analytics.com

mPharma Ghana Focus: Medical Network www.mpharma.co

Viomedo UG Germany Focus: Clinical Trials www.viomedo.de

NG Needle Israel Focus: Needle Navigation Aid www.ngneedle.com

NG Need e smart.needles

Benefits The “WHS Startup Track” offers participants the chance to display their business ideas and to network with the world’s leading minds in the healthcare sector. They will establish strategic partnerships to improve their visibility and credibility with potential investors, industry, political decision makers, doctors, and patients.

TISSUEANALYTICS SIMPLIFYING WOUNDCARE

VivoSensMedical Germany Focus: Fertility www.vivosensmedical.com Pitch & Award Finalists will pitch their ideas on Monday, October 12, at 13:00 in the “Europasaal”. The winner will be awarded at the “WHS Night” on the evening of Monday October 12. Further information on the WHS Startup Track, the shortlisted companies and the finalists is available at: www.worldhealthsummit.org/the-summit/startup-track.html

31

32

NEW VOICES IN GLOBAL HEALTH

NEW VOICES IN GLOBAL HEALTH

NEW VOICES IN GLOBAL HEALTH – POSTER PRESENTATIONS The selected “New Voices” are: OCTOBER 11–12, 2015 09:00•–•17:30 OCTOBER 13, 2015 09:00•–•13:30 EUROPASAAL

The New Voices in Global Health (NVGH) initiative promotes the active participation of young scientists in the World Health Summit. It is supported by the M8 Alliance of Academic Health Centers, Universities and National Academies. The NVGH is aimed at empowering research, policy and advocacy initiatives among future leaders in global health, who are invited to send in abstracts of their scientific work and ideas. The M8 Alliance Executive Committee identified the best applications based on international academic standards. The selected candidates will present their work in a special poster exhibition, thus playing an active role in the World Health Summit.

Assef Hamdan An-Najah National University | Palestine Prevalence of Uncontrolled Hypertension among Patients Taking Anti-hypertensive Medications in Nablus Governorate – Palestine Netsanet Berhe French School of Public Health | France Prevalence and Risk Factors of Hypertension in Urban and Rural India: A Nationally Representative Survey Heiko Phillipin Kilimanjaro Christian Medical Centre | Tansania Fighting the Burden of Blindness: Establishing a Diabetic Retinopathy Network in 1 1 Low-Income Countries Caroline Ramirez Ateneo School of Medicine and Public Health | Philippines Factors affecting access to prenatal, delivery, and postpartum services in the Eastern Visayas Region, Philippines

Jacob Novignon PATH Ghana | Ghana Fiscal space for health in Sub-Saharan African countries: an efficiency approach Teeranee Techasrivichien Kyoto University | Japan Behind The Mask: a mixed method, nationwide cross-sectional study on mental and psychological correlates of mask use among Japanese high school students Dorcus Henriksson Karolinska Institutet, Stockholm | Sweden Community empowerment and dialogue with health service providers in Uganda: An approach for health systems strengthening. Experiences from the CODES project Jyoti Shrestha Asian University for Women | Bangladesh Increasing Health Literacy to Minimize Stigmatization against People with Epilepsy in Developing Countries

Xiong-Fei Pan London School of Hygiene and Tropical Medicine | UK Economic evaluation of including Haemophilus influenzae type b vaccine in the national Expanded Program on Immunization in China Jared Bakuza Dar es Salaam University | Tansania On the Factors maintaining neglected tropical diseases infections in Endemic Countries: Field Observations from a Rural Setting in Tanzania

33

34

WHS NIGHT

WHS COMMUNITY & SOCIAL MEDIA

WHS NIGHT 2015

DATE: October 12 OPENING: 6:30pm BEGINNING: 7pm LOCATION: Allianz Forum, Pariser Platz 6, 10117 Berlin

After two days of intense work with fellow World Health Summit participants from all over the world, take an evening to relax at our social event, the WHS Night. The WHS Night offers an excellent opportunity to meet and exchange with our distinguished guests including speakers, delegates and representatives from our supporting institutions. Snacks and drinks will of course be served, whilst a DJ will satisfy the needs of those who wish to dance! A shuttle service will be available for transportation between the Summit venue and the Allianz Forum, where the WHS Night will be hosted. Tickets are available for 39 Euros at the venue.

WHS COMMUNITY

SOCIAL MEDIA

The World Health Summit provides an ideal framework for networking with like-minded experts from all over the world. The WHS Community has been designed to ease the way for participants to get in touch prior to, during, and after the Summit.

The vision of the World Health Summit is improved health worldwide – catalyzed through collaboration and open dialogue. This dialogue already starts before the meeting and does not end when participants leave Berlin after three days of intense and fruitful discussions.

This networking tool offers contact details, CV and pictures of speakers and attendants to fully registered participants. Reserve your admission to this exclusive part of the WHS and optimize your WHS experience:

Stay in touch with fellow participants and the World Health Summit team via our social media outlets and be informed 365 days a year. We are looking forward to exchanging opinions and insights before, during, and after the World Health Summit via:

• Enhance your networking opportunities prior to the Summit • Gain access to profiles of other registered participants • Promote your presence by publishing your personalized participant profile, visible to all registered participants Simply click on the “Login” button at the top-right corner of our homepage’s navigation bar and type in the login data all registered participants received via email to access the WHS Community. www.worldhealthsummit.org/login

www.facebook.com/worldhealthsummit www.twitter.com/WorldHealthSmt www.linkedin.com/company/whs-foundation-gmbh This year’s Twitter handle is: #WHS2015 To access the complimentary Wi-Fi within the venue, please use: Name: WorldHealthSummit Password: #WHS2015

35

Summit Program

SUNDAY, OCTOBER 11

Program, SUN 11

Summit Program, Sunday, October 11, 2015

SUNDAY, OCTOBER 11, 2015

SUMMIT PROGRAM

39

WORKSHOP EDUCATION AND LEADERSHIP

WS02 ROOM 2 | ADENAUER 10:30•–•12:00

DEVELOPING YOUNG LEADERS IN HEALTH

HOSTS

SPEAKERS

European Students’ Conference (ESC)

Alexandra Bartsch European Students’ Conference | Fundraising | Germany

German Medical Students’ Association (bvmd) Global Health Next Generation Network (GHNGN) M8 Alliance: Monash University Universities Allied for Essential Medicines (UAEM) Young Leaders for Health (YLH) e.•V.

Karin Geffert German Medical Students’ Association (bvmd) e.V. | National Officer, Public Health | Germany

Developing young leaders in medicine and global health is crucial to improving national health and well-being. Health is a cornerstone of economic progress, sustainable development, democratic governance and global security. Many countries are embarking on efforts

to provide universal access to health care, increasing the efficiency and quality of public health services, improving health outcomes particularly for women and children. The next generation of health professionals will build the fundament for the future of health worldwide.

Ben Canny

Tanya Herfurth

Mathias Krisam

Alexandra Bartsch

Caity Jackson

Julius Murke

Karin Geffert

Joceline Kranenburg

Chris Redd

Tanya Herfurth Young Leaders for Health ( YLH) e.V. | Student | Germany

CHAIRS

Caity Jackson Women in Global Health | Associate | Sweden

Ben Canny Monash University | President, Academic Board, Faculty of Medicine Nursing and Health Sciences | Australia

Joceline Kranenburg Global Health Next Generation Network (GHNGN) | Board Member & Project Coordinator | Netherlands

Julius Murke Young Leaders for Health ( YLH) e.V. | Student | Germany

Mathias Krisam Charit鍖Universitätsmedizin Berlin | Student | Germany Chris Redd Universities Allied for Essential Medicines (UAEM) | Executive Board Member | United Kingdom

PROGRAM, SUN 11

38

SUNDAY, OCTOBER 11, 2015

SUMMIT PROGRAM

41

WORKSHOP RESEARCH AND INNOVATION

WS03 ROOM 3 | STRESEMANN 10:30•–•12:00

SUSTAINABLE RESEARCH CAPACITY STRENGTHENING AIMING BEYOND OUTBREAKS AND EMERGENCIES

HOSTS

SPEAKERS

World Health Organization (WHO)

Nancy Edwards Building Sustainable and Scalable Implementation Research Capacity: Is Community Engagement a Missing Institute of Population and Public Health (CIHR) | Scientific Director, Community Health Research Unit | Canada

M8 Alliance: World Federation of Academic Institutions for Global Health (WFAIGH) CHAIRS Garry Aslanyan World Health Organization (WHO) | Manager, Partnerships and Governance | Switzerland Pierre Buekens Tulane University | W. H. Watkins Professor & Dean, School of Public Health and Tropical Medicine (SPHTM) | United States of America

Jill Gilmour Building and Sustaining Research Capacity: Perspectives from IAVIs Work in Eastern Africa Imperial College London | Head, IAVI’s Human Immunology Laboratory | United Kingdom Thomas Kariuki Research Capacity Building in Africa: The AESA Approach Alliance for Accelerating Excellence in Science in Africa (AESA) | Director | Kenya Chris Lewis Experiences of Funding Research during the Ebola Crisis Department for International Development (DFID) | Health Advisor | United Kingdom

Michael Makanga European-African Capacity Building Partnerships on Emerging Infectious Diseases European and Developing Countries Clinical Trials Partnership (EDCTP) | Head of Africa Office, South South Cooperation | South Africa

John Reeder Suistainable Research Capacity Strenghtening World Health Organization (WHO) | Director, Special Program for Research and Training in Tropical Diseases | Switzerland

The Ebola outbreak in West Africa exposed the fragility of the health systems and lack of health research capacity. In the 24 previous occurrences of Ebola, the virus was controlled early by rapid response, active surveillance and quarantine. This time, the outbreak occurred in countries recovering from conflict, without the health infrastructure or quantity/quality of trained personnel to effectively deal with the problem. The outbreak catalysed a number of research and development activities that were focused on delivering effective therapeutic, diagnostic and preventive interventions. However, the successful testing and implementation of these interventions required the availability of functioning health research infrastructures and increased research capacity

in the affected countries, as well as willingness of affected populations to engage in research activities. This panel will discuss how to build and strengthen regional, national, institutional and individual capacities to conduct high quality health research (e. g. clinical trials, operational and/or implementation research) during infectious disease outbreaks resulting in health emergencies. It will critically assess what types of efforts would ensure sustainable research capacity building beyond outbreaks and emergencies that would result in an increased health system preparedness and community engagement in research. Panellists will share their current and future plans as well as global collaboration efforts under way towards achieving these goals.

Garry Aslanyan

Thomas Kariuki

Pierre Buekens

Chris Lewis

Nancy Edwards

Michael Makanga

Jill Gilmour

John Reeder

PROGRAM, SUN 11

40

SUNDAY, OCTOBER 11, 2015

SUMMIT PROGRAM

43

WORKSHOP

WS04 ROOM 4 | STRESEMANN 10:30•–•12:00

UNDERSTANDING OPPORTUNITIES AND CONTRADICTIONS BETWEEN HUMANITARIAN HEALTH ASSISTANCE VERSUS HEALTH SYSTEM SUPPORT IN CONFLICT-AFFECTED STATES HOSTS

SPEAKERS

Harvard Medical School

Christian Janke Munich Centre for Global Health Security | Co-Founder | Germany

LinkGlobalHealth.org Initiative CHAIRS Margaret Bourdeaux Brigham and Women’s Hospital Boston | Instructor in Medicine, Global Health Equity | United States of America Christian Haggenmiller LinkGlobalHealth.org | Co-Founder | Germany

Fatime Arenliu Qosaj Post Conflict Health System Development in Kosovo Ministry of Health | Kosovo Nezar Ismet Taib Providing Public Health During Conflict Directorate General of Health in Duhok Governorate | General Director | Iraq Florian Westphal Humanitarian Assistance in Complex Emergencies Médecins Sans Frontières (MSF) | Managing Director | Germany

Recent armed conflicts have stripped fragile states of health infrastructure, workforces, supply chains, records, and instruments of health governance. As a result, the 1.2 billion people living in these fragile and conflict-affected states shoulder an outsized burden of disease. These populations account for half of the world’s HIV infected, a third of its TB, half of its infant mortality and a third of its maternal mortality. Most diseases with pandemic potential emerge first in fragile states. Worse, studies show civilian mortality and morbidity increase after the cessation of conflict and remain high for decades after the end of hostilities, never returning to pre-conflict baselines in many cases. Yet, despite multiple international agreements urging donors to invest in health system recovery and rebuilding, donors collectively are more reluctant to do so than they were a decade ago. One reason for this reluctance is that supporting indigenous institutions of any kind is fundamentally a political act and thus cuts against traditional humani-

tarian notions of engaging in these states in neutral and impartial ways, independent from political influence. A second related reason springs from the concern that the ways indigenous health sectors may allocate resources or undertake initiatives can fuel conflict; thus support will only propagate conflict dynamics. It is clear international actors need better ways to protect and recover health systems in conflict-affected states – methods that honor the spirit of the humanitarian movement and its call to ‘lessen human suffering from armed conflict’ and yet also support the emergence of indigenous health systems and institutions that can deliver coordinated, need-based and well-resource health care to their populations for years to come. This workshop will consider this thorny problem, hearing from indigenous health sector leaders, humanitarian organization personnel, fragile state health system researchers, and development and security organization actors.

Margaret Bourdeaux

Christian Haggenmiller

Florian Westphal

PROGRAM, SUN 11

42

SUNDAY, OCTOBER 11, 2015

SUMMIT PROGRAM

45

WORKSHOP EVIDENCE TO POLICY

WS05 ROOM 1 | BRANDT 13:00•–•14:30

QUALITY IMPROVEMENT & PATIENT SAFETY NATIONAL STANDARDS OF CARE

HOSTS

SPEAKERS

Geneva Health Forum

Benedetta Allegranzi Successful Models to Reduce Patient Harm due to Infection Through Safety Climate Improvements University of Geneva | Professor, Institute of Global Health | Switzerland

M8 Alliance: National University of Singapore (NUS) 6TH EDITION

APRIL 19-21 2016

Andreas Roos VAMED Management und Service Schweiz AG I CEO I Switzerland

M8 Alliance: University of Geneva (UGE) VAMED CHAIRS José Otávio Auler Jr. University of São Paulo Medical School I Dean I Brazil John Eu Li Wong National University of Singapore | Dean | Singapore

Robert Andrew Johnstone The Empowered Patient as a Part of the Team Managing Quality & Safety European Patients Forum (EPF ) | Board Member | United Kingdom Daphne Khoo National Standards for Healthcare•–• The Singapore Experience Ministry of Health | Group Director, Healthcare Performance Group | Singapore Aymeric Lim Systems Approach to Improving Quality and Safety in the National University Hospital National University Hospital | Chairman of the Medical Board | Singapore

Patient safety issues are the avoidable errors in healthcare that can cause harm to patients. Harm in this context means injury, suffering, disability or death. Not all harm is avoidable. Some treatments or drugs are expected to cause harm, such as chemotherapies or certain drug therapies. Rare allergic reactions, for example, are “expected” in the sense that

Anupam Sibal Patient Safety and Quality•–• Beyond Accreditation Apollo Hospitals Group | Group Medical Director | India Indraprastha Apollo Hospitals | Senior Consultant Pediatric Gastroenterologist and Hepatologist | India

they will happen to a very small number of patients – we just can’t predict which ones. But these are not patient safety issues. Patient safety improvement is about tackling the causes of errors in care that can come from bad working environments or the lack of training and support for staff.

Benedetta Allegranzi

Aymeric Lim

José Otávio Auler, Jr.

Andreas Roos

Robert Andrew Johnstone

Anupam Sibal

Daphne Khoo

John Eu Li Wong

PROGRAM, SUN 11

44

SUNDAY, OCTOBER 11, 2015

SUMMIT PROGRAM

47

WORKSHOP GLOBAL HEALTH FOR DEVELOPMENT

WS06 ROOM 2 | ADENAUER 13:00•–•14:30

MIGRATION AND REFUGEE HEALTH MAINTAINING HEALTHCARE

HOSTS

SPEAKERS

Bielefeld University

Philipa Mladovsky Migration and Health in Europe•–• Challenges for Health Systems and Policy London School of Economics and Political Sciences | Professor, International Development | United Kingdom

Pulitzer Center on Crisis Reporting CHAIRS Zulfikar G. Abbany Deutsche Welle | Science Editor | Germany Alexander Krämer Bielefeld University | Professor and Chair | Germany Charles Yankah African Cultural Institute e.V. (ACI) | President | Germany

Christian Haggenmiller Refugee Health Challenges and Opportunities LinkGlobalHealth.org | Co-Founder | Germany Samuel Loewenberg The Refugee Health Crisis Pulitzer Center on Crisis Reporting | Journalist | United States of America Roumyana Petrova-Benedict Overview of Migration Health in Europe International Organization for Migration (IOM) | Senior Regional Migration Health Manager for Europe and Central Asia | Belgium

The current migration wave to Western Europe is unmatched in the history of the continent, sign and symptom of the recent globalization process and the increasing political unrest in diffe rent parts of the world. This migration is massive, unprecedented, extremely diverse and mostly unregulated. In Germany, the number of asylum seekers increased from 30,100 persons in the year 2006 to 202,834 persons in 2014 and is expected to grow up to 1 million in 2015. In the future migration into Europe will become a routine for which Germany and other European countries ought to be prepared.

nomic prospects for migrants and their families in countries of destination.

There are multiple driving forces like civil wars and political instability as well as environmental degradation due to extreme weather events and climate change in countries of origin. On the other hand these forces include better life and eco -

In the workshop renowned experts in migrant and refugee health and international journalists will present their views of this currently most burning problem in Europe.

Established migration concepts like pull and push factors and the so-called healthy migrant effect are not sufficient to explain and understand the impacts on health and society of this global phenomenon. New concepts are needed to adapt health policy strategies that take into account the social transformation processes in sending and receiving regions. These policies need to respect various domains, internal as well as external policies, in order to refer to the concept of “health in all policies”.

Zulfikar G. Abbany

Philipa Mladovsky

Christian Haggenmiller

Roumyana Petrova-Benedict

Alexander Krämer

Charles Yankah

Samuel Loewenberg

PROGRAM, SUN 11

46

SUNDAY, OCTOBER 11, 2015

SUMMIT PROGRAM

49

WORKSHOP RESEARCH AND INNOVATION

WS07

BIG DATA

ROOM 3 | STRESEMANN 13:00•–•14:30

HOSTS AbbVie Deutschland GmbH & Co.•KG Elsevier GmbH M8 Alliance: Johns Hopkins Bloomberg School of Public Health CHAIRS Tarik Möröy Clinical Research Institute Montreal | President and Scientific Director | Canada Ingo Ruczinski Johns Hopkins Bloomberg School of Public Health | Professor, Biostatistics | United States of America SPEAKERS Jeffrey Leek Personalized Medicine is a Population Health Intervention Johns Hopkins Bloomberg School of Public Health | Professor, Biostatistics | United States of America

Olaf Lodbrok Connecting Basic Research and Healthcare Big Data Elsevier GmbH | Managing Director, Health Analytics EMEA/LA | Germany Jonathan Mangion Thermo Fisher Inc. | Senior Manager, Bioinformatics Next Generation Sequencing, Live Technologies | United Kingdom Lydia Pintscher Wikidata: Giving More People More Access to More Knowledge Wikimedia Deutschland–Gesellschaft zur Förderung Freien Wissens e.V. | Product Manager | Germany

Healthcare produces data, Big Data. Every day laboratory results, patient histories, trial outcomes, surgery reports and many more are collected continuously by healthcare systems worldwide. Today, modern ascertainment systems, storing devices and the Internet make it possible to gather, save and share all this data more efficiently. These circum-

stances provide great opportunities for the medical enterprise and bring enormous potential especially in the field of Personalized Medicine in which, establishing models based on big amounts of data is a central element. However, the potential of Big Data has not been reached so far.

Jeffrey Leek

Lydia Pintscher

Olaf Lodbrok

Ingo Ruczinski

Jonathan Mangion

Jutta Ulbrich

Jutta Ulbrich Realizing the Potential of Big Data Requires a Dialogue of all Stakeholders Involved AbbVie Deutschland GmbH & Co.KG | Head, Patient Engagement | Germany Tarik Möröy

PROGRAM, SUN 11

48

SUNDAY, OCTOBER 11, 2015

SUMMIT PROGRAM

51

WORKSHOP GLOBAL HEALTH FOR DEVELOPMENT

WS08 ROOM 4 | RATHENAU 13:00•–•14:30

CIVIL SOCIETY PARTICIPATION IN HEALTH POLICY PROCESSES

HOSTS Brot für die Welt –  Evangelischer Entwicklungsdienst Oxfam Deutschland e.•V. CHAIRS Susan Purcell Gilpin World Council of Churches (WCC) | Program Executive, Health and Healing | Switzerland Mareike Haase Brot für die Welt–Evangelischer Entwicklungsdienst | Policy Advisor, Health | Germany Barbara Kühlen Oxfam Deutschland e.V. | Advisor, Global Health Policy | Germany SPEAKERS Björn Kümmel Civil Society Participation in Health Policy Processes•–•A German Governmental Perspective Federal Ministry of Health (BMG) | Deputy Head, Global Health | Germany

Shecku Kawusu Mansaray How Community Mobilization was a Key to Fight the Ebola Crisis in Sierra Leone Sierra Leone Adult Education Association (SLADEA) | Advisor | Sierra Leone Martin Ekeke Monono Institutionalized Engagement with Civil Society on Country Level World Health Organization (WHO) Regional Office for Africa | Coordinator, Organization of Service Delivery | Congo Kenneth Mwehonge Are Civil Society Organizations Equal Partners at the Negotiation Table in Shaping National Health Policy? Coalition for Health Promotion and Social Development (HEPS) | Program Officer, Advocacy and Networking | Uganda Cornelia Ulbert The Global Health Architecture in the Year 2015: Room for Meaningful Participation of Civil Society? Duisburg-Essen University | Scientific Director, The Institute for Development and Peace (INEF ) | Germany

Based on a human rights approach, people – often represented by Civil Society Organisations (CSOs) – are recognized as key actors in their own development and protectionists for their right to health, rather than passive recipients of commodities and services. Nonetheless, CSOs are often acting as a ‘gap filler’ in terms of service provision, stepping into doing what governments cannot or fail to do and not perceived as an equal partner in developing strategies and instruments for achieving Health for All. This is often related to a not-involving attitude of governments and parts of the international community, but occasionally also to the lack of capacity of CSOs to engage. Thus, even CSOs often play a crucial role in terms of advocacy and accountability, their participation and voice in policy and decision making processes is still very limited. The Ebola outbreak in 2014 dramatically illustrated that many health systems are too weak to cope with a serious health crisis. As communities and CSOs played a key role in the emergency response and controlling the spread of Ebola, it is crucial to involve them as an important partner in the elaboration of future res-

ponse strategies and their implementation and to build on lessons learned for a future strategy against health crises and in achieving Universal Health Coverage. In the last years the World Health Organisation (WHO) has given strategic prominence to the renewal of the concept of Primary Health Care, focussing also on an institutionalized participation of civil society in policy dialogue and accountability mechanisms. The workshop aims on analyzing the following questions: How does the Global Health Architecture look like in the year 2015? How are CSOs involved in shaping the agenda and what is their role? How can CSOs engage more meaningfully with political and decision making processes and how can we bene fit more from their experiences and capacities? What do CSOs perceive as major challenges, what are examples of best practice? How does WHO engage with CSOs and foster their capacities and participation in global health processes? Can a stronger and more institutionalized relationship between WHO and CSOs support WHO’s role as a responsive global health agency?

Susan Purcell Gilpin

Shecku Kawusu Mansaray

Mareike Haase

Martin Ekeke Monono

Barbara Kühlen

Kenneth Mwehonge

Björn Kümmel

Cornelia Ulbert

PROGRAM, SUN 11

50

SUNDAY, OCTOBER 11, 2015

SUMMIT PROGRAM

53

WORKSHOP RESEARCH AND INNOVATION

WS09 ROOM 1 | BRANDT 15:00•–•16:30

SOCIAL ENTREPRENEURS AND TRADITIONAL SOCIAL ORGANIZATIONS MAKING MORE HEALTH

HOSTS Boehringer Ingelheim GmbH & Co.•KG Karl Kübel Stiftung für Kind und Familie CHAIRS Kerstin Maria Humberg Karl Kübel Stiftung für Kind und Familie | Vice Chairperson of the Foundation Council | Germany Michael Rabbow Boehringer Ingelheim GmbH & Co.KG | Team Leader, Corporate Affairs | Germany SPEAKERS Sylvester Osei Ageykum Making More Health Boehringer Ingelheim GmbH & Co.KG | Corporate Communications & Public Affairs | Ghana Krystian Fikert MyMind: Making More Health Through Social Innovation. A Social Entrepreneur Meets Corporate MyMind Ltd. | CEO | Ireland

Frank Kornely Managers Onsite: An Exposure Week in India•–•Social and Entrepreneurial Learnings Boehringer Ingelheim GmbH & Co.KG | Team Leader, Cardiovascular Marketing | Germany Manuela Pastore Making More Health: Partnering “Across the Borders” is Like a Startup Boehringer Ingelheim GmbH & Co.KG | Leading Manager, Team Making More Health I Communications | Germany Ralf Tepel The MMH Pilot Project: Doing the First Steps Together•–• Seen from the NGO Perspective Karl Kübel Stiftung für Kind und Familie | Member of the Board, Development Cooperations | Germany

Making More Health (MMH) is a global initiative run by Boehringer Ingeheim (BI) to identify, support and scale social entrepreneurial solutions to global health challenges. Together with Ashoka (the largest global network of social entrepreneurs) we explore innovative pathways with non-traditional stakeholders to make more health happen for individuals, families and communities by including its employees throughout the process. The knowledge of social entrepreneurship approaches and projectspecific implementation are reinforced – inside and outside the company. Volunteering and Youth Venture Programmes as well as an Executive in Residence program for the employees are part of the initiative. “Co-Creation and collaboration with unusual partners and across the different sectors, that’s what we are looking for now. There is much more in it, if we just try…” says Manuela Pastore, MMH core project manager at BI. The workshop session will focus on this innovative partnering and explain via the MMH pilot project in India how a social entrepreneurial initiative driven by a pharma business and Ashoka and traditional NGO activities can be combined to create a win-win to all: to the

people in need, the NGO and business world, and social entrepreneurial ideas. Michael Rabbow from Boehringer Ingelheim and Kerstin Maria Humberg from the KKS (Karl Kübel foundation) open the session with thoughts on the potential of co-creation among the business and social world. Manuela Pastore will highlight some relevant aspects and key challenges to make co-creation happen – inside the company and outside – and introduces into the MMH pilot project in India. The speakers, all actively involved into the example MMH pilot project in India will share the different standpoints, chances and challenges of such a collaborative approach: Ralf Tepel, representing the Karl Kübel Institute for Development Education in India, represents the “social” world and introduce into the main activities run together with Boehringer Ingelheim during the MMH pilot project. As a participant of the MMH exposure week in India, Frank Kornely, manager from Boehringer Ingelheim, explains how the exposure led to changemaking ideas and leadership learnings inside the company. The Irish MMH and Ashoka fellow, Krystian Fikert, will explain how in this collaboration even social entrepreneurial ideas can grow. A final discussion with all workshop participants is very welcome!

Sylvester Osei Ageykum

Manuela Pastore

Krystian Fikert

Michael Rabbow

Frank Kornely

Ralf Tepel

PROGRAM, SUN 11

52

SUNDAY, OCTOBER 11, 2015

SUMMIT PROGRAM

55

WORKSHOP EDUCATION AND LEADERSHIP

WS10 ROOM 2 | ADENAUER 15:00•–•16:30

MEDICAL EDUCATION WHY DON’T DOCTORS AND PATIENTS FOLLOW EVIDENCE AND WHAT CAN BE DONE ABOUT IT?

HOSTS

SPEAKERS

M8 Alliance: Monash University

Sophia Ang Safety and Evidence (Hospital Setting): The Art and Science of Achieving Compliance in Doctors• –•Our Experience in•Closed Loop Communication of Critical Results and Correct Site Surgery Checklists National University Health Services (NUHS) | Vice Chairman, Medical Board | Singapore

M8 Alliance: National University of Singapore (NUS) M8 Alliance: National University Health System Singapore (NUHS) CHAIRS Shing Chuan Hooi National University of Singapore (NUS) | Vice Dean (Education), Yong Loo Lin School of Medicine | Singapore Dujeepa Samarasekera National University Health System (NUHS) | Director, Yong Loo Lin School of Medicine, Centre for Medical Education (CenMED) | Singapore

Yee Keow Chiong Behaviour Change and Evidence in the Community: Neighbourhood Health Service National University Health System (NUHS) | Resident, Paediatric Medicine | Singapore Paul Glasziou An Overview of Evidence Based Practice Bond University | Head, Faculty of Health Sciences and Medicine | Australia Dragan Ilic Strategies for Teaching EBM to Health Care Professional Students Monash University | Head, Medical Education Research and Quality Unit (MERQ) | Australia

Susan Michie Health Psychology•–•Changing Behaviour in Health Professionals University College London | Director, UCL Centre for Behaviour Change | United Kingdom

Joanne Yoong Health Economics: The Economic Cost of Non-adherence by Patients and Physicians National University of Singapore (NUS) | Professor, Health Economics | Singapore

The last thirty years has seen an explosion in the discipline of Evidence Based Medicine, to the extent that it is now the pervasive and dominant paradigm guiding clinical practice. The principles of EBM inform health professionals’ decision making by integrating the best available evidence with clinical expertise and patient values. Competency in EBM requires that clinicians are competent across a variety of disciplines including clinical epidemiology, biostatistics, information science and knowledge transfer.

implement a form of continuous quality improvement; and be willing to change behaviour with respect to the adherence to evidence.

For evidence of best practice to be adopted by clinicians, it must survive the ‘evidence pipeline’. Clinicians must be able to implement the five steps of EBM;

Despite its ascent, it is clear that for many practitioners and patients care and selfmanagement is conducted ignoring much available evidence. This extends from the lack of adherence to guidelines and consensus statements, irregular prescription of therapeutic interventions to the failure of the adoption of lifestyle interventions for common, preventable non-communicable diseases. In this session we will explore various challenges to the use of evidence in health, and how educational strategies might overcome these.

Sophia Ang

Dragan Ilic

Yee Keow Chiong

Susan Michie

Paul Glasziou

Dujeepa Samarasekera

Shing Chuan Hooi

Joanne Yoong

PROGRAM, SUN 11

54

SUNDAY, OCTOBER 11, 2015

SUMMIT PROGRAM

57

WORKSHOP RESEARCH AND INNOVATION

WS11 ROOM 3 | STRESEMANN 15:00•–•16:30

WHS SCIENCE & INDUSTRY CIRCLE

HOSTS

SPEAKERS

Fraunhofer-Institut für Bildgestützte Medizin MEVIS

Alexander Kekulé Universitätsklinikum Halle (Saale) UKH | Director, Institute for Medical Microbiology | Germany

German Healthcare Partnership (GHP) CHAIRS Detlev Ganten World Health Summit President Charité Foundation | Chairman of the Board | Germany Roland Göhde Sysmex Partec GmbH | Senior Managing Director | Germany German Healthcare Partnership (GHP) | Chairman of the Board | Germany Horst Karl Hahn Fraunhofer Institute for Medical Image Computing MEVIS | Head of Institute | Germany

Jochen Maas Sanofi-Aventis Deutschland GmbH | Director, Research and Development | Germany Markus Neumann Bioscientia–Institut für Medizinische Diagnostik GmbH | Managing Director, International Business | Germany Stefan Oelrich Sanofi Aventis Deutschland GmbH | General Manager, Commercial Operations | Germany Hagen Pfundner Roche Pharma AG | Managing Director | Germany Verband Forschender Arzneimittelhersteller e.V. (vfa) | Chairman of the Board | Germany Ernst Th. Rietschel Berlin Institute of Health (BIH) | Chairman of the Board of Directors | Germany

Andreas Vilcinskas Fraunhofer Society | Head of the Project Group “Bio-Ressources” | Germany

State Senator Cornelia Yzer Federal Government Berlin | Senator for Economics, Technology and Research | Germany

Germany looks back on a unique tradition in the field of Life Sciences and Health Industry. The close cooperation between science and economy is key to this success and accelerates the result-orientated translation process from basic research to the application in patient care and product development. The “World Health Science & Industry Circle” (WHS-SIC), jointly launched in June 2015 by the World Health Summit, the Fraunhofer-Gesellschaft (FHG) and the German Healthcare Partnership (GHP), aims to intensify the dialogue between science and industry, to activate, establish and expand national

and international networks and to improve structures and pro cesses through translational and applied sciences that lead to market-ready products which are essential to improve the health of people in need and global health worldwide. Progress in health and health systems will only be sustainable and successful if academia, the private sector, politics and civil society take responsibility and closely work together. WHS-SIC also actively participates in the World Health Summit and uses this international forum to create new opportunities for exchange and collaboration.

Detlev Ganten

Markus Neumann

Andreas Vilcinskas

Roland Göhde

Stefan Oelrich

Cornelia Yzer

Horst Karl Hahn

Hagen Pfundner

Jochen Maas

Ernst Th. Rietschel

PROGRAM, SUN 11

56

SUNDAY, OCTOBER 11, 2015

SUMMIT PROGRAM

59

WORKSHOP GLOBAL HEALTH FOR DEVELOPMENT

WS12 ROOM 4 | RATHENAU 15:00•–•16:30

GLOBAL HEALTH: RESEARCH AND DEVELOPMENT

HOSTS

SPEAKERS

Drugs for Neglected Diseases initiative (DNDi)

Ann Aerts The Relationship Between R&D and Effective Healthcare Delivery in low-Income Settings Novartis Foundation | Director | Switzerland

Global Health Innovative Technology Fund (GHIT ) CHAIRS Kei Katsuno Global Health Innovative Technology Fund (GHIT ) | Director, Investment Strategy & Development | Japan Jean-Pierre Paccaud Drugs for Neglected Diseases initiative (DNDi) | Director, Business Development | Switzerland

Robert Arch NTDs as a Sustainable Business Investment: Cross-Sector Glbal Health R&D Collaboration in the 21st Century Takeda Pharmaceutical Company Ltd. | Director, Value Creation Alternatives | United States of America David Reddy Relevance of Global Health R&D in the Age of SDGs Medicines for Malaria Venture (MMV) | CEO | Switzerland Lorenzo Savioli Importance of Cross-Sector Partnerships and High-Level Policy Buy-in Global Schistosomiasis Alliance (GSA) | Chair of the Executive Group| Switzerland

The magnitude of the infectious disease problem in the developing world and the failure of the commercial market to catalyze needed health solutions serve as critical obstacles to global economic development and prosperity. Over the past decade, innovative R&D partnerships have given rise to unprecedented hope: several drugs and vaccines are now being developed for malaria, tuberculosis, Chagas disease and other neglected tropical diseases. What shifted?

The simple acknowledgement that not one sector or institution can solve the big global health challenges alone. Companies need to share the technical and financial risk with governments and charities. Rapid air travel and urbanization make global health R&D more critical than ever, and now is the time for countries to harness their research and industry expertise and know-how for game-changing partnerships.

Ann Aerts

Jean-Pierre Paccaud

Robert Arch

David Reddy

Kei Katsuno

Lorenzo Savioli

PROGRAM, SUN 11

58

60

SUNDAY, OCTOBER 11, 2015

SUMMIT PROGRAM

61

KEYNOTE

KEY01 PLENARY HALL | WELTSAAL 17:00•–•21:00

OPENING CEREMONY & RECEPTION

STATEMENTS OF YOUNG LEADERS IN HEALTH Roopa Dhatt Initiative Director | Women Leaders in Global Health Initiative (WLGHI) | United States of America

HOSTS

SPEAKERS

German Federal Foreign Office (AA)

Hermann Gröhe Federal Ministry of Health (Bundesministeriuim für Gesundheit) | Federal Minister of Health | Germany

German Federal Ministry of Health (BMG) M8 Alliance World Health Organzation (WHO) CHAIRS Shunichi Fukuhara World Health Summit President, Kyoto University | Dean, Vice President, School of Public Health, Vice President Department of Healthcare Epidemiology | Japan Detlev Ganten World Health Summit President Charité Foundation | Chairman of the Board | Germany

Myriam El Khormi Ministry of Social Affairs and Employment (Ministère du Travail, de l’Emploi et du Dialogue social) | Minister of Social Affairs and Employment | France

Hermann Gröhe

Axel R. Pries

Margaret Chan

Shunichi Fukuhara

Victor J. Dzau

Detlev Ganten

Aymen Meddeb Founder and President | Young Leaders for Health e.V. | Germany Lana Zaim Public Relations and Applicants’ Support | 26th European Students’ Conference | Germany

Margaret Chan World Health Organization (WHO) | Director General | Switzerland Victor J. Dzau National Academy of Medicine | President | United States of America Birgit König Allianz Private Krankenversicherungs-AG | CEO | Germany Axel R. Pries Charit鍖Universitätsmedizin Berlin | Dean | Germany

Birgit König

PROGRAM, SUN 11

GLOBAL HEALTH FOR DEVELOPMENT

Summit Program

MONDAY, OCTOBER 12

Program, Mon 12

Summit Program, Monday, October 12, 2015

64

M ONDAY, OCTOBER 12, 2015

SUMMIT PROGRAM

65

PANEL DISCUSSION

SYM01 PLENARY HALL | WELTSAAL 9:00•–•10:30

ANTIMICROBIAL RESISTANCE

HOSTS M8 Alliance: National University of Singapore (NUS) Robert Koch Institute (RKI) CHAIRS Lothar Wieler Robert Koch Institute (RKI) | President | Germany John Eu Li Wong National University of Singapore (NUS) | Dean | Singapore SPEAKERS Manica Balasegaram Innovation and Access in the Fight Against AMR Médecins Sans Frontières (MSF) | Executive Director, Access Campaign | Switzerland Sally Davies AMR•–•The Global Problem Government UK Department of Health | Chief Medical Officer | United Kingdom

Marie-Paule Kieny Implementing the Global Action Plan on AMR World Health Organization ( WHO) | Assistant Director-General, Health Systems and Innovation | Switzerland Lewis Schrager TB Vaccine Development: A Critical, Long-Term Investment Strategy in Combatting the Spread of DrugResistant Mycobacterium Tubercolosis Aeras | Vice-President, Scientific Affairs | United States of America BT Slingsby The Necessity of Global Health R&D in the Context of Antimicromial Resistance Global Health Innovative Technology Fund (GHIT ) | Executive Director and CEO | Japan Ada E. Yonath Species-Specificity in Infectious-Diseases Susceptibility and the Microbiome Weizmann Institute of Science | Director, Helen and Milton A. Kimmelman Center for Biomolecular Structure and Assembly | Israel

Antimicrobial resistance (AMR) is defined as the resistance of a microorganism to an antimicrobial drug that was originally effective for treatment of infections caused by it. Standard treatments become ineffective and infections persist, increasing the risk of spread to others. New resistance mechanisms emerge and spread globally, thus threat-

ening our ability to treat common infectious diseases, resulting in death and disability of individuals whom until recently could continue a normal course of life. Without effective anti-infective treatment, many standard medical treatments will fail or turn into very high risk procedures.

Manica Balasegaram

BT Slingsby

Sally Davies

Lothar Wieler

Marie-Paule Kieny

John Eu Li Wong

Lewis Schrager

Ada E. Yonath

PROGRAM, MON 12

RESEARCH AND INNOVATION

M ONDAY, OCTOBER 12, 2015

SUMMIT PROGRAM

67

WORKSHOP GLOBAL HEALTH FOR DEVELOPMENT

WS13

CULTURES AND HEALTH

ROOM 1 | BRANDT 9:00•–•10:30

HOSTS

SPEAKERS

M8 Alliance: Charité•–•Universitätsmedizin Berlin

Andreas Heinz Urbanicity, Poverty and Minority Status•–• Mental Health in Inner Cities Charit鍖Universitätsmedizin Berlin | Director, Clinic for Psychiatry and Psychotherapy | Germany

Stiftung Preussischer Kulturbesitz (SPK) CHAIRS Detlev Ganten World Health Summit President Charité Foundation | Chairman of the Board | Germany H. E. Reinhard Schäfers WHS Foundation GmbH–World Health Summit | Ambassador | Germany Günter Stock Berlin-Brandenburg Academy of Sciences and Humanities (BBAW ) | President | Germany

Inge Missmahl Treating People in Seemingly Hopeless Situations•–•Implementing Mental Health in Afghanistan Ipso gemeinnützige Gesellschaft mbH | Founder and Director | Germany David Napier The Cultural Determinants of Health and Wellbeing University College London | Director, Department of Anthropology | United Kingdom Jalid Sehouli Culture & Women’s Health Charit鍖Universitätsmedizin Berlin | Director, Clinic for Gynecology | Germany Michael Stanley-Baker Max Planck Institute for the History of Science | Postdoctoral Research Fellow | Germany

Paul Ulrich Unschuld Patient-Physician Relationship: A Matter of Trust Charit鍖Universitätsmedizin Berlin | Director, Horst-GoertzInstitute for the Theory, History and Ethics of Chinese Life Sciences | Germany

Ella Watson-Stryker Impact of Culture on Treatment of Patients During the Ebola Crisis Médecins Sans Frontières (MSF) | Manager, Health Promotion | United States of America

Cultural diversity is defined as the differences that exist in the world, a society or an institution. This concept is important to understand and take into account when trying to bring about transformative ideas to a society, especially concerning the healthcare of the public. Recent catastrophic events such as the 2011 Earthquake and Tsunami in Japan, or the 2014 and continuing Ebola crisis in

West Africa have highlighted the need for healthcare workers to be properly trained in respect to the cultural diversity in these countries in order to provide adequate help. In the current climate of expansion of noncommunicable diseases in the world, it is very important for all the stakeholders to be aware and properly informed about this topic when developing solutions to the public health issues in their countries.

Detlev Ganten

Reinhard Schäfers

Paul Ulrich Unschuld

Andreas Heinz

Jalid Sehouli

Ella Watson-Stryker

Inge Missmahl

Michael Stanley-Baker

David Napier

Günter Stock

PROGRAM, MON 12

66

M ONDAY, OCTOBER 12, 2015

SUMMIT PROGRAM

69

WORKSHOP GLOBAL HEALTH FOR DEVELOPMENT

WS14 ROOM 2 | ADENAUER 9:00•–•10:30

NEWBORN MORTALITY REDUCING NEONATAL DEATH

HOST M8 Alliance: Monash University CHAIRS Ben Canny Monash University | President, Academic Board, Faculty of Medicine Nursing and Health Sciences | Australia Euan Wallace Monash University | Professor and Obstetrician, Department of Obstetrics & Gynaecology | Australia SPEAKERS Hege Ersdal Delayed Cord Clamping: Reducing Newborn Mortality in sub-Saharan Africa Stavanger Acute medicine Foundation for Education and Research (SAFER) | Project Manager and Principal Investigator, Stavanger University Hospital, Departments of Health Studies | Norway

Jessica Holden Providing Newborn Care in a Conflict Zone Médecins Sans Frontières (MSF ) | Doctor, Obstetrics and Gynaecology | Australia Jayasree Iyer Progress Towards Therapy for Reducing Newborn Mortality Access to Medicine Foundation | Head, Global Health and Research | Netherlands Vishwajeet Kumar Enculturating Science•–•From Scientific Evidence to Community Impact Shivharh Community Empowerment Lab | Founder and CEO | India Graeme Polglase The Physiology of the Newborn Transition Monash University | Research Group Head, Perinatal Transition | Australia

Every year worldwide about 3 million babies die within the first month of life. Of these, about one million die within 24 hours of birth and three of four die within the first week of life. As a proportion of child deaths, these neonatal deaths represent about 40% of all deaths of children under the age of 5 – a proportion that is increasing. If the Millennium Goal 4 of reducing early child mortality by two thirds is to be achieved, then action to reduce neonatal deaths – deaths within the first week of life – is urgently required. As Joy Lawn and colleagues appealed “Innovative approaches are required to…improve care in settings where far too many babies do not cry at birth”.

increasing attendance rates in labor, birth asphyxia remains the major cause of death within the first 24 hours. For example, in India, where 60% of women are attended by a skilled care provider in labor, a third of all neonatal deaths occur within the first day – and of these a third are due to birth asphyxia. Overall, birth asphyxia ranks eighth as a global burden of disease, with estimated numbers of disability-adjusted life years (DALYs) due to birth asphyxia exceeding those due to all childhood conditions preventable by immunization. If we are to reduce neonatal death rates, and improve child health among survivors, then the consequences of birth asphyxia must be tackled.

To date, approaches to improve neonatal outcome have been, justifiably, focused on ensuring that women are attended by a trained health professional in labour and on simple measures to protect the baby from infection and cold. However, even in low resource countries that have

Using experiences from resource-limited settings, this session will illustrate how cheap cost-effective training of basic healthcare workers can be integrated with experimental research to improve care and introduce novel therapies, re ducing asphyxia mortality and morbidity.

Ben Canny

Vishwajeet Kumar

Hege Ersdal

Karsten Lunze

Jessica Holden

Graeme Polglase

Jayasree Iyer

Euan Wallace

DISCUSSANT Karsten Lunze Boston University School of Medicine I Research Assistant Professor I United States of America

PROGRAM, MON 12

68

M ONDAY, OCTOBER 12, 2015

SUMMIT PROGRAM

71

WORKSHOP EDUCATION AND LEADERSHIP

WS15 ROOM 3 | STRESEMANN 9:00•–•10:30

YOUNG PHYSICIAN LEADERS

HOST

SPEAKERS

M8 Alliance: InterAcademy Medical Panel (IAMP)

Selected Young Physician Leaders ( YPL)

CHAIRS Jo Ivey Boufford The New York Academy of Medicine | President | United States of America Peter McGrath The World Academy of Sciences | Program Officer | Italy

Successful institutions need good leaders. And whether they are in highincome countries or poorer countries, institutions providing healthcare, educating future physicians or promoting the public’s health are no different. Yet decision-makers in such institutions are often appointed from among people trained in medicine, not leadership. The InterAcademy Medical Panel (IAMP) Young Physician Leaders (YPL) programme aims to bridge this gap. Launched in 2011, to date some 108 young physicians from 32 countries have participated in 5 international and one regional edition

of this personalized leadership training programme (a dedicated IAMP YPL Directory is available here: www.iamp-online. org/iamp-young-physician-leadersdirectory). These training events take place immediately prior to WHS meetings. This session will be designed by the 20 participants of the 2015 YPL event taking place on 9 –1 1 October. Discussions will likely focus on leadership challenges for young physicians and their solutions in countries with different socio-economic conditions. The session is open to everyone – students, young medical personnel at the start of their careers, as well as delegates holding more senior positions.

Jo Ivey Boufford

Peter McGrath

PROGRAM, MON 12

70

M ONDAY, OCTOBER 12, 2015

SUMMIT PROGRAM

73

WORKSHOP EVIDENCE TO POLICY

WS16 ROOM 4 | RATHENAU 9:00•–•10:30

SEXUAL VIOLENCE THE HEALTH SECTOR RESPONSE

HOSTS

SPEAKERS

M8 Alliance: Charité•–•Universitätsmedizin Berlin

Rolf Holmqvist Treatment Programs for Juvenile Offenders with Antisocial Behaviour Linköping University | Professor, Behavioural Sciences and Learning | Sweden

Pennsylvania State University CHAIRS Klaus Beier Charit鍖Universitätsmedizin Berlin | Director, Institute of Sexual Sciences and Sexual Medicine | Germany Christine Heim Charit鍖Universitätsmedizin Berlin | Director, Institute of Medical Psychology | Germany

Berit Kieselbach Epidemiology of Sexual Violence Against Women and Children: International View; WHO-Perspectives on Prevention of Sexual Violence Within the Health Care System World Health Organization (WHO) | Technical Officer, Prevention of Violence Management of Noncommunicable Diseases, Disability, Violence and Injury Prevention | Switzerland Jennie Noll Sexual Traumatization and Health: The Victims Pennsylvania State University | Professor, Human Development and Family Studies | United States of America

Vikram Patel Mental Health of Adolescents in Fast Developing Countries Like India London School of Hygiene & Tropical Medicine | Professor, International Mental Health, Human Development and Family Studies | United Kingdom

Swati Shirwadkar Exploring Hidden Spaces: Sexual Abuse of Children in India University of Pune | Professor, Sociology | India

Prevalence rates derived from epidemiological studies confirm that sexual violence suggest that without doubt represents a global health problem. Research in victims demonstrates marked longterm effects of sexual traumatization in childhood on neurobiological systems in adulthood, and these changes contribute to health problems. Recently, neuroimaging studies provided new evidence suggesting neural correlates of sexual deviancy (e.g. pedophilia), which is one of the risk factors for sexual offending against children. Furthermore, research on anti-social behaviour (another important risk factor for sexual offending) indicates the need for early intervention in adolescents or young adults.

Comparing a fast developing country, such as India, to developed European countries, large differences concerning criminological data and cultural conditions influencing the probability of sexual offending against women and children become obvious. This does not necessarily mean that there is no transferability of health science knowledge across countries. This workshop will scrutinize the main epidemiological, neurobiological and therapeutic knowledge concerning sexual violence against women and children in order to translate this knowledge to devise strategies for the improvement of primary and secondary prevention from an international level focusing on the healthcare system.

Klaus Beier

Berit Kieselbach

Christine Heim

Jennie Noll

Rolf Holmqvist

Vikram Patel

PROGRAM, MON 12

72

74

M ONDAY, OCTOBER 12, 2015

SUMMIT PROGRAM

75

KEYNOTE

KEY02 PLENARY HALL | WELTSAAL 11:00•–•12:30

THE POST-2015 DEVELOPMENT AGENDA

HOSTS

SPEAKERS

M8 Alliance

Mark Dybul The Changing Landscape of Global Health and Development The Global Fund to Fight AIDS, Tuberculosis and Malaria | Executive Director | United States of America

United Nations (UN) World Health Organization Regional Office for Europe CHAIRS Rifat Atun Harvard T. H. Chan School of Public Health | Professor, Global Health and Population | United States of America Macharia Kamau United Nations (UN) | Ambassador & Permanent Representative, Kenya Mission to United Nations | United States of America

Dagfinn Høybråten Gavi, The Vaccine Alliance | Chairman of the Board | Switzerland Zsuzsanna Jakab Health in the Post-2015 Development Agenda: A call for Integrated Action World Health Organization | Regional Director for Europe | Denmark Debra A. Jones SDGs and Health – From Implementation to Delivery Save the Children | Director | United States of America Freda C. Lewis-Hall Pfizer Inc. | Chief Medical Officer | United States of America

When addressing current and future social, economic, and environmental challenges that are facing the planet, there is now an established consensus that these challenges are interlinked and must be addressed through an integrated approach. The social and economic and environment factors play an undeniable role in human health; only through integration of the three dimensions will it be possible to achieve the transformative change required to secure long-term environmental and human well-being. As we reach the target deadline for the UN’s Millennium Development Goals, it is time to reassess in which areas global

development is meeting our expectations and in which directions we need to focus our future efforts. Firstly, some of the targets set in 2000 are yet to be met; the reasons behind this must be addressed and new strategies devised to accelerate progress in these areas. Secondly, we must consider how our planet, and with it the development agenda, has evolved over the past 15 years; the constantly changing environment means that our future goals are also ever-changing. Most importantly, we must ensure that our future plans for healthcare and development are not only achievable but truly sustainable in order to achieve long-term, stable progress.

Rifat Atun

Debra A. Jones

Mark Dybul

Macharia Kamau

Dagfinn Høybråten

Freda C. Lewis-Hall

Zsuzsanna Jakab

PROGRAM, MON 12

EVIDENCE TO POLICY

76

M ONDAY, OCTOBER 12, 2015

SUMMIT PROGRAM

77

PANEL DISCUSSION

SYM02 PLENARY HALL | WELTSAAL 14:00•–•15:30

VALUE-BASED HEALTHCARE TRANSLATIONAL RESEARCH

HOSTS The Boston Consulting Group (BCG) Berlin Institute of Health (BIH) CHAIR Stefan Larsson The Boston Consulting Group | Senior Partner & Managing Director | Sweden SPEAKERS Christina Rångemark Åkerman On the Road to Value, Outcomes are the First Step International Consortium for Health Outcomes Measurement (ICHOM) | President | United States of America Mark Dybul The Impact of Focusing More on Health Outcomes in Developing Countries The Global Fund to Fight AIDS, Tuberculosis and Malaria | Executive Director | United States of America

Hartwig Huland Standardized PROM for Science and Quality Control Martini Klinik at UKE GmbH | Chief Physician, Urology | Germany Joseph Jimenez Towards Sustainble Healthcare•–• an Industry Perspective Novartis International AG | CEO | Switzerland European Federation of Pharmaceutical Industries and Associations (EFPIA) | President | Belgium Jonas Oldgren (Health Care) Registry-Based Randomized Trials•–•a Disruptive Technology in Clinical Research Uppsala University | Executive Director, Uppsala Clinical Research Center | Sweden Melvin Samsom Developing the Value Focussed University Hospital•–• Learnings from the Karolinska Karolinska University Hospital | Chief Executive Offer, Research and Education | Sweden

In healthcare, the days of business as usual are over. Around the world, every healthcare system is struggling with rising costs and uneven quality despite the hard work of well-intentioned, welltrained clinicians. Healthcare leaders and policy makers have tried countless incremental fixes – attacking fraud,

reducing errors, enforcing practice guidelines, making patients better “consumers,” implementing electronic medical records – but none have had much impact. At its core is maximizing value for patients: that is, achieving the best outcomes at the lowest cost.

Christina Rångemark Åkerman

Stefan Larsson

Mark Dybul

Jonas Oldgren

Hartwig Huland

Melvin Samsom

Joseph Jimenez

PROGRAM, MON 12

EVIDENCE TO POLICY

M ONDAY, OCTOBER 12, 2015

SUMMIT PROGRAM

79

WORKSHOP GLOBAL HEALTH FOR DEVELOPMENT

WS17 ROOM 1 | BRANDT 14:00•–•15:30

UNIVERSAL HEALTH COVERAGE

HOSTS German Federal Ministry for Economic Cooperation and Development (BMZ) German Healthcare Partnership (GHP) Rabin Martin The Graduate Institute Geneva CHAIRS Ilona Kickbusch The Graduate Institute of International and Development Studies | Program Director, Global Health Programme | Switzerland Michael Rabbow Boehringer Ingelheim GmbH & Co. KG | Corporate Affairs, Team Leader | Germany SPEAKERS Charles-Etienne de Cidrac AXA Global Life | Director, Health Strategy and Innovation | France

Richard Sezibera Regional Efforts to Strengthen UHC: The EAC Experience East African Community (EAC) | Secretary General | Rwanda Lilian Dudley Implementing UHC: An Academic Perspective University of Stellenbosch | Director and Professor | South Africa Roland Göhde How is the German Healthcare Partnership Helping Countries to Achieve UHC? Sysmex Partec GmbH | Senior Managing Director | Germany German Healthcare Partnership (GHP) | Chairman of the Board | Germany Heike Kuhn UHC and the SDGs in the Year of the German G7 Presidency and the Addis Ababa Funding for Development Conference: A German Perspective German Federal Ministry for Economic Cooperation and Development (BMZ) | Head of Department | Germany H. E. Dorcas Makgato-Malesu Botswana’s Experience with the Private Sector in Promoting UHC Ministry of Health | Minister of Health | Botswana

The private sector has longmade significant contributions to improving the health of billions of people around the world, creating novel solutions to some of the largest health and development challenges. Universal Health Coverage (UHC) has been recognized as an enabler to improve access to higher quality health services and a critical component of achieving the Sustainable Development Goals. Following the United Nations Summit to adopt the Post-2015 Development Agenda, this panel will explore the multiple and complex processes required to help countries achieve the vision UHC, with a focus on the role of the private sector.

Jeffrey Sturchio The Private Sector Role in Achieving Universal Health Coverage: Progress and Prospects Rabin Martin | President and CEO | United States of America

There is no single blueprint for long-term sustainability of UHC. The discussion will address the role that the private sector plays(and could play) in helping countries to achieve this goal. Particularly with respect to innovative financing and developing products and services with a systemic approach to meet ongoing health challenges such as maternal health, child survival, infectious disease and chronic illness. The workshop will also examine the challenges of scaling up and sustaining public-private partnerships and private-private partnerships that seek to improve access to affordable and quality care for all.

Charles-Etienne de Cidrac

Ilona Kickbusch

Michael Rabbow

Lilian Dudley

Heike Kuhn

Richard Sezibera

Roland Göhde

Dorcas Makgato-Malesu

Jeffrey Sturchio

PROGRAM, MON 12

78

M ONDAY, OCTOBER 12, 2015

SUMMIT PROGRAM

81

WORKSHOP EDUCATION AND LEADERSHIP

WS18 ROOM 2 | ADENAUER 14:00•–•15:30

EQUITY AND HEALTH LITERACY

HOSTS

SPEAKERS

Hertie School of Governance

Cynthia Baur Health Literacy•–•the Policy Landscape to Drive Change Centers for Disease Control and Prevention | Strategic Communication Professional, US Department of Health and Human Services | United States of America

World Health Organization (WHO) CHAIRS Klaus Hurrelmann Hertie School of Governance | Professor, Public Health and Education | Germany Richard Osborne Deakin University | Chair in Public Health, School of Health and Social Development | Australia

Sujavee Good Health Literacy in low and Middle-Income Countries World Health Organization (WHO) | Program Coordinator, Sustainable Development and Healthy Environments | India Marie Birk Jørgensen Health Literacy in Daily Life and the Workplace National Research Center for the Working Environment | Senior Researcher | Denmark Kai Kolpatzik Health Literacy Challenges and Solutions for Germany’s Largest Private Health Insurer AOK Bundesverband | Head, Prevention | Germany

Health literacy is the personal characteristics and social resources needed for individuals and communities to access, understand, appraise and use information and services to make decisions about health. Health literacy is increasingly recognised as not just an individual trait but also a characteristic related to organisations. Health literacy responsiveness describes the way in which services, environments and products make health information and support available and accessible to people with different health literacy strengths and limitations. Low health literacy is associated with • Reduced understanding and access to healthcare and health insurance • Increased use of medical services • Higher patient-related and doctorrelated medical errors • Poor health outcomes At the individual level, people are required to recognise health opportunities, understand and follow advice, yet deal

with competing daily concerns. At the organisational and policy level we need to ensure provision of services that both mitigate diagnosis and treatment delay, yet ensure judicious provision of limited healthcare and disease prevention resources. How can we: • provide advice and services through public/private sectors, workplaces, healthcare professionals that optimise access and uptake of health services? • maximise health literacy of people, and health literacy responsiveness of organisations/health systems, to maximise health outcomes and equality? This workshop will take a whole of system approach to generating health outcomes while maximising health equity. Presenters are global leaders and innovators in their respective fields. Based on their experience, which is at the cutting edge of their respective fields, real world and contrasting solutions will be presented and discussed.

Cynthia Baur

Marie Birk Jørgensen

Sujavee Good

Kai Kolpatzik

Klaus Hurrelmann

Richard Osborne

PROGRAM, MON 12

80

M ONDAY, OCTOBER 12, 2015

SUMMIT PROGRAM

83

WORKSHOP RESEARCH AND INNOVATION

WS19 ROOM 3 | STRESEMANN 14:00•–•15:30

STEM CELL RESEARCH• – PAVING THE PATH TO APPLICATION TRANSFER OF KNOWLEDGE FROM BASIC RESEARCH TO APPLICATION IS CHALLANGING – WHAT ARE THE IMPLICATIONS FOR THE USE OF STEM CELLS

HOSTS

CHAIRS

Innovative Medicines Initiative (IMI)

Daniel Besser German Stem Cell Network (GSCN) | Managing Director | Germany

German Stem Cell Network (GSCN) EBiSC StemBancc Berlin Institute of Health (BIH)

Joachim Müller-Jung Frankfurter Allgemeine Zeitung (FAZ) | Head of Department | Germany

Daniel Pipeleers (Stem) Cell-based Approaches for Cell Therapy in Diabetes Brussels Free University (VUB) | Director, Center for Beta Cell Therapy in Diabetes | Belgium

Fatiha Sadallah Innovative Medicines Initiative | Principal Scientific Officer | Belgium

Elly M. Tanaka Stem Cells and Organ Regeneration Center for Regenerative Therapies TU Dresden (CRTD) | Project Section Leader | Germany

SPEAKERS

DISCUSSANTS

Tim Allsopp Translating Human Pluripotent Stem Cell Research into Reliable Tools Pfizer Inc. | Head, Cell Improve Outreach Programme | United Kingdom

Egbert Flory Paul-Ehrlich-Institut | Head, Tissue Engineering | Germany

Zameel Cader StemBancc•–•Stem Cells for Drug Discovery University of Oxford | Director, The Oxford Headache Centre, StemBANCC | United Kingdom Ulrich Martin Induced Pluripotent Stem Cells for Heart Repair German Stem Cell Network (GSCN) | Designated President 2016 | Germany

Arnd Hoeveler European Commission | Head, Advanced Therapies and Systems Medicine | Belgium Casja Lindberg UNG Diabetes | Sweden Mohan C. Vermuri Thermo Fisher Scientific Inc. | Director Research & Development, Cell Biology, Life Sciences Solutions | United States of America

Stem cells are considered as exciting new tools for deciphering disease mechanisms, as an important resource for the de velopment of new medicines, as well as for regenerative medicine strategies. Societal expectations for a rapid translation of research are high. Recognition of the considerable potential has triggered translational research initiatives at EU level, such as the Horizon 2020, several national programs as well as public and private funding initiatives. The rewards of a successful advancement using human stem cells are po tentially substantial, but uncertainties exist. Based on the recent substantial progress in basic and applied stem cell research, robust and cost-effective manufacture of stem cell products at an industrial scale, standardization of quality criteria and product efficacy as well as development of better application technologies are areas of intense and innovative development. The first clinical trials to include products derived from pluripotent human stem cells are just taking place.

This workshop will present a number of current case studies with focus towards applied re search such as the use of pluripotent stem cells for drug de velopment and clinical translation of therapeutic concepts. It will discuss the issues determining their use as tools, and hurdles of pre-clinical development prior to entering clinical trials. Examples will be drawn from the translation of stem cell research from academic and industrial sectors. Discussion framework will include: • Matching expectation from stakeholders involved (clinicians, scientists, patients, SME, pharma)? • Can translation be accelerated without compromising utility, especially patient safety? • How to ensure that results are reliable, particularly when society expectations are elevated? • What are the barriers to pro duct development and can manufacturing be made costeffective? • When can society expect to see the first results and how likely will it be that healthcare systems are ready to reimburse?

Tim Allsopp

Arnd Hoeveler

Daniel Pipeleers

Daniel Besser

Casja Lindberg

Fatiha Sadallah

Zameel Cader

Ulrich Martin

Elly M. Tanaka

Egbert Flory

Joachim Müller-Jung

Mohan C. Vermuri

PROGRAM, MON 12

82

M ONDAY, OCTOBER 12, 2015

SUMMIT PROGRAM

85

WORKSHOP

WS20 ROOM 4 | RATHENAU 14:00•–•15:30

A EUROPEAN EFFICACY•/ EFFECTIVENESS ASSESSMENT ARE WE THERE YET?

HOSTS

SPEAKERS

European Federation of Pharmaceutical Industries and Association (EFPIA)

Michael Berntgen European Medicines Agency (EMA) | Head, Scientific and Regulatory Management | United Kingdom

Sanofi CHAIR Karen Facey University of Glasgow | Honorary Senior Research Fellow, Health Economics and Health Technology Assessment, Scotland | United Kingdom

Elisabeth George National Institute for Health and Care Excellence (NICE) | Associate Director, Appraisals | United Kingdom Ricardo Augustus Guerreiro Baptista Leite Parliament of Portuguese Republic | Scientific Coordinator for Public Health | Portugal Claire Le Jeunne University Hospital Paris Centre–Cochin | Chief, Internal Medicin | France Andrea Rappagliosi Sanofi Pasteur MSD | Vice President, Market Access, Health Policy and Medical Affairs | France Bettina Ryll Melanoma Patient Network Europe | Founder | Sweden

The session seeks to discuss the challenges in developing and using EU relative efficacy/effectiveness assessments that can inform member states’ decisionmaking processes about the clinical added value of new medicines at the point of regulatory approval (market launch). It will gather representatives from the various actors most concerned in this issue: member states’ Health Technology Assessment (HTA) authorities, law-makers, decisionmakers, industry, patients, medical professionals. They will debate what European member states can deliver jointly to support better and faster reimbursement decisions that are based on the concept of clinical added value, with the aim of facilitating patient access to new medicines.  The premise of the EU in its efforts to move towards joint relative efficacy/ effectiveness assessments, and more broadly all joint work in aspects affecting HTA is simple. Health is a preserved authority and so each member state needs to determine where a new medicine will be placed in its health system’s clinical pathway and to determine whether it adds value to currently existing treatments. But this can lead to duplication of effort across member states as the same clinical evidence is assessed and delays in decision-making. Hence it has been a driving ethos of the European network for HTA (EUnetHTA) for the past nine years to develop agreed methods for HTA and

produce EU relative effectiveness assessments that can inform national decisionmaking. Despite this, national HTA authorities still seem to use their own methods and few joint assessments have led to actual decisions. National processes still take precedence. EUnetHTA is about to enter its third EU Joint Action of Member States and is tasked with showing how its fairly theoretical work and pilot ventures can be translated into decisions that make a real difference for patients’ access to medicines. This panel will debate the challenges of developing a rapid effectiveness assessment at the point of product launch so that it can inform the reimbursement of a new medicine. Will we see the same evolution as in the field of Europe’s regulatory framework, or have times changed too much for history to repeat itself? What role can European regulators play in ensuring clinical data is not reinterpreted 28 times across Europe? What can politicians do to foster a better understanding of the need for this cooperation? What role can medical professionals play in ensuring that the output from joint work can make a meaningful contribution to clinical practice in member states? Is industry ready to adapt to the risk inherent in joint assessments in exchange for more speed and predictability? How can the system ensure patient-driven priorities become truly part of the effort?

Karen Facey

Andrea Rappagliosi

Ricardo Augustus Guerreiro Baptista Leite

Bettina Ryll

PROGRAM, MON 12

84

86

M ONDAY, OCTOBER 12, 2015

SUMMIT PROGRAM

87

KEYNOTE

KEY03

DIGITAL HEALTH

PLENARY HALL | WELTSAAL 16:00•–•18:00

HOSTS European Commission Helmholtz Association of German Research Centres e.•V. CHAIR Otmar D. Wiestler Helmholtz Association of German Research Centres e.V. | President | Germany SPEAKERS Günther H. Oettinger European Commission | Commissioner, Digital Economy & Society | Belgium Saïd Aïdi Modernizing Tunisia’s Healthcare System Ministry of Health | Minister of Health | Tunisia

Klaus Lindpaintner Democratizing Precision Medicine – a Next Generation Sequencing Paradigm Thermo Fisher Scientific Inc. | Chief Scientific Officer | United States of America Luka Mucic Big Data and Networks Shaping the Future of Healthcare SAP SE | CFO & COO | Germany Thomas Südhof The Post-Genomic Age in Neuroscience: Challenges for Understanding Brain Diseases Stanford University School of Medicine | Avram Goldstein Professor, Molecular & Cellular Physiology | United States of America Friedrich von Bohlen und Halbach Precision Medicine: The Paradigm-Shifting Merger of Molecular Medicine With IT dievini Hopp BioTech holding GmbH & Co.KG | Managing Director | Germany

As the digital and genetics revolutions converge with healthcare into the exciting new field of Digital Health, we are increasingly able to track, manage, and improve both our own health and that of our loved ones. Digital Health is also helping to reduce inefficiencies in healthcare delivery, while at the same time streamlining access, reducing costs, improving quality and making medicine

more personalized and precise. The essential elements that are making the digital health revolution a reality include wireless devices, hardware sensors and software sensing technologies, microprocessors and integrated circuits, the Internet, social networking, mobile and body area networks, health information technology, genomics, and personal genetic information.

Günther H. Oettinger

Thomas Südhof

Saïd Aïdi

Friedrich von Bohlen und Halbach

Klaus Lindpaintner

Otmar D. Wiestler

Luka Mucic

PROGRAM, MON 12

RESEARCH AND INNOVATION

M ONDAY, OCTOBER 12, 2015

SUMMIT PROGRAM

89

SOCIAL EVENT ALLIANZ FORUM BERLIN PARISER PLATZ 6 18:30•–•21:00

WHS NIGHT AT THE ALLIANZ FORUM BERLIN

HOSTS Allianz Deutschland AG M8 Alliance SPEAKERS Antoine Flahault University of Geneva | Director, Institute of Global Health | Switzerland Shunichi Fukuhara World Health Summit President Kyoto University | Dean, Vice President, School of Public Health, Vice President Department of Healthcare Epidemiology | Japan

Detlev Ganten World Health Summit President Charité Foundation | Chairman of the Board | Germany State Senator Cornelia Yzer Federal Government Berlin | Senator for Economics, Technology and Research | Germany

The WHS Night provides participants with an excellent opportunity to meet and mingle with our distinguished guests, among them WHS speakers, delegates and representatives from supporting institutions. Tickets will be available on site for €39. We hope you’ll be able to join us!

Antoine Flahault

Detlev Ganten

Shunichi Fukuhara

Cornelia Yzer

PROGRAM, MON 12

88

Summit Program

TUESDAY, OCTOBER 13

Program, TUE 13

Summit Program, Tuesday, October 13, 2015

92

TUESDAY, OCTOBER 13, 2015

SUMMIT PROGRAM

93

PANEL DISCUSSION

SYM03 PLENARY HALL | WELTSAAL 9:00•–•10:30

EBOLA: ASSESSMENT, TREATMENT AND PREVENTION

HOSTS Institut Pasteur M8 Alliance The Graduate Institute of International and Development Studies CHAIRS Ilona Kickbusch The Graduate Institute of International and Development Studies | Program Director, Global Health Programme | Switzerland Jean-Claude Manuguerra Institut Pasteur | Director, Laboratory for Urgent Response to Biological Threats (CIBU) | France SPEAKERS Wim Leereveld How to Strengthen Research for Neglected Tropical Diseases Access to Medicine Foundation | CEO and Founder | Netherlands

Amy Maxmen The Role of the Global Media in Disease Outbreaks Pulitzer Center on Crisis Reporting | Journalist | United States of America Suerie Moon, Ph.D Strengthening a Fragile Global System for Disease Outbreak Response: Reflections on Reforms Harvard T. H. Chan School of Public Health | Research Director and Co-Chair | United States of America Samba O. Sow Learning from Mali’s Successful Response to the Ebola Outbreak Center for Vaccine Development, Mali (CVD-MALI) | Director General | Mali

The Ebola virus causes an acute, serious illness which is often fatal if untreated. The current outbreak in west Africa (first cases notified in March 2014) is the largest and most complex Ebola outbreak since the Ebola virus was first discovered in 1976. There have been more cases and deaths in this outbreak than in all others combined. Good out-

break control relies on applying a package of interventions, namely case management, surveillance and contact tracing, a good laboratory service, safe burials, and social mobilization. Community engagement is key to successfully controlling outbreaks and to reduce human transmission.

Ilona Kickbusch

Suerie Moon

Wim Leereveld

Samba O. Sow

Jean-Claude Manuguerra

Florian Westphal

Florian Westphal Working Together for the Benefit of Patients• –•The Cooperation Between Humanitarian and Public Health Actors Médecins Sans Frontières (MSF ) | Managing Director | Germany Amy Maxmen

PROGRAM, TUE 13

RESEARCH AND INNOVATION

TUESDAY, OCTOBER 13, 2015

SUMMIT PROGRAM

95

WORKSHOP RESEARCH AND INNOVATION

WS21 ROOM 1 | BRANDT 9:00•–•10:30

ANTIMICROBIAL RESISTANCE

HOSTS Koch-Metschnikow-Forum e.•V. M8 Alliance: Monash University CHAIR Anton Peleg Global Epidemic of Antimicrobial Resistance• –•Where do we Currently stand? Monash University | Director, Infectious Diseases | Australia SPEAKERS David C. Grolman An Industry Perspective on Antimicrobial Resistance: What Does the Future Hold? Pfizer Inc. | Medical Director, Global Established Pharma Business | Australia

Dena Lyras The Vicious Cycle of Antibiotics: The Emergence of Clostridium Difficile Monash University | Professor and Deputy Head, Microbiology | Australia Canice Nolan Tackling Antimicrobial Resistance•–• The Role of Government, Policy and International Health Agencies European Commission | Senior Coordinator for Global Health, Strategy and International | Belgium Timo Ulrichs The Growing Threat of Antimicrobial Resistance in Tuberculosis Akkon Univerity for Human Science | Head, Department for Emergency Relief and Disaster | Germany Koch-Metchnikov Forum e.V. (KMF) | Founder | Germany

Antimicrobial resistance (AMR) is defined as the resistance of a microorganism to an antimicrobial drug that was originally effective for treatment of infections caused by it. Resistant microorganisms (including bacteria, fungi, viruses and parasites) are able to withstand attack by antimicrobial drugs, such as antibacterial drugs (e. g., antibiotics), antifungals, antivirals, and antimalarials, so that standard treatments become ineffective and infections

persist, increasing the risk of spread to others. New resistance mechanisms emerge and spread globally, thus threatening our ability to treat common infectious diseases, resulting in death and disability of individuals whom until recently could continue a normal course of life. Without effective anti-infective treatment, many standard medical treatments will fail or turn into very high risk procedures.

David C. Grolman

Anton Peleg

Dena Lyras

Timo Ulrichs

Canice Nolan

PROGRAM, TUE 13

94

TUESDAY, OCTOBER 13, 2015

SUMMIT PROGRAM

97

WORKSHOP GLOBAL HEALTH FOR DEVELOPMENT

WS22 ROOM 2 | ADENAUER 9:00•–•10:30

ACCESS TO ESSENTIAL MEDICINES AND HEALTH COMMODITIES IN AFRICA THE EXAMPLE OF ARVS AND DIAGNOSTICS

HOSTS

CHAIRS

German Healthcare Partnership (GHP)

Roland Göhde German Healthcare Partnership (GHP) | Chairman of the Board | Germany

UNAIDS

Luiz Loures United Nations (UN) | Assistant Secretary-General | Switzerland UNAIDS | Deputy Executive Director | Switzerland SPEAKERS Manica Balasegaram Médecins Sans Frontières (MSF) | Executive Director, Access Campaign | Switzerland Xavier Crespin West African Health Organization (WAHO) | Director General | Burkina Faso Sandra Lambert Merck (Pty) Ltd. South Africa | Regional Director, Cardio metabolic Care and General Medicine for South East Africa | South Africa

Margareth Ndomondo-Sigonda The New Partnership For Africa’s Development (NEPAD) | Pharmaceutical Coordinator | South Africa Skhumbuzo Ngozwana Serenus Biotherapeutics Ltd. | President | South Africa Michael Rabbow Boehringer Ingelheim GmbH & Co. KG | Team Leader, Corporate Affairs | Germany Robert Sebbag Sanofi | Vice President, Access to Medicines | France Representative from the East African Community Secretariat (tbd) DISCUSSANTS Janet Byaruhanga African Union Commission | Healthy Policy Officer | Ethopia Jürgen Schulze European Diagnostic Manufacturers Association (EDMA) | President | Belgium

Many countries in Africa have made substantial progress in scaling up access to medicines for HIV, malaria and tuberculosis, with support from international agencies. Nevertheless, problems still persist with low or inconsistent availability and affordability of essential medicines, including antiretroviral medicines, in low income and lower middle income countries. These problems arise in part due to persistent bottlenecks in the multiple phases of the drug supply chain, and because of funding constraints. Rapidly emerging threats, such as Ebola, have highlighted the need for the timely development and sustainable supply of affordable and innovative medicines, and the critical need for Africa to develop competencies to deal with its specific challenges including neglected tropical diseases. Developing domestic markets within Africa requires sound national strategies, a coherent policy framework, robust and wellcoordinated health systems, and a research and development agenda for health that is focused on the needs of African countries, with sufficient and consistent investment.

This panel discussion will explore: • The potential crisis in the supply of antiretrovirals in Africa and what can be done to secure affordable, quality supplies while also aggressively scaling up Treatment coverage. • The implications of the FastTrack AIDS response, including 90-90-90: providing tests to 90% of all people living with HIV, treatment to 90% of all people diagnosed, and • viral suppression for 90% of all people on HIV treatment. • The evolving demand for pharmaceuticals in Africa. • Procurement efficiencies and the impact of donors. • Industrial policy and its role in public health. • Regulatory harmonization and trade barriers. • Technology transfer and capacity development, including South-South, North-South and triangulation approaches. • Investment oppor tunities including private, State and public-private partnerships. • Quality assurance for local manufacturers and imported medicines.

Manica Balasegaram

Sandra Lambert

Michael Rabbow

Janet Byaruhanga

Luiz Loures

Robert Sebbag

Xavier Crespin

Margareth Ndomondo-Sigonda

Roland Göhde

Skhumbuzo Ngozwana

PROGRAM, TUE 13

96

TUESDAY, OCTOBER 13, 2015

SUMMIT PROGRAM

99

WORKSHOP RESEARCH AND INNOVATION

WS23 ROOM 3 | STRESEMANN 9:00•–•10:30

VISION RESEARCH INNOVATION & CHALLENGES

HOSTS

SPEAKERS

Fukushima Medical University

Akira Murakami Global Burden of Eye Diseases and Blindness Juntendo University Tokyo | Professor and Head, Ophthalmology I Center for Prevention of Blindness | Japan

M8 Alliance: Charité•–•Universitätsmedizin Berlin CHAIRS Antonia Joussen Charit鍖Universitätsmedizin Berlin | Management, Clinic of Ophthalmology | Germany Ryo Kawasaki Fukushima Medical University | Professor, Public Health | Japan

Jonathan Shaw Epidemiology of Diabetes and Diabetic Retinopathy•–•Lessons from AusDiab, and Australian Screening Program Monash University | Head, Clinical Diabetes and Epidemiology Group | Australia David Wong Screening Experience in Hong Kong University of Hong Kong | Chair, Professor| Hong Kong

Vision is the main source of human sensation, and blindness is a burden for both individual health and society. There are innovations in vision research for reducing preventable blindness, establishing screening framework to mitigate the burden of advanced diseases and devel-

oping novel diagnostic modalities to predict both eye diseases and systemic diseases. This session will highlight those innovators in vision research, and provide a glimpse of what is coming in the field of vision research in very near future.

Antonia Joussen

Jonathan Shaw

Ryo Kawasaki

David Wong

Akira Murakami

PROGRAM, TUE 13

98

TUESDAY, OCTOBER 13, 2015

SUMMIT PROGRAM

101

WORKSHOP EVIDENCE TO POLICY

WS24 ROOM 4 | RATHENAU 9:00•–•10:30

TRADE, DIPLOMACY AND GLOBAL HEALTH

HOSTS

SPEAKERS

German Federal Foreign Office (AA)

Peter Beyer WHOs Experience from Free Trade Agreements: Is Win Win Possible? World Health Organization (WHO) | Senior Advisor, Essential Medicines & Health Products | Switzerland

M8 Alliance: World Federation of Academic Institutions for Global Health (WFAIGH) CHAIRS Kevin O’Brian Handelsblatt GmbH Global Edition | Editor in Chief | Germany Leonel A. Valdivia University of Chile | Director for International Relations, School of Public Health, Faculty of Medicine | Chile Susanne Weber-Mosdorf World Health Organization (WHO), Office European Union | former Executive Director | Germany

Thomas Krafft Trade Agreement Negotiations: Implications for Global Health Maastricht University | Professor, International Health | Netherlands Srinath Reddy Global Health Diplomacy Challenges Posed by the New Generation of Trade and Investment Treaties•–• a View from the Global South Public Health Foundation of India | President and CEO | India

The relationship between health, foreign policy and trade is at the cutting edge of global health diplomacy (WHO), and is the subject matter of much discussion and literature, most notably with respect to the current and next generation of trade and investment treaties. This workshop will review the ‘state of play’ (what is known and theorized) about such treaties as TTIP, TPP and TISA, among others. It will address such burning questions as: how do these treaties affect public health particularly in low and middle income countries (LMICs)? How can public health protection and equity concerns be brought to bear in treaty negotiations? Where are there good examples of ‘best practices’ in trade and global health diplomacy? While, there is a rather great commitment with regard to global health concerns embedded in TRIPS flexibilities related to HIV/Aids, there is evidence of

strong resistance in accepting the same principles with regard to NCDs. (e.g. cancer in Thailand, India). Also bilateral trade and other treaties with IP provisions eroded the policy space for public health protection within the multi-lateral IP regime. Within this context, the workshop will be an opportunity to: • discuss current challenges on innovation/public health and on access to essential medicines, • review the recent evolution and current IP issues in bilateral treaties (linking to the discussion at the 2014 WHS); • Offer a perspective on trade and GH diplomacy from the LMICs and NGOS; and • present a the interplay between health policy and trade promotion viewed from an official foreign ministry perspective. The workshop will give ample opportunity for questions and comments from participants.

Peter Beyer

Leonel A. Valdivia

Kevin O’Brian

Susanne Weber-Mosdorf

Srinath Reddy

PROGRAM, TUE 13

100

102

TUESDAY, OCTOBER 13, 2015

SUMMIT PROGRAM

103

KEYNOTE EVIDENCE TO POLICY

PLENARY HALL | WELTSAAL 11:00•–•12:30

GLOBAL HEALTH POLICY IN THE G7/G20

HOSTS

SPEAKERS

M8 Alliance

Joe Cerrell The G7/G20’s Role in Helping All People Live Healthy and Prosperous Lives Bill & Melinda Gates Foundation/ European Office | Managing Director, Global Policy and Advocacy | United Kingdom

The Rockefeller Foundation The Global Fund CHAIR John Kirton University of Toronto | Director, G7 G20 Research Group | Canada

Norbert Hauser Translating Political Commitment and Financial Resources into Concrete Results•–•The Role of the G7/20 on Global Health Policy The Global Fund to Fight AIDS, Tuberculosis and Malaria | Chair of the Board | Switzerland Mitchell Morris Emerging Models of Health: Predictive Maintenance Deloitte Consulting LLP | Vice Chairman, Global Leader, Healthcare | United States of America

Michael Myers The Planet as Doctor: Building Public Health 2.0 The Rockefeller Foundation | Managing Director | United States of America

Global health has gained in political relevance and as a consequence there is an increasing interest of political bodies such as the G7 and the G20 to consider global health challenges. The G7/G20 research group has shown that proposals from these groups on health have been taken forward – yet many have challenged the leading economies in the world to provide more political and financial commitment to global health matters, especially in relation to health development,

Hiroki Nakatani The Japanese Presidency of the G7; Reminiscence and Perspectives Keio University | Professor, Global Health Initiatives | Japan Ministry of Health, Labour and Welfare | Minister’s Assistant for Global Health | Japan

Universal Health Coverage and to health security. This is even more relevant in view of the adoption of the Sustainable Development Goals. The panel will explore – with representatives of the G7/G20, as well as major business and foundation leaders how the G7/G20 can contribute to the achievement of the SDGs in relation to health and how they can provide the political support to take the global health agenda forward.

Joe Cerrell

Mitchell Morris

Norbert Hauser

Michael Myers

John Kirton

Hiroki Nakatani



PROGRAM, TUE 13

KEY04

104

TUESDAY, OCTOBER 13, 2015

SUMMIT PROGRAM

105

PANEL DISCUSSION RESEARCH AND INNOVATION

PLENARY HALL | WELTSAAL 14:00•–•15:30

NCDs: A CALL FOR COMMON ACTION AND SUSTAINABLE CHANGE

HOST Sanofi CHAIR Catherine Fiankan-Bokonga United Nations (UN) | Journalist and International Correspondant | Switzerland SPEAKERS Douglas W. Bettcher NCDs: What are the key needs and gaps? What should be the coordinating role of WHO? World Health Organization (WHO) | Director, Prevention of Noncommunicable Diseases (PND) | Switzerland Katie Dain What is the Role of Civil Society in Catalyzing Efforts Both at Global and Local Levels in the NCD Fight? The NCD Alliance | Executive Director | United Kingdom

Linong Ji How to Best Harness the Expertise, Knowledge and Resources of Academia for Improved Solutions to NCDs in the Field? International Diabetes Federation | Vice President | Belgium Mabvuto Kango  How to Set the Frame for Feasible, Effective and Sustainable Solutions for NCDs When Resources are Limited? African Union Commission | Head for Health Nutrition & Population, Social Affairs | Ethiopia Hon. Suresh Kumar How Could the Health Industry’s Expertise and Skills be Better Leveraged to Address NCDs Globally? Sanofi Aventis Groupe S.A. | Executive Vice President, External Affairs & Former US Assistant Secretary of Commerce | Switzerland Srinath Reddy Which Partnerships Should be Fostered to Deliver a Sustainable Response to NCDs, in Particular for the Most Vulnerables? Public Health Foundation of India | President and CEO | India

Non-Communicable Diseases (NCDs) are the world’s leading cause of death and disability, bringing hardship to rich and poor nations alike. Worldwide, the four main types of NCDs, namely cardiovascular diseases (like heart attacks and stroke), cancers, chronic respiratory diseases (such as chronic obstructed pulmonary disease and asthma) and diabetes, account for 60% (35 million) of global deaths. The largest burden – 80% (28 million) – occurs in low- and middleincome countries (LMICs), making NCDs a major cause of poverty and an urgent development issue. This rapidly changing health and disease profile has serious implications for poverty reduction and economic development, with severe impacts on individuals, communities, and countries. LMICs still grappling with heavy burdens of infectious disease risk being overwhelmed by this wave of

largely preventable NCDs. Without any action now, the NCD burden will increase globally by 17% in the next ten years, and in the African region alone by 27%. Because of the size of the immense challenges at hand, the diverse causes, and the universal impact, NCDs are everyone’s problem. No single actor or sector can turn the tide on NCDs alone. Tackling the global NCD crisis requires a concerted and coordinated multi-sectoral response, committed to by world decision makers, academia, civil society and the private sector, and driven by governments. Given the heterogeneity of situations across countries, tailoring global NCD actions and demands for policy change and resource mobilization to local contexts will be critical to deliver adapted, proven, cost-effective solutions that work.

Douglas W. Bettcher

Linong Ji

Katie Dain

Suresh Kumar

Catherine Fiankan-Bokonga

Srinath Reddy

PROGRAM, TUE 13

SYM04

TUESDAY, OCTOBER 13, 2015

SUMMIT PROGRAM

107

WORKSHOP EVIDENCE TO POLICY

WS25 ROOM 1 | BRANDT 14:00•–•15:30

CLIMATE CHANGE AND HEALTH

HOSTS

SPEAKERS

Leopoldina•–•German National Academy of Science

Robert Barouki The “exposome”•–•a new Concept Unifying Social and Environmental non-Genetic Determinants of Health Across the Life Course. University Paris Descartes | Director of Inserm Unit 1124, Toxicology Pharmacology and Cellular Signaling | France

M8 Alliance: London School of Hygiene & Tropical Medicine CHAIRS Antoine Flahault University of Geneva | Director, Institute of Global Health | Switzerland Rainer Sauerborn University Hospital Heidelberg | Head, Institute of Public Health | Germany

Boubacar Barry Innovative Research Tools (Satallite Imagery, Meteo Station Information, Crop Models, Population Cohorts) to Quantify the Contribution of Climate Change to Malnutrition West African Science Service Center on Climate Change and Adapted Land Use (WASCAL) | Coordinator | Burkina Faso Anneliese Depoux Increasing Interest of Media in the Health Aspect of Climate Change, 1992–2015: Print Media, Social Networks and Scientific Journals. Centre Virchow-Villermé (CVV ) | Executive Director | France

Arnaud Fontanet Intelligent Use of the Institut Pasteur Network for Research and Surveillance of Climate-Sensitive Infectious Diseases in Africa and Asia Institut Pasteur | Head, Epidemiology of Emerging Diseases Unit | France

Sir Andrew Haines The Concept of Planetary Health (Lancet Commission): Old Wine in new Bottles? London School of Hygiene & Tropical Medicine | Director | United Kingdom

Although global warming may bring some localized benefits – such as fewer winter deaths in temperate climes or increased food production in certain areas – the overall health effects of a changing climate promise to be overwhelmingly negative. That’s because

climate change will affect a wide range of social and environmental factors that influence health, and it also looks set to have a serious impact on issues like clean air, safe drinking water, food supply and housing/shelter security.

Robert Barouki

Arnaud Fontanet

Anneliese Depoux

Sir Andrew Haines

Antoine Flahault

Rainer Sauerborn

PROGRAM, TUE 13

106

TUESDAY, OCTOBER 13, 2015

SUMMIT PROGRAM

109

WORKSHOP EDUCATION AND LEADERSHIP

WS26 ROOM 2 | ADENAUER 14:00•–•15:30

EDUCATION AND TRAINING OF CLINICAL AND TRANSLATIONAL SCIENTISTS

HOSTS German Centers for Health Research (DZG) Berlin Institute of Health (BIH) CHAIRS Richard Friebe Scientific Journalist | Germany Martin Krönke German Center for Infection Research e.V. (DZIF ) | Director | Germany SPEAKERS Christian Boitard The National Institute for Health and Medical Research (INSERM) | Director | France Petra Kaufmann National Center for Advancing Translational Sciences (NCATS) | Director, Rare Diseases Research and Division of Clinical Innovation | United States of America

Elmar Nimmesgern European Commission | Deputy Head, Innovative and Personalised Medicine | Belgium Ernst Th. Rietschel Berlin Institute of Health (BIH) | Head of the Board | Germany Georg Schütte German Federal Ministry of Education and Research (BMBF) | State Secretary | Germany Peter Suter University Medical Center | President | Switzerland and DZG Representatives

In response to the ever increasing number of people suffering from common diseases such as cancer, cardiovascular, metabolic, infectious, pulmonary, or neurodegenerative diseases, between 2009 and 2011 the German Federal Ministry of Education and Research (BMBF) initiated the founding of six German Centers for Health Research (DZG). A key aim of the BMBF in establishing the DZGs was to create favorable research conditions in which to combat major public health problems by optimizing the translational research process. The six DZGs ( The German Centers for Neurodegenerative Diseases, Diabetes Research, Cardiovascular Research, Infection Research, Lung Research, and the German Consortium for Translational Cancer Research) are structured as long-term, equal partnerships between non-university research institutions and universities with university hospitals throughout Germany. By bringing basic and clinical scientists

together and capitalizing on existing expertise and resources throughout Germany, the DZGs are making significant inroads on the prevention, diagnosis and treatment of diseases which are widespread in the population. A key component of the DZG mission is the education and training of translational and clinical researchers. Ensuring that investigators have the comprehensive skills they need to effectively and efficiently accelerate discoveries toward better health is essential. In the panel discussion “Education and training of clinical and translational scientists – Different models in different countries” the speakers of the DZGs will be joined by guests from the international translational research community to share perspectives on translational training and education in their respective countries/organizations.

Christian Boitard

Ernst Th. Rietschel

Petra Kaufmann

Georg Schütte

Elmar Nimmesgern

Peter Suter

PROGRAM, TUE 13

108

TUESDAY, OCTOBER 13, 2015

SUMMIT PROGRAM

111

WORKSHOP EVIDENCE TO POLICY

WS27 ROOM 3 | STRESEMANN 14:00•–•15:30

STRESS AND THE CITY: FLIGHT, MIGRATION AND MENTAL HEALTH EVIDENCE AND RESEARCH

HOSTS

M8 Alliance: Charité•–•Universitätsmedizin Berlin

Ute Weiland Opening and Closing Remarks Alfred Herrhausen Society– The International Forum of Deutsche Bank| Deputy Director | Germany

CHAIRS

SPEAKERS

Mazda Adli Charit鍖Universitätsmedizin Berlin | Director, Mood Disorders Research Group | Germany Fliedner Klinik Berlin | Chair | Germany

Andreas Heinz Mental Health in Minorities in Inner Cities Charit鍖Universitätsmedizin Berlin | Director, Clinic for Psychiatry and Psychotherapy | Germany

Sir Robin Murray King’s College London | Professor, Psychosis Studies | United Kingdom

Kenneth Miller War Child Holland | Senior Psychosocial Advisor | Netherlands

Fliedner Klinik Berlin

Jacqueline Weekers International Organization for Migration (IOM) | Senior Migration Health Policy Adviso, Migration Health Division | Switzerland

The rapidly growing cities of our world are the primary destinations for both intra- and interregional migration including flight. Particularly the last two years have witnessed substantial migration movements and the advent of refugees to Europe. Against this background cities are the essential integration motors of our societies. City authorities and healthcare services in particular have to deal with populations who are frequently traumatized, present with culture and language barriers, suffer from poverty and experience social exclusion. If the

governance of integration processes fails social conflicts and mistrust between residents and migrants frequently impact the social cohesion of urban areas and challenge mental health of all residents. Therefore cities are in need of public mental health strategies which take migration processes under clear consideration. This workshop brings together views and lessons from mental healthcare and psychiatry, social sciences and governance and aims at developing consequences from an interdisciplinary debate.

Mazda Adli

Ute Weiland

Andreas Heinz

Jacqueline Weekers

Sir Robin Murray

PROGRAM, TUE 13

110

TUESDAY, OCTOBER 13, 2015

SUMMIT PROGRAM

113

WORKSHOP GLOBAL HEALTH FOR DEVELOPMENT

WS28 ROOM 4 | RATHENAU 14:00•–•15:30

ONE WORLD•–•ONE HEALTH WILDLIFE CONSERVATION, COORDINATED POLICIES AND ONE HEALTH

HOSTS

SPEAKERS

M8 Alliance: InterAcademy Medical Panel (IAMP)

Thomas R. Gillespie Emory College of Arts and Sciences | Professor, Environmental Sciences | United States of America

Robert Koch Institute (RKI) World Wide Fund for Nature (WWF Germany) CHAIRS Detlev Drenckhahn World Wide Fund for Nature (WWF Germany) | President I Chairman | Germany Lai-Meng Looi Academy of Sciences Malaysia | IAMP Co-chair, Department of Pathology | Malaysia Lothar Wieler Robert Koch Institute (RKI) | President | Germany

Ilka Herbinger One Health and Conservation Strategies World Wide Fund for Nature (WWF Germany) | Program Officer Africa | Germany Fabian Leendertz One Health and the Human-Wildlife Interface Robert Koch Institute (RKI) | Research Leader, Epidemiology of Highly Pathogenic Microorganisms | Germany

Pathogens such as the Ebola and Nipah viruses are circulating in animal populations and can threaten both animal and human health. Thus both animal and human health sectors have a stake in, and a responsibility for, their surveillance and control. There is, therefore, a need for greater integration and coordination between medical researchers and practitioners, and researchers and practitioners involved in both domestic and wild animal health. This integration has been defined as the ‘One Health’ approach and is an approach that has taken hold in many developing countries where infectious diseases remain prevalent, but less so in developed countries. The proposed session will review the One Health concept, outlining its current reach and impact, which is perceived to be greater in the wildlife/veterinary

community than in the human medicine community. Case studies, focusing especially on the human/wildlife interface, will also show how health surveillance in wildlife and humans living at the wildlife interface can act as an early warning system for deadly infectious diseases such as Ebola. Through improved health and hygiene rules in humans in close contact with wildlife as well as surveillance systems, disease transmission of zoonotic and other infectious diseases can be significantly reduced and hence profit both human and wildlife health. Holding a dedicated session on One Health at the WHS is an opportunity to raise awareness of the One Health concept, especially among the human health practitioners, researchers, and, perhaps more importantly, decision-makers.

Detlev Drenckhahn

Fabian Leendertz

Thomas R. Gillespie

Albert Osterhaus

Ilka Herbinger

Marcel Tanner

Lai-Meng Looi

Lothar Wieler

Albert Osterhaus The One Health Platform Foundation University of Veterinary Medicine Hannover | Professor, Wildlife Virology and Virus Discovery | Germany Marcel Tanner History of and Introduction to One Health Swiss Tropical & Public Health Institute | Director | Switzerland

PROGRAM, TUE 13

112

114

TUESDAY, OCTOBER 13, 2015

SUMMIT PROGRAM

115

KEYNOTE EVIDENCE TO POLICY

PLENARY HALL | WELTSAAL 16:00•–•17:00

CLIMATE CHANGE AND HEALTH

HOSTS

SPEAKERS

Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety (BMUB)

Rita Schwarzelühr-Sutter Climate Change and Health: A Government Perspective Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety (BMUB) | Parlamentary State Secretary | Germany

Leopoldina•–•German National Academy of Sciences e.•V. M8 Alliance CHAIR Hartmut Graßl Max Planck Institute for Meteorology (MPI-M) | former Director | Germany

Sir Andrew Haines London School of Hygiene & Tropical Medicine | Director | United Kingdom Rainer Sauerborn University Hospital Heidelberg | Head, Institute of Public Health | Germany Hans Joachim Schellnhuber Potsdam Institute for Climate Impact Research (PIK ) | Director | Germany Ali Sié Research Center for Health of Nouna | Director | Burkina Faso

Health is currently not prominent in climate policy. It is regarded as one of 33 climate sensitive sectors. However, arguments deriving from health and physiology, if properly communicated to climate decision makers, could play a strong role as a driving force to motivate them (and citizens) to accept new policies and new behaviors for the transformation towards a low carbon society. This is based on three sets of arguments, which have recently been corroborated by new evidence (since IPCC AR5) and highlights further the need to communicate this evidence and the policy options properly to the highest level of climate policy makers. • There are huge health benefits from climate friendly policies and behaviors. Although the concept is not new, new evidence points to the large scope of known health benefits accruing from physical activity from walking and biking, insulated housing, low meat diets. Two recently identified co-benefits generate considerable additional health gains: a) Large health gains from reducing local pollutants, particularly in low and middle income countries. Fine particles and black carbon have recently been recognized as “climate active pollut-

ants”. Black carbon is of particular interest for climate policy, as reducing its emissions leads to a fast reduction of levels in the atmosphere. b) Recent population projections until 2100 significantly exceed previous UN estimates. Gerland et al. publishing their modeling results in Science 2014, project a 2100 population size of between 9.3 to 12.6 billion. This urgently calls for even greater efforts in voluntary family planning, hence reaping even larger the linked health benefits accruing to mothers and their fewer children. • There are clear limits to society’s capacity to adapt to the projected health impact of climate change. This applies to some extent in a 2°C, but definitely in a 4°C warmer world, even given maximal resource allocation to the task. • Heat stress leads to a reduction in work productivity in a warmer world, particularly in a 4° warmer climate. This concerns mainly the large populations in (sub-) tropical and arid areas and applies both to outdoor work, such as farming and construction and to indoor industrial production in non-air conditioned buildings.

Rita Schwarzelühr- Rainer Sauerborn Sutter

Hartmut Graßl

Sir Andrew Haines

Hans Joachim Schellnhuber

PROGRAM, TUE 13

KEY05

116

TUESDAY, OCTOBER 13, 2015

SUMMIT PROGRAM

117

KEYNOTE

KEY06 PLENARY HALL | WELTSAAL 17:00•–•18:00

GLOBAL HEALTH SECURITY•– M8 ALLIANCE STATEMENT & CLOSING CEREMONY HOSTS

SPEAKERS

M8 Alliance

Luiz Loures United Nations (UN) | Assistant Secretary-General | Switzerland UNAIDS | Deputy Executive Director | Switzerland

Munich Security Conference Foundation gGmbH (MSC) CHAIRS Shunichi Fukuhara World Health Summit President Kyoto University | Dean, Vice President, School of Public Health, Vice President Department of Healthcare Epidemiology | Japan Detlev Ganten World Health Summit President Charité Foundation | Chairman of the Board | Germany Wolfgang Ischinger Munich Security Conference Foundation gGmbH (MSC) | Chairman | Germany

Sir Robin Murray King’s College London | Professor, Psychosis Studies | United Kingdom

The Global Health Security agenda is an effort to create synergies between nation-states, international organizations and public & private stakeholders. Its goal is to accelerate progress toward a world that is safe from threats posed by infectious disease, and to promote global health security as an international security priority.

Shunichi Fukuhara

Luiz Loures

Detlev Ganten

Sir Robin Murray

Wolfgang Ischinger

Richard Sezibera

Richard Sezibera East African Community (EAC) | Secretary General | Rwanda

PROGRAM, TUE 13

EVIDENCE TO POLICY

GENERAL INFORMATION

SUMMIT VENUE

SUMMIT VENUE

e

ße ra

st ra ß

Presidential Lounge

Auswärtiges Amt mt (Altbau)

Federal Foreign Office (old building)

st er ss wa

M8 Lounge

Entrance World Health Summit Unterwasserstraße 10

er Ob

Arriving by train: From Berlin Hauptbahnhof (main station): Take bus line 147 in the direction of U Märkisches Museum and exit at “Spittelmarkt“. Please check the area-map on page 123 for further orientation.

e

Bag Counter

Federal Foreign Office (new building)

ße

Weltsaal

Arriving by air: • From Tegel Airport: Take the bus line X9 to “Ernst-Reuter-Platz“, connect to the underground line U2 in the direction of Pankow and exit at “Spittelmarkt“. • From Schönefeld Airport: Take the S-Bahn (train) to “Friedrichstraße“, connect to bus line 147 in the direction of Ostbahnhof and exit at “Spittelmarkt“. Alternatively take the S-Bahn line S9 to “Schönhauser Allee“, connect to the line U2 (underground train) in the direction of Ruhleben and exit at “Spittelmarkt“. • Transfer time by taxi is approximately 25 minutes from Tegel Airport and 50–60 minutes from Schönefeld Airport.

Auswärtiges uswärtiges Amt (Neubau)

traß ers

Rathenau-Saal

• From the underground station “Spittelmarkt“ (Line U2): Walk along the left side of the water canal. Shortly after the antique draw bridge, the Summit entrance will be on your left. • From the underground station “Hausvogteiplatz“ (Line U2): Turn into “Oberwallstraße“, turn right onto Werderscher Markt, go past the Auswärtiges Amt and turn right again directly afterwards. Continue along the side of the building to the Summit entrance.

rkt

Ma

Ku r

Stresemann-Saal

her

rsc rde We

stra Kur

Please be aware: You will not be able to enter the Summit venue, if you are not able to present your passport or ID-card. Unfortunately this procedure may produce a slight delay for entrance into the building. We therefore kindly ask you to refrain from bringing your luggage to the Summit venue, as this will slow down the security check process.

Adenauer-Saal

Arriving by public transportation:

ass erw Unt

raße

serst rwas Unte

The World Health Summit will be taking place at the Federal Foreign Office. Please be advised that due to security reasons, all delegates will be subject to a security check including a passport identification confirmation.

rat ist

g Re

Federal Foreign Office (Auswärtiges Amt) Entrance: Unterwasserstraße 10

ne

ion

HOW TO GET TO THE SUMMIT VENUE

e

ei

fe

Jung

121

ß ra st en

Kl

Europa-Foyer

cke rnbrü

p Europasaal tu s ar St tche i P r a ke di ea ter Me ffice Sp en C O p tu ar n St tatio en es Pr Willy-Brandt-Saal

Interview Area

120

d

au tr

G

er

ACCOMMODATION

Hotel Name

ACCOMMODATION

Address

Distance to Summit Venue

Category

Single Room

Double Room

1

Westin Grand Berlin

Friedrichstraße 158–164

0.8 km

5*

€ 189.00

€ 209.00

7

Radisson Blu

Karl-Liebknecht-Straße 3

0.9 km

5*

€ 149.00

€ 199.00

2

Sofitel Berlin

Charlottenstraße 50

0.6 km

5*

€ 215.00

3

Arcotel John F.

Werderscher Markt 1 1

0.2 km

4*

€ 139.00

4

Cosmo Hotel Berlin Mitte

Spittelmarkt 13

0.4 km

4*

€ 1 14.00

€ 124.00

5

Courtyard by Marriott Berlin

Axel-Springer-Straße 55

0.6 km

4*

€ 135.00

€ 145.00

6

Motel One Spittelmarkt

Leipziger Straße 50

0.4 km

2*

€ 76.50

€ 99.00

U ROSENTHALER PLATZ

NATURKUNDEMUSEUM

U ROSALUXEMBURGPLATZ

U

CENTRAL STATION

€ 159.00

Charité

U

ORANIENBURGER TOR

ORANIENBURGER STRASSE

U

WEINMEISTERSTRASSE

U

HACKESCHER MARKT ALEXANDERPLATZ

CONTACT: Email: [email protected]

Berliner Dom

1 Westin Grand Berlin

U

FRANZÖSISCHE CHE STRASSE SSE

U

Unter den

U

Radisson Blu

U BRANDENBURGER TOR

Sofitel Berlin

Arcotel John F. 3

2

Gendarmenmarkt

FRANZÖSISCHE STRASSE

Federal Foreign Office

Unter den

Linden

U

U

U

e er Straß Leipzig

6

U

POTSDAMER PLATZ

U

STADTMITTE

e

er Straß

Leipzig

U

SPITTELMARKT

Motel One Spittelmarkt 5 Coutyard by Marriott Berlin

U

HAUSVOGTEIPLATZ

MOHRENSTRASSE

Cosmo Hotel Berlin Mitte 4

U

Auswärtiges Amt

Gendarmenmarkt

U

KLOSTERSTRASSE

Federal Foreign Office

Auswärtiges uswärtiges Amt

HAUSVO GTEIHAUSVOGTEIPLATZ STADTMITTE

Berliner Dom

Allianz Forum

Linden

U

FRIEDRICHSTRASSE

ße Friedrichstra

ENTRANCE: Unterwasserstraße 10

U

7

VENUE: Federal Foreign Office Werderscher Markt 1 10117 Berlin

aße Friedrichstr

122

U

KOCHSTRASSE

U

MÄRKISCHES MUSEUM SPITTELMARKT

123

124

CITY OF BERLIN

CITY OF BERLIN

BERLIN: A METROPOLIS FOR HEALTH AND CAPITAL OF CULTURE Health check in the morning, opera in the evening – hardly any other city combines culture, lifestyle and healthy living as well as Berlin. The capital’s tradition as a metropolis for health and science spans more than 300 years. Today, some 8,000 doctors at the city’s approximately 81 hospitals treat 780,000 patients every year.

For more information on Berlin, visit health.visitBerlin.com

One of its most famous medical institutions is the renowned Charité, Europe’s largest university hospital and one of Germany’s leading hospitals. The doctors and scientists at the Charité are well recognised in international medicine, and co-operate with foreign research institutes like the Johns Hopkins Bloomberg School of Public Health in Baltimore, USA. 2014 saw Berlin host 193 events run by international associations, ranking the city among the top 5 in the ICCA (International Congress and Convention Association) statistics, and further building on its position as a suitable metropolis for major conferences. The German capital is also increasingly positioning itself as a location for events in science and medicine: eleven per cent of the approximately 131,000 meetings, conventions and events held in 2014 were in the fields of medicine, science and research, according to the latest statistics. International conferences such as the World Health Summit show that the German capital has been able to consolidate its strong position as a destination for medical events. More and more foreign guests are discovering Berlin’s potential as a “health city”. In 2014, more than 1 1,000 international patients travelled to the German capital to receive a medical treatment in one of Berlin’s top seven clinics. They combined their trip with a relaxing holiday. Apart from excellent medical care, visitors to the capital can also enjoy its wide range of wellness hotels and spas, as well as its unique character.

BERLIN¡–¡A CULTURAL METROPOLIS Along with first-class health services and scientific conferences, Berlin also provides varied cultural experiences. From ancient art by the Old Masters to avantgarde design, from classical opera to musicals to pop concerts, Berlin’s cultural calendar leaves nothing to be desired. Visitors to the capital can choose from around 1,500 events a day. Culture and art enthusiasts can also admire new styles and prominent works from all eras every day in Berlin’s over 180 museums and approximately 440 galleries. The city’s best known museums include the five buildings at Museum Island (Museumsinsel), which is in the historic centre. All buildings display valuable artistic treasures from 3,000 years of human history, e. g. the famous bust of Nefertiti in the New Museum, while the Hamburger Bahnhof and Martin Gropius Building present contemporary art. Berlin is the world’s only city to have three opera houses: the Berlin State Opera (Berliner Staatsoper), the Deutsche Oper and the Komische Oper. Classical music lovers can choose from a repertoire of famous works, such as Mozart’s Don Giovanni, or new and experimental operas. Apart from these opera houses, the city’s eight large orchestras, including the world famous Berlin Philharmonic conducted by Sir Simon Rattle, also make for high-class musical enjoyment.

The autumn of this year will see the 25th anniversary of German reunification. With photographs, audio and video recordings as well as original exhibits from the reunification period, the exhibition “Unification–German society in transition” at the Deutsches Historisches Museum depicts the process of re-uniting the two Germanys and its impact on daily life not only in Berlin but throughout the entire Federal Republic. The Italian painter and draughtsman Sandro Botticelli is regarded as one of the most important artists of the early Renaissance, with the “Birth of Venus” counting as one of his most famous works. In cooperation with London’s Victoria & Albert Museum, “The Botticelli Renaissance” exhibition in the Gemäldegalerie proves that, more than any other old master, Botticelli had a major impact on the art of the modern and contemporary periods.

For more events, go to events.visitBerlin.com

125

126

FEDERAL FOREIGN OFFICE

THE HOUSE ON WERDERSCHER MARKT Since its return to Berlin in 1999, the Federal Foreign Office has been located in the “Haus am Werderscher Markt“ (House on Werderscher Markt). After the former Tempelhof airport terminal, this is the second largest building in Berlin with its 550,000 m3 of enclosed space. Like many other buildings in Germany’s capital, the building and surrounding area is a Berlin icon which has witnessed Germany’s eventful and turbulent history. 1690 A court building was constructed to the south west of Werderscher Markt.

FEDERAL FOREIGN OFFICE

1765 The “Royal Savings and Loan Bank“, (Königliche Giro- und Lehnbank) founded by Frederick the Great, moved into the building. Thanks to con siderable economic growth and development in Prussia the following decades saw a number of modifications and extensions to the building. 1846 First as the “Prussian Bank“ (Preußische Bank) and then starting in 1876 as the “Reichsbank“ (Reichsbank) the building continued to grow until 1903 when it took up the entire block between Jäger-, Kur-, Oberwall- and Kleiner Jägerstraße. In 1913 Even before the First World War, the premises of the “Reichsbank“ were too small. In 1913 the bankbegan to buy land in the surrounding area. 1932 Plans were formulated for a new building close by, and two years later the foundation stone was laid. 1940 After six years of construction, the building was completed and the “Reichsbank“ moved in, atwhich time its main task had changed to primarily funding the war. The new bank building was located on the opposite side of the road from Werderscher Markt, but a bridge was built between the two which provided access to the first floor of each building.

1945 During the Second World War the “Reichsbank“ extension suffered severe damage. After the initialrepairs were carried out, the “Berlin City Office“(Stadtkontor) took over several rooms in the house. 1949 In autumn, the Ministry of Finance of the newlyfounded German Democratic Republic (GDR) took over the building. 1959 In summer, the Central Committee of the SED (Socialist Unity Party) moved in. With this move, the building on Werderscher Markt came to be at the center of political power in the GDR. 1989 In the course of the political demise of the GDR, the central committee of the SED was dissolved on December 8. 1990 In the first few weeks of the year, the house on Werderscher Market was vacated. A little later the building was renamed the “House of Parliamentarians“ (Haus der Parlamentarier). This new name came about on March 18 when the members had a free election to select their new “People’s Chamber“ (Volkskammer), which would now occupy the space.

1999 Thanks in part to the design by Berlin architects Thomas Müller and Ivan Reimann, a new building was added on Werderscher Markt to accommodate the Federal Foreign Office (Auswärtiges Amt). The two buildings are connected by a shared courtyard. A photovoltaic system on the roof of the older building with a connection to the newer building’s heating network provides an environmentally-friendly energy supply.

INTERIOR VIEWS − THE FEDERAL FOREIGN OFFICE The old and new buildings of the Federal Foreign Office provide 62,500 m2 office space for more than 2,000 employees. In addition, the two buildings house several conference halls, the political archives, medical and social services, a canteen, as well as the library. The nerve center of the Federal Foreign Office is the old building erected in 1934, which served as the Reichsbank from 1934 to 1938. In 1959, the building became the headquarters of the Socialist Unity Party of Germany, the ruling party in the GDR. The Central Committee and the Politburo met there. In 1995 it was decided to locate the Federal Foreign Office in this building and to add a new building on Werderscher Markt.

127

128

FEDERAL FOREIGN OFFICE

The new building was designed by the architects Thomas Müller and Ivan Reimann and constructed from 1997 to 1999. The transparent facade of glass and travertine stone invites visitors to enter the atrium and its visitor center, which is open to the public. All in all, the new building with its three partially open inner courts recalls the link between the old building and the Spree Canal, Schlossplatz and Werderscher Markt. The architect commissioned to refurbish and alter the old building, Hans Kollhoff, faced a threefold task. Firstly, he had to make it evident that Germany’s new foreign policy had nothing to do with the policies pursued in this building during the two German dictatorships. On the other hand, however, he could not simply wipe out all traces of the past. What is more, the building had to be redesigned to meet the Federal Foreign Office’s spatial and functional requirements. To this end, Hans Kollhoff developed the threelayer concept. The first layer highlights the modern aspects of the old building, which should not be transformed solely as an embodiment of National Socialist architecture. The second layer preserves in an exemplary fashion the building’s design during the GDR era. For the third layer, a color concept which developed in collaboration with the artist Gerhard Merz whose large monochrome surfaces lend the building a modern flair.

THE WELTSAAL (WORLD HALL) At the heart of the old building on the first floor lies a large conference center, almost 900m2 in size. The former Reichbank Hall 1 was considerably altered for use by the SED leadership as a conference hall. During this process the luminous ceiling was covered over. When the Federal Foreign Office was refurbished, however, it was uncovered, as was the original wood paneling in the central part of the ceiling. The entire room can be divided by a 9 meter high and 16 meter wide mobile partition. It was designed by Gerhard Merz as part of the three layer concept. The surface consists of numerous small squares in various colors. This deviation here in the Weltsaal from the monochrome surface principle applied in the rest of the Old Building was intended to highlight the world’s cultural diversity. The lower part of the walls and the doors to the lounges are clad in German cherrywood. The interpretation booths, screened off from the hall, are situated on top. This screen is divided into three monochrome sections, each of which has a slim aluminum frame. The lower sections consist of black glass, the larger middle sections of a white screen, while the upper sections are mirrors.

130

GENERAL INFORMATION

GENERAL INFORMATION

ACCESS TO THE VENUE•/•SECURITY

COFFEE BREAKS

HOMEPAGE

MEDIA

To enter the World Health Summit venue (Federal Foreign Office), participants are required to present a valid identity card/passport or a similar personal identification document (photo included). Please be advised that due to security reasons, all participants will be subject to a security check including a passport identification confirmation. This procedure may cause a slight delay for entrance into the building. We there fore kindly ask you to refrain from bringing your luggage to the venue, as this will slow down the security check process.

Refreshments will be served during the coffee breaks.

For up-to-date information regarding the World Health Summit, please visit www.worldhealthsummit.org.

Media representatives have access to all official sessions of the World Health Summit. Prior accreditation is required via www.worldhealthsummit.org/press-media/ accreditation

AVAILABILITY Please note that the capacity of the venue and of single session rooms is limited. If the maximum number of delegates is reached, the organizers reserve the right to refuse access.

CURRENCY INSURANCE AND LIABILITY The currency used in Berlin is the Euro (€ or EUR). Automated teller machines (ATMs), are located everywhere in Berlin and they accept most main credit cards such as Visa, Mastercard and American Express. CASH POINT BBBank eG Berlin Hausvogteiplatz 3–4 10117 Berlin

The organizers cannot accept liability for personal injury, loss of or damage to belongings of participants, either during or as a result of the Summit. Please check the validity of your own insurance. Attendees are advised to arrange their own adequate travel and medical insurance for medical treatment, accidents, cancellation of bookings etc. No responsibility will be accepted by the World Health Summit organizers. INTERNET•/•WIRELESS LAN

EMERGENCY NUMBERS

CERTIFICATE OF ATTENDANCE

Fire: 112 Ambulance: 112 Police: 110

Complimentary Wi-Fi will be available within the venue: Name: WorldHealthSummit Password: #WHS2015

A Certificate of Attendance for all registered participants will be available upon request at the registration desk.

FILMING AND TAKING PICTURES

LANGUAGE

The organizer will provide a broad spectrum of pictures and other graphical material for the representation of all World Health Summit events. These files will be made available at www.worldhealthsummit.org.

The official World Health Summit language is English. There will be no simultaneous translation.

CLOAKROOM A cloakroom will be open in the back of the venue (next to the “Weltsaal“) during the registration opening times.

MOBILE PHONES As a courtesy to speakers and other attendees, we kindly request that all mobile phones and similar devices will be turned to silent mode before entering a session. NAME BADGE A badge is required for admittance to all World Health Summit sessions and events. Each participant is asked to present the badge in order to gain access to the Summit. PEOPLE WITH DISABILITIES The venue is accessible to participants with disabilities. Please contact the Secretariat for assistance: Phone: +49 30 49855035 or [email protected] LOST AND FOUND

LUNCHES Lunches will be available during the lunch breaks.

Lost items can be collected at the registration desk during the Summit. Any objects found during the event and not claimed will remain at the venue.

131

132

GENERAL INFORMATION

GENERAL INFORMATION

LIVE-STREAM•/•WEBCASTS

Fees: Short Trip 1,60 €

All sessions in the “Weltsaal” will be available as live-stream at www.worldhealthsummit.org. Recorded webcasts will be available online after the event.

(max. 3 stations, one way only)

PARKING Please note that there are no public parking facilities at the venue.

Single Trip AB 2,70 € (one way only) Single Trip BC 3,00 € (one way only) Single Trip ABC 3,30 € (one way only) Day Ticket ABC 7,40 € (all directions) (AB, BC, ABC are indicating the travel zone.) Detailed information regarding public transpor tation is available at www.bvg.de

or a CD-ROM. Please note that you cannot run the presentation from your personal laptop in the session room. Video support is at the sole responsibility of the speaker. The Speaker Center is open during the following times: Sunday, October 11, 2015 Monday, October 12, 2015 Tuesday, October 13, 2015

09:00 – 18:00 08:00 – 18:00 08:00 – 18:00

REGISTRATION PROGRAM CHANGES The organizers cannot assume liability for any changes in the program due to external or unforeseen circumstances. Please check the website for regular updates. The organizers reserve the right to cancel, postpone, relocate or change any of the sessions.

TAXIS The registration desk is open during the following times: Sunday, October 11, 2015 Monday, October 12, 2015 Tuesday, October 13, 2015

09:00 – 22:00 08:00 – 19:00 08:00 – 19:00

SMOKING POLICY POSTERS A poster exhibition will be located at the poster area in the “Europa Foyer”.

It is forbidden to smoke in any part of the World Health Summit venue. SPEAKER CENTER

PUBLIC TRANSPORTATION Berlin’s public transport provides safe and comfortable rides to almost all destinations in the city. Tickets can be purchased directly at most train stations and in all busses.

All speakers and presenters must report to the Speaker Center, located at the “Europasaal”, at least two hours prior to their presentation in order to check and upload their presentation. Please provide the data on a USB Memory Stick

All official taxis are colored off-white with a yellow taxi sign on the roof. The meter starts at a set minimum price. Major Taxi Hotlines: Taxi Berlin +49 30 202020 Taxi Würfelfunk +49 30 210101 Taxi Funk +49 30 443322 If there is no taxi available, please ask the registration desk staff for assistance.

133

134

MEDIA INFORMATION

CONTACTS

MEDIA INFORMATION

Media Registrations Media Registrations are available free of charge to journalists (pending proof of affiliation). Prior to the Summit, please establish your accreditation online via www.worldhealthsummit.org. During the Summit, please contact the media accreditation counter at the registration desk.

PRESS CONTACT Tobias Gerber, Daniela Levy [email protected] [email protected] Tel.: +49 30 450 572 114

Media Access Media has access to all official sessions of the World Health Summit. Media Office Location: Room “Europasaal“ Sunday, October 11, 2015 Monday, October 12, 2015 Tuesday, October 13, 2015

09:00 – 20:00 08:30 – 17:30 08:30 – 17:30

It is possible to arrange interviews with our speakers in a designated interview-area.

PRESS CONFERENCE Date: Sunday, October 11, 15:30•–•16:30 Room: Europasaal

WHS Foundation GmbH c/o Charit鍖 Universitätsmedizin Berlin Charitéplatz 1 10117 Berlin, Germany

Strategic Communications Daniela Levy [email protected] Tel.: +49 30 450 572 114 Fax: +49 30 450 517 91 1

WHS Presidents Shunichi Fukuhara Detlev Ganten

Secretariat Pascale Schulte [email protected]

Managing Directors Jörg Heldmann [email protected] Tel.: +49 30 450 572 1 18 Fax: +49 30 450 517 91 1

Conference Manager•/•Office Assistant Sarah-Maria Riedel [email protected] Tel: +49 30 450 572 219 Fax: +49 30 450 517 91 1

Alexander Hewer [email protected]

PA to the Managing Director Petra Neitzel [email protected] Tel: +49 30 450 572 219 Fax: +49 30 450 517 91 1

Program Director Julian Kickbusch [email protected] Tel.: +49 30 450 572 102 Fax: +49 30 450 517 91 1

Partner and Co-Host

Press & Public Relations Director Tobias Gerber [email protected] Tel.: +49 30 450 572 1 14 Fax: +49 30 450 517 91 1

Organizing Secretariat Agentur WOK GmbH Palisadenstraße 48 10243 Berlin Project Manager Katrin Meischner Registration Department Felix Heller

135

136

KEYNOTE SPEAKERS AND CHAIRS

KEYNOTE SPEAKERS AND CHAIRS

KEYNOTE SPEAKERS AND CHAIRS SAÏD AÏDI

CHRISTINA RÅNGEMARK ÅKERMAN

Mr. Saïd Aïdi currently serves as Minister of Health of Tunisia within the government of Habib Essid. He previously worked as Deputy of Tunis 2 District (December 2014) and Minister of Vocational Training and Employment within the government of Mohamed Ghannouchi and Beji Caid Essebsi (2011). He also held presidency position of the International Association “Education for Employment Tunisia” until April 2013.

Christina Rångemark Åkerman is President of the International Consortium for Health Outcomes Measurement (ICHOM), a nonprofit organization with the purpose to transform health care systems worldwide by measuring and reporting patient outcomes in a standardized way.

RIFAT ATUN

MANICA BALASEGARAM

Rifat Atun is Professor of Global Health Systems and the Director of Global Health Systems Cluster at Harvard University, Harvard School of Public Health. In 2006–2013, Dr. Atun was Professor of International Health Management and Head of the Health Management Group at Imperial College London.

Balasegaram is a medical doctor. He Joined MSF In 2001, working as a doctor in the field in several countries in Sub-Saharan Africa and Southern Asia. He then joined MSF Partner organization Drugs For Neglected Diseases Initiative (DNDi) in 2008, where he worked for four and a half years, finishing as DNDi’s Head Of Leishmaniasis Clinical Development Team before joining the Access Campaign.

DOUGLAS WILLIAM BETTCHER

JOE CERRELL

Douglas William Bettcher is the Director the Department for Prevention of Noncommunicable Diseases, World Health Organization (WHO), Geneva, Switzerland. He was previously the Director of WHO’s Tobacco Free Initiative Department, which has now become an integral programme within the new Prevention of Noncommunicable Diseases Department.

Joe Cerrell, managing director, Global Policy and Advocacy, is based in the Gates Foundation’s European Office in London. In this role, Joe oversees the foundation’s relationships with donor governments in North America, Europe, Asia-Pacific, and the Middle East. His team seeks to expand the foundation’s partnerships with these governments.

MARGARET CHAN

KATIE DAIN

Margaret Chan is the Director-General of World Health Organisation. Born in the People’s Republic of China, Dr Chan joined WHO as Director of the Department for Protection of the Human Environment in 2003. She was elected Director-General in 2006 and was appointed for a second five-year term in 2012.

Katie Dain is Executive Director of the NCD Alliance. Sheis widely recognized as a leading advocate and expert on NCDs, and has authored or co-authored numerous papers and commentaries on global health and development policy issues. She is a member of advisory groups and committees for a range of international NCD initiatives.

DAME SALLY DAVIES

MARK DYBUL

Prof Dame Sally Davies is the Chief Medical Officer for England and Chief Medical Advisor to the UK Government. She founded the National Institute for Health Research (NIHR) in the UK, is a member of the World Health Organization Executive Board and has advised many others on research stra tegy and evaluation. Dame Davies is Emeritus Professor at Imperial College.

Mark Dybul is the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. He has worked on HIV and public health for more than 25 years as a clinician, scientist, teacher and administrator.

VICTOR J. DZAU

CATHERINE FIANKAN-BOKONGA

Victor J. Dzau is the President of The Institute of Medicine at National Academy of Sciences, USA. He is also Chancellor of Health Affairs, Director of Molecular and Genomic Vascular Biology and President and Chief Executive Officer at Health System of Duke University Medical Center.

Ms. Fiankan-Bokonga has been a correspondent in Geneva since 1999. She is also a presenter and producer of television news reports. She is the Vice President of the Foreign Press Association of Switzerland and Lichtenstein (APES) and a member of the Board of the Swiss Press Club and the Association of Accredited Correspondents to the United Nations (ACANU).

SHUNICHI FUKUHARA

DETLEV GANTEN

Shunichi Fukuhara is a Professor and Dean of the Kyoto University School of Public Health and Associate Dean of Graduate School of Medicine. He represents Kyoto University as a member of the M8 Alliance, academic advisors of the WHS and is the 2015 WHS international co-president.

Detelv Ganten is the President of the World Health Summit since 2009. Since 2005 he holds the position as Chairman of the Foundation Board of the Charité Foundation, and Chairman of the joint Board of Trustees of the Max Planck Institute of Colloids and Interfaces and of the Max Planck Institute of Molecular Plant Physiology.

137

138

KEYNOTE SPEAKERS AND CHAIRS

KEYNOTE SPEAKERS AND CHAIRS

HARTMUT GRASSL

HERMANN GRÖHE

JOSEPH JIMENEZ

DEBRA A. JONES

Hartmut Graßl is the former director of the Max Planck Institute of Meteorology and professor emeritus at the Hamburg University for General Meteorology.

Hermann Gröhe is the Minister of Health of Federal German Republic. From 2005 to 2008, he acted as legal counsel to the CDU/CSU parliamentary group and, from 2006 to 2008 as a spokesperson of the CDU/CSU parliamentary group in the First Committee of Inquiry.

Joseph Jimenez has been Chief Executive Officer (CEO) of Novartis since 2010. He is responsible for leading the company’s healthcare portfolio of businesses in pharmaceuticals, eye care and generics.

Ms. Debra A Jones serves as Save the Children’s Director and UN Representative in New York, engaging with UN agencies, delegations, and civil society partners to create lasting positive change for the world’s poorest and most vulnerable children.

NORBERT HAUSER

DAGFINN HØYBRÅTEN

MACHARIA KAMAU

ILONA KICKBUSCH

Norbert is currently the Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria. As a a former Member of Parliament and international auditor from Germany Mr. Hauser previously served as interim Inspector General at the Global Fund in 2012–2013 and as a member of the HighLevel Panel that created a blueprint for reform at the Global Fund.

Dagfinn Høybråten is the Chair of the GAVI Alliance Board and the Secretary General of the Nordic Council of Ministers. Mr Høybråten has held several senior positions in Norwegian Government including Vice President of The Norwegian Parliament representing the Christian Democratic Party and a member of the Standing committee for Foreign Affairs and Defence.

Mr. Kamau is currently the co-facilitator for the intergovernmental negotiations on the post-2015 development agenda and was the co-chair of the UN Open Working Group on the Sustainable Development Goals (SDGs).

Ilona Kickbusch is the Director of the Global Health Program at the Graduate Institute of International and Development Studies, Geneva. She is a leading contributor to academic and political debates on governance for health at the national and the global level. She conducts global health diplomacy seminars in many countries and regions and advises the WHO at global and regional level.

HARTWIG HULAND

WOLFGANG ISCHINGER

Hartwig Huland holds the position as Urologist and Chief Physician at the Martini Klinik, Hamburg since 2004. He also is a member of the German, European and American Society of Urology and serves as a reviewer for the American “Journal of Urology” and “European Urology”.

Ambassador Wolfgang Ischinger is the chairman of the Munich Security Conference on the initiative of the German government. Ischinger began his diplomatic career when he joined the Federal Republic of Germany’s Foreign Service. He initially worked in the Policy Planning Staff and at the German Embassy in Washington, D.C. He became Political Director of the Foreign Office.

MARIE-PAULE KIENY

JOHN KIRTON

Marie-Paule Kieny was appointed Assistant Director-General at the World Health Organization (WHO) in October 2010 and is now leading the Health Systems and Innovation cluster.

John Kirton is Director of the G7 Research Group, established at the University of Toronto in 1987, Co-director of the G20 Research Group, Co-director of the Global Health Diplomacy Program, and a Research Associate of the Munk School of Global Affairs.

ZSUZSANNA JAKAB

LINONG JI

Zsuzsanna Jakab is the World Health Organization (WHO) Regional Director for Europe. In this role, she has engaged at first hand with many partners and Member States, making progress on a joint health agenda for the WHO European Region.

Linong Ji is a Professor of Medicine and Vice-President of the International Diabetes Federation (IDF) 2013–2015. He is the Director of Department of Endocrinology and Metabolism at Peking University People’s Hospital and Co-Director of the Diabetes Centre of Peking University.

BIRGIT KÖNIG

SURESH KUMAR

Birgit König is the first female member of the Executive Committee of Allianz Germany, as Head of the Management Board. She has a PhD in Biochemistry and is a member of the European Health Care Practice.

Suresh Kumar currently serves as Member of the Executive Committee and the Global Leadership Team as well as Executive Vice President for External Affairs. He has an Economics degree from Delhi University and a Masters in Management from Bombay University and more than 30 years of experience in the healthcare industry.

139

140

KEYNOTE SPEAKERS AND CHAIRS

KEYNOTE SPEAKERS AND CHAIRS

STEFAN LARSSON

WIM LEEREVELD

MITCHELL MORRIS

LUKA MUCIC

Stefan Larsson joined BCG in 1996 and is a Senior Partner. He is the global leader of BCG’s Health Care Payor and Provider sector and a member of the global Health care leadership team. Mr. Larsson has worked across all aspects of the Health Care industry.

Wim Leereveld is CEO and Founder of the Access to Medicine Index, an NGO which ranks the world’s largest pharmaceutical companies every two years on their policies and practices for improving access to medicine for people living in low-income and middle-income countries.

Mitchell Morris is Vice Chair and the Global Leader for the Healthcare Sector at Deloitte. He is responsible for leading the US and global healthcare practice for one of the world’s largest professional services firms offering audit, risk, tax, financial advisory and a range of consultative services.

Luka Mucic is a member of the Executive Board and Global Managing Board of SAP SE and is the Chief Financial Officer as well as Chief Operating Officer (COO).

FREDA C. LEWIS-HALL

KLAUS LINDPAINTNER

MICHAEL MYERS

HIROKI NAKATANI

As Chief Medical Officer, Freda Lewis-Hall leads Pfizer Medical, the division of Pfizer responsible for the safe, effective and appropriate use of the company’s medicines and vaccines everywhere in the world.

Klaus Lindpaintner is Chief Scientific Officer at Thermo Fisher Scientific Inc. He served as a Roche Distinguished Scientist and director of the Roche Center for Medical Genomics, as well as global head of molecular medicine policy and external affairs for F. HoffmanLa Roche AG.

Michael Myers performs a number of leadership roles at The Rockefeller Foundation. He leads the Foundation’s global health work including its Transforming Health Systems initiative and the campaign for universal health coverage. He also coordinates strate gies for the Foundation’s work in the United States with a focus on building inclusive economies in cities.

Hiroki Nakatani is presently Advisor for International Affairs to the Minister of Health, Labour and Welfare, Government of Japan, and, Professor for Global Initiatives at Keio University. He served as Assistant Director-General of WHO from March 2007 to May 2015.

GÜNTHER H. OETTINGER

AXEL R. PRIES

Günther H. Oettinger is currently the European Commissioner for Digital Economy and Society. Following several years of work as a lawyer, he entered the political arena, where he has been active both in BadenWürttemberg and the European Commission.

Axel R. Pries holds the position Dean of the Charité since January 2015. He also is the Head of the Institute of Physiology at the Charit鍖Universitätsmedizin Berlin.

LUIZ LOURES

JEAN-CLAUDE MANUGUERRA

Loures is a medical doctor with nearly 30 years’ experience in the AIDS response. He joined UNAIDS in 1996 and was appointed Deputy Executive Director of Programme and Assistant Secretary-General of the United Nations in January 2013. He leads UNAIDS’ efforts in leveraging critical support to coun tries to meet the 2015 global AIDS targets and establish a sustainable response to AIDS.

Jean-Claude Manuguerra is a Virologist at the Pasteur Institute in Paris. He is the Chairman of the National Committee against the flu and seats the Scientific Council of the global program against the flu by the World Health Organization (WHO).

AMY MAXMEN

SUERIE MOON

K. SRINATH REDDY

MELVIN SAMSOM

Amy Maxmen is a science journalist, editor, and photographer who covers the entanglements of evolution, medicine, policy and of the people behind research. Her stories appear in a variety of outlets, including National Geographic, Nature, Newsweek, Nova/PBS, Al Jazeera and the New York Times.

Suerie Moon is the Study Director of the Independent Panel on the Global Response to Ebola, a joint initiative of the Harvard Global Health Institute, Harvard University and the London School of Hygiene and Tropical Medicine.

K. Srinath Reddy is currently President of the Public Health Foundation of India (PHFI) and formerly headed the Department of Cardiology at All India Institute of Medical Sciences (AIIMS).

Melvin Samsom has been the Chief Executive Officer of Karolinska University Hospital since October 1, 2014. Mr. Samsom has been department chairman and division chairman at the University Medical Center Utrecht, then becoming CMO, and in 2011 Chief Executive Officer of Radboud University Medical Center.

141

142

KEYNOTE SPEAKERS AND CHAIRS

KEYNOTE SPEAKERS AND CHAIRS

RAINER SAUERBORN

HANS JOACHIM SCHELLNHUBER

FRIEDRICH VON BOHLEN UND HALBACH

FLORIAN WESTPHAL

Rainer Sauerborn is the drector of the Institute of Public Health at Heidelberg University since 1997. He also holds the position of a guest pofessor at Umea University in Sweden for “Global Health and Climate Change”.

Hans Joachim Schellnhuber founded the Potsdam Institute for Climate Impact Research (PIK) in 1992 and has been its Director ever since. He holds a Chair in Theoretical Physics at Potsdam University and is an External Professor at the Santa Fé Institute (USA).

Friedrich von Bohlen und Halbach is a managing partner at dievini Hopp BioTech Holding GmbH & Co.KG., the company managing the life science activities and investments of SAP co-founder Dietmar Hopp. He has more than 15 years of entrepreneurial experience in the field of Life Sciences.

Florian Westphal currently works as General Director at Médecins Sans Frontières Germany. He worked for 15 years as a member of the International Committee of the Red Cross (ICRC) in various countries such as Democratic Republic of Congo, Sierra Leone and Kenya and subsequently served as the ICRC’s Head of Media.

LEWIS SCHRAGER

RITA SCHWARZELÜHR-SUTTER

Schrager oversees and maintains key external relationships focused on research and development and represents Aeras at major scientific meetings and symposiums. He has held a variety of leadership roles across several divisions at the FDA.

Rita Schwarzelühr-Sutter is Parliamentary State Secretary at the Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety.

RICHARD SEZIBERA

BT SLINGSBY

Richard Sezibera is the current Secretary General of the East African Community, an Inter-Governmental Organization bringing together the Partner States of Burundi, Kenya, Rwanda, the United Republic of Tanzania and Uganda.

BT Slingsby is CEO and Executive Director of the Global Health Innovative Technology Fund. Previously, he was Director for Global Access Strategies for Eisai & Co., where he developed new business models for Research & Development and market access in the developing world. He is a former professional triathlete and member of the U.S. World Cup Team.

SAMBA O. SOW

THOMAS SÜDHOF

Samba Sow is Director General of the Center for Vaccine Development – Mali (CVD Mali) and a Professor of Medicine at the University of Maryland School of Medicine. Previously, Mr. Sow has served as the coordinator for WHO Multi-Center Field Trial on Leprosy Chemotherapy.

Thomas Südhof is the Avram Goldstein Professor in the School of Medicine at Stanford University. He performed his doctoral thesis work at the Max Planck Institute in his home-town of Göttingen and was awarded the Nobel Prize for Medicine and Physiology in 2013 for his work on synaptic transmission.

LOTHAR WIELER

OTMAR WIESTLER

Lothar H. Wieler is the president of Robert Koch Institute, the central institution responsible for disease control and prevention in Germany. He is also a Professor of Veterinary Medicine at the Institute of Microbiology and Epizootics of the Free University in Berlin and a diplomat of the European College of Veterinary Public Health.

Otmar Wiestler joined the Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ) in Heidelberg as Chairman and Scientific Member of the Management Board in 2004. Since September 2015 he serves as the President of the Helmholtz Association in Berlin.

JOHN EU LI WONG

ADA YONATH

John Eu Li Wong is Vice Provost (Academic Medicine) of the National University of Singapore (NUS) as well as the Deputy Chief Executive of the National University Health System (NUHS), and Director of the National University Cancer Institute, Singapore (NCIS).

Ada E. Yonath won the Nobel Prize for Chemistry together with Venkatraman Ramakrishnan and Thomas Steitz for their work on ribosomal structure and function. She is a professor at the Department of Structural Biology and Director of The Helen and Milton A. Kimmelman Center for Biomolecular Structure, Weizmann Institute, Israel.

143

144

SPEAKER INDEX WITH PICTURES

SPEAKER INDEX WITH PICTURES

SPEAKER INDEX

ABBANY, ZULFIKAR G. Deutsche Welle | Germany

ADLI, MAZDA Charit鍖Universitätsmedizin Berlin | Fliedner Klinik Berlin | Germany

AERTS, ANN Novartis Foundation| Switzerland

AGEYKUM, SYLVESTER OSEI Boehringer Ingelheim GmbH & Co.KG | Ghana

AÏDI, SAÏD Minister of Health | Tunisia

ÅKERMAN, RÅNGEMARK CHRISTINA International Consortium for Health Outcomes Measurement (ICHOM) | USA

BESSER, DANIEL German Stem Cell Network (GSCN) | Germany

BETTCHER, DOUGLAS W. World Health Organization (WHO) | Switzerland

BEYER, PETER World Health Organization (WHO) | Switzerland

BOITARD, CHRISTIAN The National Institute for Health and Medical Research (INSERM) | France

BOUFFORD, JO IVEY The New York Academy of Medicine | United States of America

BOURDEAUX, MARGARET Brigham and Women’s Hospital Boston | United States of America

ALLEGRANZI, BENEDETTA World Health Organization (WHO) | Switzerland

ALLSOPP, TIM Pfizer Inc. | United Kingdom

ANG, SOPHIA National University Health Services | Singapore

ARCH, ROBERT Takeda Pharmaceutical Company Ltd. | United States of America

ASLANYAN, GARRY World Health Organization (WHO) | Switzerland

ATUN, RIFAT Harvard T. H. Chan School of Public Health | United States of America

BUEKENS, PIERRE Tulane University | United States of America

BYARUHANGA, JANET African Union Commission | Ethopia

CADER, ZAMEEL University of Oxford| United Kingdom

CANNY, BEN Monash University | Australia

CERRELL, JOE Bill & Melinda Gates Foundation/ European Office | United Kingdom

CHAN, MARGARET World Health Organization (WHO) | Switzerland

AULER JR., JOSÉ OTÁVIO COSTA University of São Paulo Medical School I Brazil

BALASEGARAM, MANICA Médecins Sans Frontières (MSF) | Switzerland

BAROUKI, ROBERT University Paris Descartes | France

BARTSCH, ALEXANDRA European Students’ Conference | Germany

BAUR, CYNTHIA Centers for Disease Control and Prevention | United States of America

BEIER, KLAUS Charit鍖Universitätsmedizin Berlin | Germany

CHIONG, YEE KEOW National University Health System (NUHS) | Singapore

CRESPIN, XAVIER West African Health Organization (WAHO) | Burkina Faso

DAIN, KATIE International Diabetes Federation| Belgium

DAVIES, SALLY Government UK Department of Health | United Kingdom

DE CIDRAC, CHARLES-ETIENNE AXA Global Life | France

DEPOUX, ANNELIESE Centre VirchowVillermé (CVV) | France

145

146

SPEAKER INDEX WITH PICTURES

SPEAKER INDEX WITH PICTURES

DRENCKHAHN, DETLEV WWF Germany | Germany

DUDLEY, LILIAN University of Stellenbosch | South Africa

DYBUL, MARK The Global Fund to Fight AIDS, Tuberculosis and Malaria | United States of America

DZAU, VICTOR J. National Academy of Medicine | United States of America

EDWARDS, NANCY Institute of Population and Public Health (CIHR) | Canada

EKEKE MONONO, MARTIN World Health Organization (WHO) Regional Office for Africa | Congo

GILPIN, SUSAN PURCELL World Council of Churches (WCC) | Switzerland

GLASZIOU, PAUL Bond University | Australia

GÖHDE, ROLAND Sysmex Partec GmbH | German Healthcare Partnership (GHP) | Germany

GOOD, SUJAVEE World Health Organization | India

GRASSL, HARTMUT Max Planck Institute for Meteorology (MPI-M) | Germany

GRÖHE, HERMANN Federal Ministry of Health | Germany

ERSDAL, HEGE Stavanger Acute medicine Foundation for Education and Research (SAFER) | Norway

FACEY, KAREN University of Glasgow | United Kingdom

FIANKANBOKONGA, CATHERINE United Nations (UN)| Switzerland

FIKERT, KRYSTIAN MyMind Ltd. | Ireland

FLAHAULT, ANTOINE University of Geneva | Switzerland

FLORY, EGBERT Paul-EhrlichInstitut| Germany

GROLMAN, DAVID C. Pfizer Inc. | Australia

GUERREIRO BAPTISTA LEITE, RICARDO AUGUSTUS Parliament of Portuguese Republic | Portugal

HAASE, MAREIKE Brot für die Welt– Evangelischer Entwicklungsdienst| Germany

HAGGENMILLER, CHRISTIAN LinkGlobalHealth. org | Germany

HAHN, HORST KARL Fraunhofer Institute for Medical Image Computing MEVIS | Germany

HAINES, SIR ANDREW London School of Hygiene & Tropical Medicine | United Kingdom

FONTANET, ARNAUD Institut Pasteur | France

FUKUHARA, SHUNICHI Kyoto University | Japan

GANTEN, DETLEV Charité Foundation | Germany

GEFFERT, KARIN German Medical Students’ Association (bvmd) e.V. | Germany

GILLESPIE, THOMAS R. Emory College of Arts and Sciences | United States of America

GILMOUR, JILL Imperial College London | United Kingdom

HAUSER, NORBERT The Global Fund to Fight AIDS, Tuberculosis and Malaria | Switzerland

HEIM, CHRISTINE Charit鍖Universitätsmedizin Berlin | Germany

HEINZ, ANDREAS Charit鍖Universitätsmedizin Berlin | Germany

HERBINGER, ILKA WWF Germany | Germany

HERFURTH, TANYA Young Leaders for Health (YLH) e.V. | Germany

HOEVELER, ARND European Commission | Belgium

147

148

SPEAKER INDEX WITH PICTURES

SPEAKER INDEX WITH PICTURES

HOLDEN, JESSICA Médecins Sans Frontières (MSF)| Australia

HOLMQVIST, ROLF Linköping University | Sweden

HOOI, SHING CHUAN National University of Singapore | Singapore

HØYBRÅTEN, DAGFINN Gavi, The Vaccine Alliance | Switzerland

HULAND, HARTWIG Martini Klinik at UKE GmbH| Germany

HURRELMANN, KLAUS Hertie School of Governance | Germany

KARIUKI, THOMAS Alliance for Accelerating Excellence in Science in Africa (AESA) | Kenya

KATSUNO, KEI Global Health Innovative Technology Fund | Japan

KAUFMANN, PETRA National Center for Advancing Translational Sciences (NCATS) | United States of America

KAWASAKI, RYO Fukushima Medical University | Japan

KHOO, DAPHNE Ministry of Health | Singapore

KICKBUSCH, ILONA The Graduate Institute of International and Development Studies | Switzerland

ILIC, DRAGAN Monash University | Australia

ISCHINGER, WOLFGANG Munich Security Conference | Germany

IYER, JAYASREE Access to Medicine Foundation | Netherlands

JACKSON, CAITY Women in Global Health | Sweden

JAKAB, ZSUZSANNA World Health Organization | Denmark

JI, LINONG International Diabetes Federation| Belgium

KIENY, MARIE-PAULE World Health Organization | Switzerland

KIESELBACH, BERIT World Health Organization | Switzerland

KIRTON, JOHN University of Toronto | Canada

KOLPATZIK, KAI AOK Bundesverband | Germany

KÖNIG, BIRGIT Allianz Private Krankenversicherungs-AG | Germany

KORNELY, FRANK Boehringer Ingelheim GmbH & Co.KG | Germany

JIMENEZ, JOSEPH

JOHNSTONE, ANDREW European Patients Forum (EPF) | United Kingdom

JONES, DEBRA A. Save the Children | United States of America

JØRGENSEN, MARIE BIRK National Research Center for the Working Environment | Denmark

JOUSSEN, ANTONIA Charit鍖Universitätsmedizin Berlin | Germany

KAMAU, MACHARIA United Nations (UN)| United States of America

KRÄMER, ALEXANDER Bielefeld University | Germany

KRANENBURG, JOCELINE Global Health Next Generation Network (GHNGN) | Netherlands

KRISAM, MATHIAS Charit鍖Universitätsmedizin Berlin | Germany

KÜHLEN, BARBARA Oxfam Deutschland e.V. | Germany

KUHN, HEIKE German Federal Ministry for Economic Cooperation and Development (BMZ) | Germany

KUMAR, SURESH Sanofi Aventis Groupe S.A. | Switzerland

Novartis International AG | Switzerland European Federation of Pharmaceutical Industries and Asso ciations (EFPIA) | Belgium

149

150

SPEAKER INDEX WITH PICTURES

SPEAKER INDEX WITH PICTURES

KUMAR, VISHWAJEET Shivharh Community Empowerment Lab | India

KÜMMEL, BJÖRN Federal Ministry of Health (BMG) | Germany

LAMBERT, SANDRA Merck (Pty) Ltd. | South Africa

LARSSON, STEFAN The Boston Consulting Group | Sweden

LEEK, JEFFREY Johns Hopkins Bloomberg School of Public Health | United States of America

LEENDERTZ, FABIAN Robert Koch Institute| Germany

MAAS, JOCHEN Sanofi-Aventis Deutschland GmbH| Germany

MAKANGA, MICHAEL European and Developing Countries Clinical Trials Partnership (EDCTP) | South Africa

MAKGATO-MALESU, DORCAS Ministry of Health | Botswana

MANGION, JONATHAN Thermo Fisher Inc. | United Kingdom

MANSARAY, SHECKU KAWUSU Sierra Leone Adult Education Association (SLADEA) | Sierra Leone

MANUGUERRA, JEAN-CLAUDE Institut Pasteur | France

LEEREVELD, WIM Access to Medicine Foundation | Netherlands

LEWIS, CHRIS Department for International Development (DFID) | United Kingdom

LEWIS-HALL, FREDA C. Pfizer Inc. | United States of America

LIM, AYMERIC National University Hospital | Singapore

LINDBERG, CASJA UNG Diabetes | Sweden

LINDPAINTNER, KLAUS Thermo Fisher Scientific Inc. | United States of America

MARTIN, ULRICH German Stem Cell Network (GSCN) | Germany

MAXMEN, AMY Pulitzer Center on Crisis Reporting | United States of America

MCGRATH, PETER The World Academy of Sciences | Italy

MICHIE, SUSAN University College London | United Kingdom

MISSMAHL, INGE Ipso gemeinnützige Gesellschaft mbH | Germany

MLADOVSKY, PHILIPA London School of Economics and Political Sciences | United Kingdom

LODBROK, OLAF Elsevier GmbH | Germany

LOEWENBERG, SAMUEL Pulitzer Center on Crisis Reporting | United States of America

LOOI, LAI-MENG Academy of Sciences | Malaysia

LOURES, LUIZ United Nations (UN)| UNAIDS | Switzerland

LUNZE, KARSTEN Boston University School of Medicine I United States of America

LYRAS, DENA Monash University | Australia

MOON, SUERIE Harvard T. H. Chan School of Public Health | United States of America

MÖRÖY, TARIK Clinical Research Institute Montreal (IRCM) | Canada

MORRIS, MITCHELL Deloitte Consulting LLP | United States of America

MUCIC, LUKA SAP SE | Germany

MÜLLER-JUNG, JOACHIM Frankfurter Allgemeine Zeitung (FAZ) | Germany

MURAKAMI, AKIRA Juntendo University Tokyo | Center for Prevention of Blindness | Japan

151

152

SPEAKER INDEX WITH PICTURES

SPEAKER INDEX WITH PICTURES

MURKE, JULIUS Young Leaders for Health (YLH) e.V. | Germany

MURRAY, SIR ROBIN King’s College London | United Kingdom

MWEHONGE, KENNETH Coalition for Health Promotion and Social Development (HEPS) | Uganda

MYERS, MICHAEL The Rockefeller Foundation | United States of America

NAKATANI, HIROKI Keio University | Japan Ministry of Health, Labour and Welfare| Japan

NAPIER, DAVID University College London | United Kingdom

PACCAUD, JEAN-PIERRE Drugs for Neglected Diseases initiative (DNDi) | Switzerland

PASTORE, MANUELA Boehringer Ingelheim GmbH & Co.KG | Germany

PATEL, VIKRAM London School of Hygiene & Tropical Medicine | United Kingdom

PELEG, ANTON Monash University | Australia

PETROVABENEDICT, ROUMYANA International Organization for Migration (IOM) | Belgium

PFUNDNER, HAGEN Roche Pharma AG | Verband Forschender Arzneimittelhersteller e.V. (vfa) | Germany

NDOMONDOSIGONDA, MARGARETH

NEUMANN, MARKUS Bioscientia–Institut für Medizinische Diagnostik GmbH | Germany

NGOZWANA, SKHUMBUZO Serenus Biotherapeutics Ltd. | South Africa

NIMMESGERN, ELMAR European Commission | Belgium

NOLAN, CANICE European Commission | Belgium

NOLL, JENNIE Pennsylvania State University | United States of America

PINTSCHER, LYDIA Wikimedia Deutschland e.V. | Germany

PIPELEERS, DANIEL Brussels Free University (VUB) | Belgium

POLGLASE, GRAEME Monash University | Australia

PRIES, AXEL R. Charit鍖Universitätsmedizin Berlin | Germany

RABBOW, MICHAEL Boehringer Ingelheim GmbH & Co.KG | Germany

RAPPAGLIOSI, ANDREA Sanofi Pasteur MSD | France

OELRICH, STEFAN Sanofi Aventis Deutschland GmbH| Germany

OETTINGER, GÜNTHER H. European Commission | Belgium

OLDGREN, JONAS Uppsala University | Sweden

OSBORNE, RICHARD Deakin University | Australia

OSTERHAUS, ALBERT University of Veterinary Medicine Hannover | Germany

REDD, CHRIS Universities Allied for Essential Medicines (UAEM) | United Kingdom

REDDY, DAVID Medicines for Malaria Venture (MMV) | Switzerland

REDDY, SRINATH Public Health Foundation of India| India

REEDER, JOHN World Health Organization | Switzerland

RIETSCHEL, ERNST TH. Berlin Institute of Health (BIH) | Germany

ROOS, ANDREAS VAMED Management und Service Schweiz AG I Switzerland

The New Partnership For Africa’s Development (NEPAD) | South Africa

O’BRIAN, KEVIN Handelsblatt GmbH| Germany

153

154

SPEAKER INDEX WITH PICTURES

SPEAKER INDEX WITH PICTURES

RUCZINSKI, INGO Johns Hopkins Bloomberg School of Public Health | United States of America

RYLL, BETTINA Melanoma Patient Network Europe | Sweden

SADALLAH, FATIHA Innovative Medicines Initiative | Belgium

SAMARASEKERA, DUJEEPA National University Health System | Singapore

SAMSOM, MELVIN Karolinska University Hospital | Sweden

SAUERBORN, RAINER University Hospital Heidelberg | Germany

SOW, SAMBA O. Center for Vaccine Development | Mali

STANLEY-BAKER, MICHAEL Max Planck Institute for the History of Science | Germany

STOCK, GÜNTER Berlin-Brandenburg Academy of Sciences and Humanities (BBAW)| Germany

STURCHIO, JEFFREY Rabin Martin | United States of America

SÜDHOF, THOMAS Stanford University School of Medicine | United States of America

SUTER, PETER University Medical Center | Switzerland

SAVIOLI, LORENZO Global Schistosomiasis Alliance (GSA) | Switzerland

SCHÄFERS, REINHARD WHS Foundation GmbH–World Health Summit | Germany

SCHELLNHUBER, HANS JOACHIM Potsdam Institute for Climate Impact Research (PIK) | Germany

SCHRAGER, LEWIS Aeras | United States of America

SCHÜTTE, GEORG German Federal Ministry of Education and Research (BMBF) | Germany

SCHWARZELÜHRSUTTER, RITA

TANAKA, ELLY M. Center for Regenerative Therapies TU Dresden (CRTD)| Germany

TANNER, MARCEL Swiss Tropical & Public Health Institute | Switzerland

TEPEL, RALF Karl Kübel Stiftung für Kind und Familie| Germany

ULBERT, CORNELIA Duisburg-Essen University | Germany

ULBRICH, JUTTA AbbVie Deutschland GmbH & Co. KG | Germany

ULRICHS, TIMO Akkon Univerity for Human Science | Koch-Metchnikov Forum e.V. (KMF) | Germany

SEBBAG, ROBERT Sanofi | France

SEHOULI, JALID Charit鍖Universitätsmedizin Berlin | Germany

SEZIBERA, RICHARD East African Community (EAC) | Rwanda

SHAW, JONATHAN Monash University | Australia

SIBAL, ANUPAM Apollo Hospitals Group | India Indraprastha Apollo Hospitals | India

UNSCHULD, PAUL ULRICH Charit鍖Universitätsmedizin Berlin | Germany

VALDIVIA, LEONEL A. University of Chile | Chile

VERMURI, MOHAN C. Thermo Fisher Scientific Inc. | United States of America

VILCINSKAS, ANDREAS Fraunhofer Society | Germany

VON BOHLEN UND HALBACH, FRIEDRICH dievini Hopp BioTech holding GmbH & Co.KG | Germany

WALLACE, EUAN Monash University | Australia

Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety (BMUB) | Germany

SLINGSBY, BT Global Health Innovative Technology Fund | Japan

155

156

SPEAKER INDEX WITH PICTURES

SPEAKER LIST

SPEAKER LIST A

WATSON-STRYKER, ELLA Médecins Sans Frontières (MSF) | United States of America

WEBER-MOSDORF, SUSANNE Former Executive Director of the WHO Office European Union | Germany

WEEKERS, JACQUELINE International Organization for Migration (IOM) | Switzerland

WEILAND, UTE Alfred Herrhausen Society–The International Forum of Deutsche Bank | Germany

WESTPHAL, FLORIAN Médecins Sans Frontières (MSF) | Germany

WIELER, LOTHAR Robert Koch Institute | Germany

Abbany, Zulfikar G. 46 Adli, Mazda 110 Aerts, Ann 58 Ageykum, Sylvester Osei 52 Aïdi, Saïd 86 Åkerman Rångemark, Christina 76 Allegranzi, Benedetta 44 Allsopp, Tim 82 Ang, Sophia 54 Arch, Robert 58 Aslanyan, Garry 40 Atun, Rifat 74 Auler Jr., José Otávio 44, 45

B

WIESTLER, OTMAR D. Helmholtz Association | Germany

YZER, CORNELIA Federal Government Berlin | Germany

WONG, DAVID University of Hong Kong | Hong Kong

WONG, JOHN EU LI National University of Singapore | Singapore

YANKAH, CHARLES African Cultural Institute | Germany

YONATH, ADA E. Weizmann Institute of Science | Israel

YOONG, JOANNE National University of Singapore | Singapore

Balasegaram, Manica 64, 96 Barouki, Robert 106 Barry, Boubacar 106 Bartsch, Alexandra 38 Baur, Cynthia 80 Beier, Klaus 72 Berntgen, Michael 84 Besser, Daniel 82 Bettcher, Douglas W. 104 Beyer, Peter 100 Boitard, Christian 108 Boufford, Jo Ivey 70 Bourdeaux, Margaret 42 Buekens, Pierre 40 Byaruhanga, Janet 96

C Cader, Zameel 82 Canny, Ben 38, 68 Cerrell, Joe 102 Chan, Margaret 60 Chiong, Yee Keow 54

Crespin, Xavier 96

D Dain, Katie 104 Davies, Sally 64 de Cidrac, Charles-Etienne 78 Depoux, Anneliese 106 Dhatt, Roopa 61 Drenckhahn, Detlev 112 Dudley, Lilian 78 Dybul, Mark 74, 76 Dzau, Victor 60

E Edwards, Nancy 40 Ekeke Monono, Martin 50 El Khormi, Myriam 60 Ersdal, Hege 68

F Facey, Karen 84 Fiankan-Bokonga, Catherine 104 Fikert, Krystian 52 Flahault, Antoine 88, 106 Flory, Egbert 82 Fontanet, Arnaud 107 Friebe, Richard 108 Fukuhara, Shunichi 60, 88, 116

G Ganten, Detlev 56, 60, 66, 88, 116 Geffert, Karin 38 George, Elisabeth 84 Gillespie, Thomas R. 112 Gilmour, Jill 40

Gilpin, Susan Purcell 50 Glasziou, Paul 54 Göhde, Roland 56, 78, 96 Good, Sujavee 80 Graßl, Hartmut 114 Gröhe, Hermann 60 Grolman, David C. 94 Guerreiro Baptista Leite, Ricardo Augustus 84

Ji, Linong 104 Jimenez, Joseph 76 Johnstone, Robert Andrew 44 Jones, Debra A. 74 Jørgensen, Marie Birk 80 Joussen, Antonia 98

K

Ilic, Dragan 54 Ischinger, Wolfgang 116 Iyer, Jayasree 68

Kamau, Macharia 74 Kango, Mabvuto 104 Kariuki, Thomas 40 Katsuno, Kei 58 Kaufmann, Petra 108 Kawasaki, Ryo 98 Kekulé, Alexander 56 Khoo, Daphne 44 Kickbusch, Ilona 78, 92 Kieny, Marie-Paule 64 Kieselbach, Berit 72 Kirton, John 102 Kolpatzik, Kai 80 König, Birgit 60 Kornely, Frank 52 Krafft, Thomas 100 Krämer, Alexander 46 Kranenburg, Joceline 38 Krisam, Mathias 38 Krönke, Martin 108 Kühlen, Barbara 50 Kuhn, Heike 78 Kumar, Suresh 104 Kumar, Vishwajeet 68 Kümmel, Björn 50

J

L

H Haase, Mareike 50 Haggenmiller, Christian 42, 46 Hahn, Horst Karl 56 Haines, Sir Andrew 107, 114 Hauser, Norbert 102 Heim, Christine 72 Heinz, Andreas 66, 110 Herbinger, Ilka 112 Herfurth, Tanya 38 Hoeveler, Arnd 82 Holden, Jessica 68 Holmqvist, Rolf 72 Hooi, Shing Chuan 54 Høybråten, Dagfinn 74 Huland, Hartwig 76 Humberg, Kerstin Maria 52 Hurrelmann, Klaus 80

I

Jackson, Caity 38 Jakab, Zsuzsanna 74 Janke, Christian 42

Lambert, Sandra 96 Larsson, Stefan 76 Leek, Jeffrey 48

157

158

SPEAKER LIST

Leendertz, Fabian 112 Leereveld, Wim 92 Le Jeunne, Claire 84 Lewis, Chris 40 Lewis-Hall, Freda C. 74 Lim, Aymeric 44 Lindberg, Casja 82 Lindpaintner, Klaus 86 Lodbrok, Olaf 48 Loewenberg, Samuel 46 Looi, Lai-Meng 112 Loures, Luiz 96, 116 Lunze, Karsten 68 Lyras, Dena 94

M Maas, Jochen 56 Makanga, Michael 41 Makgato-Malesu, Dorcas 78 Mangion, Jonathan 48 Mansaray, Shecku Kawusu 50 Manuguerra, Jean-Claude 92 Martin, Ulrich 82 Maxmen, Amy 92 McGrath, Peter 70 Meddeb, Aymen 61 Michie, Susan 55 Miller, Kenneth 110 Missmahl, Inge 66 Mladovsky, Philipa 46 Moon, Suerie 92 Möröy, Tarik 48 Morris, Mitchell 102 Mucic, Luka 86 Müller-Jung, Joachim 82 Murakami, Akira 98

SUPPORTING INSTITUTIONS

Murke, Julius 38 Murray, Sir Robin 110, 116 Mwehonge, Kenneth 50 Myers, Michael 102

N Nakatani, Hiroki 102 Napier, David 66 Ndomondo-Sigonda, Margareth 96 Neumann, Markus 56 Ngozwana, Skhumbuzo 96 Nimmesgern, Elmar 108 Nolan, Canice 94 Noll, Jennie 72

R

T

Rabbow, Michael 52, 78, 96 Rappagliosi, Andrea 84 Redd, Chris 38 Reddy, David 58 Reddy, Srinath 100, 104 Reeder, John 41 Rietschel, Ernst Th. 56, 108 Roos, Andreas 45 Ruczinski, Ingo 48 Ryll, Bettina 84

Taib, Nezar Ismet 42 Tanaka, Elly M. 82 Tanner, Marcel 112 Tepel, Ralf 52

S

V

Sadallah, Fatiha 82 Samarasekera, Dujeepa 54 Samsom, Melvin 76 Sauerborn, Rainer 106, 114 O Savioli, Lorenzo 58 O’Brian, Kevin 100 Schäfers, Reinhard 66 Oelrich, Stefan 56 Schellnhuber, Hans Joachim Oettinger, Günther H. 86 114 Oldgren, Jonas 76 Schrager, Lewis 64 Osborne, Richard 80 Schulze, Jürgen 96 Osterhaus, Albert 112 Schütte, Georg 108 Schwarzelühr-Sutter, Rita 114 P Sebbag, Robert 96 Paccaud, Jean-Pierre 58 Sehouli, Jalid 66 Pastore, Manuela 52 Sezibera, Richard 79, 116 Patel, Vikram 73 Shaw, Jonathan 98 Peleg, Anton 94 Petrova-Benedict, Roumyana Shirwadkar, Swati 73 Sibal, Anupam 45 46 Sié, Ali 114 Pfundner, Hagen 56 Slingsby, BT 64 Pintscher, Lydia 48 Sow, Samba O. 92 Pipeleers, Daniel 82 Stanley-Baker, Michael 66 Polglase, Graeme 68 Stock, Günter 66 Pries, Axel R. 60 Sturchio, Jeffrey 79 Südhof, Thomas 86 Q Suter, Peter 108 Qosaj, Fatime Arenliu 42

U Ulbert, Cornelia 50 Ulbrich, Jutta 48 Ulrichs, Timo 94 Unschuld, Paul Ulrich 67

Valdivia, Leonel A. 100 Vermuri, Mohan C. 82 Vilcinskas, Andreas 57 von Bohlen und Halbach, Friedrich 86

W Wallace, Euan 68 Watson-Stryker, Ella 67 Weber-Mosdorf, Susanne 100 Weekers, Jacqueline 110 Weiland, Ute 110 Westphal, Florian 42, 92 Wieler, Lothar 64, 112 Wiestler, Otmar D. 86 Wong, David 98 Wong, John Eu Li 44, 64

Y Yankah, Charles 46 Yonath, Ada E. 64 Yoong, Joanne 55 Yzer, Cornelia 57, 88

Z Zaim, Lana 61

SUPPORTING INSTITUTIONS SESSION CO-HOSTS A AbbVie Deutschland GmbH & Co.KG Allianz Deutschland AG B Berlin Institute of Health (BIH) Bielefeld University Boehringer Ingelheim GmbH & Co.KG Brot für die Welt–Evangelischer Entwicklungsdienst C Charit鍖Universitätsmedizin Berlin D Drugs for Neglected Diseases initiative (DNDi) E EBiSC Elsevier GmbH European Commission European Federation of Pharmaceutical Industries and Association (EFPIA) European Students’ Conference (ESC) F Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety (BMUB) Fliedner Klinik Berlin Fraunhofer-Institut für Bildgestützte Medizin MEVIS Fukushima Medical University

G Geneva Health Forum German Centers for Health Research (DZG) German Federal Foreign Office (AA) German Federal Ministry for Economic Cooperation and Development (BMZ) German Federal Ministry of Health (BMG) German Healthcare Partnership (GHP) German Medical Students’ Association (bvmd) German Stem Cell Network (GSCN) Global Health Innovative Technology Fund (GHIT) Global Health Next Generation Network (GHNGN) H Harvard Medical School Helmholtz Association of German Research Centres e.V. Hertie School of Governance I Innovative Medicines Initiative (IMI) Institut Pasteur InterAcademy Medical Panel (IAMP) J LinkGlobalHealth.org Initiative Johns Hopkins Bloomberg School of Public Health K Karl Kübel Stiftung für Kind und Familie Koch-Metschnikow-Forum e.V.

159

160

SUPPORTING INSTITUTIONS

SUMMIT PARTNERS

POLICY MAKERS L Leopoldina–German National Academy of Science London School of Hygiene & Tropical Medicine M M8 Alliance Monash University Munich Security Conference Foundation gGmbH (MSC) N National University Health System Singapore (NUHS) National University of Singapore (NUS) O Oxfam Deutschland e.V. P Pennsylvania State University Pulitzer Center on Crisis Reporting R Rabin Martin Robert Koch Institute (RKI) S Sanofi StemBancc Stiftung Preussischer Kulturbesitz (SPK)

T The Boston Consulting Group (BCG) The Global Fund The Graduate Institute Geneva The Graduate Institute of International and Development Studies The Rockefeller Foundation

Partner & Co-Host:

1965 - 2015

‫ שנה‬50 ‫ליחסי הדיפלומטיי‬ ‫גרמניה‬-‫ישראל‬ 50 Jahre Diplomatische Beziehungen Deutschland-Israel

U UNAIDS United Nations (UN) Universities Allied for Essential Medicines (UAEM) University of Geneva (UGE) V VAMED W World Federation of Academic Institutions for Global Health (WFAIGH) World Health Organzation (WHO) World Health Organization Regional Office for Europe World Wide Fund for Nature (WWF Germany) Y Young Leaders for Health (YLH) e.V.

ACADEMIA

161

162

SUMMIT PARTNERS

SUMMIT PARTNERS

PRIVATE SECTOR Strategic Partner

CIVIL SOCIETY Major Partner

General Partners

MEDIA PARTNERS

Supporting Partners

In Zusammenarbeit mit:

Polish Healthcare Journal Ogólnopolski System Ochrony Zdrowia

ASSOCIATES

Service Aides

Concept Partner:

Foundations

Printing Partner:

Mobility Partner:

163

164

NOTES

NOTES

165

SAVE THE DATES•!

WHS REGIONAL MEETING Photo Credits Federal Foreign Office, Page 2 © photothek/Auswärtiges Amt Brandenburger Tor, Page 19 © Noppasin/Shutterstock.com Bärbel-Maria Kurth, Page 21, © Robert Koch Institute/Dugnus Timo Ulrichs, Pages 21, 95, 155 © akkon monbijou Fernsehturm, Page 28 © turtix/Shutterstock.com Allianz Forum, Page 34 © Allianz Forum Weltzeituhr, Page 36 © pio3/Shutterstock.com Hermann Gröhe, Pages 61, 138, 147 © Bundesregierung–Steffen Kugler Berlin by Night, Page 62 © Mapics/Shutterstock.com Otmar Wiestler, Pages 87, 143, 156 © DKFZ Gendarmenmarkt, Page 90 © badahos/Shutterstock.com Wim Leereveld, Pages 93, 140, 150 © Patricia Wolf Hans-Joachim Schellnhuber, Pages 115, 142, 154 © Frédéric Batier East-Side-Gallery, Page 118 © Jana Schoenknecht/Shutterstock.com Charité, Page 124 © Charit鍖Universitätsmedizin Berlin Molecule Man, Page 125 © visitBerlin, Foto: Karin Willms Federal Foreign Office, Page 126, 129 © photothek/Auswärtiges Amt Layout Eta Friedrich, Berlin

GENEVA, SWITZERLAND APRIL 19–21, 2016 WORLD HEALTH SUMMIT BERLIN, GERMANY OCTOBER 09–11, 2016

Printer Laserline, Berlin

www.worldhealthsummit.org

Summit Organizer / Academic Office WHS Foundation GmbH World Health Summit c/o Charité – Universitätsmedizin Berlin Charitéplatz 1 10117 Berlin Germany Tel.: +49 30 450 572102 Fax: +49 30 450 572911 [email protected]